US20050049215A1 - Immunostimulatory nucleic acid molecules - Google Patents
Immunostimulatory nucleic acid molecules Download PDFInfo
- Publication number
- US20050049215A1 US20050049215A1 US10/888,449 US88844904A US2005049215A1 US 20050049215 A1 US20050049215 A1 US 20050049215A1 US 88844904 A US88844904 A US 88844904A US 2005049215 A1 US2005049215 A1 US 2005049215A1
- Authority
- US
- United States
- Prior art keywords
- dna
- cells
- cell
- creb
- oligonucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000003308 immunostimulating effect Effects 0.000 title claims description 20
- 102000039446 nucleic acids Human genes 0.000 title abstract description 15
- 108020004707 nucleic acids Proteins 0.000 title abstract description 15
- 150000007523 nucleic acids Chemical class 0.000 title abstract description 15
- 238000000034 method Methods 0.000 claims abstract 16
- 108091034117 Oligonucleotide Proteins 0.000 claims description 24
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 12
- 102000006992 Interferon-alpha Human genes 0.000 claims description 3
- 108010047761 Interferon-alpha Proteins 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 238000012986 modification Methods 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 2
- 239000007791 liquid phase Substances 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 230000004044 response Effects 0.000 abstract description 6
- 230000028993 immune response Effects 0.000 abstract description 3
- 208000012657 Atopic disease Diseases 0.000 abstract 1
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 31
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 27
- 108020004414 DNA Proteins 0.000 description 23
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 17
- 210000003719 b-lymphocyte Anatomy 0.000 description 17
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 17
- 102000005869 Activating Transcription Factors Human genes 0.000 description 15
- 108010005254 Activating Transcription Factors Proteins 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 13
- 230000004913 activation Effects 0.000 description 10
- 230000027455 binding Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 230000006698 induction Effects 0.000 description 9
- 210000004698 lymphocyte Anatomy 0.000 description 9
- 230000000638 stimulation Effects 0.000 description 9
- 241001529936 Murinae Species 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 239000003642 reactive oxygen metabolite Substances 0.000 description 8
- 230000028327 secretion Effects 0.000 description 8
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000000692 anti-sense effect Effects 0.000 description 5
- 230000001900 immune effect Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- KZELNMSPWPFAEB-UMMCILCDSA-N 2-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-8-sulfanylidene-3,7-dihydropurin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2NC(=S)N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O KZELNMSPWPFAEB-UMMCILCDSA-N 0.000 description 4
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 230000004568 DNA-binding Effects 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 235000013601 eggs Nutrition 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 239000003226 mitogen Substances 0.000 description 4
- 210000000822 natural killer cell Anatomy 0.000 description 4
- 210000004989 spleen cell Anatomy 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 3
- 230000003844 B-cell-activation Effects 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 3
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 108090000467 Interferon-beta Proteins 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 108091027981 Response element Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 229960003677 chloroquine Drugs 0.000 description 3
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000002297 mitogenic effect Effects 0.000 description 3
- 230000031942 natural killer cell mediated cytotoxicity Effects 0.000 description 3
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 3
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000003393 splenic effect Effects 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- ASUCSHXLTWZYBA-UMMCILCDSA-N 8-Bromoguanosine Chemical compound C1=2NC(N)=NC(=O)C=2N=C(Br)N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O ASUCSHXLTWZYBA-UMMCILCDSA-N 0.000 description 2
- 102000039549 ATF family Human genes 0.000 description 2
- 108091067350 ATF family Proteins 0.000 description 2
- 108010024878 Adenovirus E1A Proteins Proteins 0.000 description 2
- 108020004491 Antisense DNA Proteins 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 108020000946 Bacterial DNA Proteins 0.000 description 2
- 102000001764 CREB-Binding Protein Human genes 0.000 description 2
- 108010040163 CREB-Binding Protein Proteins 0.000 description 2
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 2
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 2
- 108050006400 Cyclin Proteins 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Natural products O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 102100026720 Interferon beta Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108091061960 Naked DNA Proteins 0.000 description 2
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 102100027584 Protein c-Fos Human genes 0.000 description 2
- 241000242680 Schistosoma mansoni Species 0.000 description 2
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000003816 antisense DNA Substances 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 102000023732 binding proteins Human genes 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 101150093710 clec-87 gene Proteins 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 229940095074 cyclic amp Drugs 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000017306 interleukin-6 production Effects 0.000 description 2
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 2
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- FNEZBBILNYNQGC-UHFFFAOYSA-N methyl 2-(3,6-diamino-9h-xanthen-9-yl)benzoate Chemical compound COC(=O)C1=CC=CC=C1C1C2=CC=C(N)C=C2OC2=CC(N)=CC=C21 FNEZBBILNYNQGC-UHFFFAOYSA-N 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 150000004713 phosphodiesters Chemical class 0.000 description 2
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 2
- 230000004850 protein–protein interaction Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- 108010044688 Activating Transcription Factor 2 Proteins 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 101150076489 B gene Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 102000015280 CCAAT-Enhancer-Binding Protein-beta Human genes 0.000 description 1
- 108010064535 CCAAT-Enhancer-Binding Protein-beta Proteins 0.000 description 1
- 101100026251 Caenorhabditis elegans atf-2 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 102100023033 Cyclic AMP-dependent transcription factor ATF-2 Human genes 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 238000011765 DBA/2 mouse Methods 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108010024212 E-Selectin Proteins 0.000 description 1
- 102100023471 E-selectin Human genes 0.000 description 1
- 102000052526 E1A-Associated p300 Human genes 0.000 description 1
- 108700039043 E1A-Associated p300 Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical class C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 1
- 230000006051 NK cell activation Effects 0.000 description 1
- XDMCWZFLLGVIID-SXPRBRBTSA-N O-(3-O-D-galactosyl-N-acetyl-beta-D-galactosaminyl)-L-serine Chemical compound CC(=O)N[C@H]1[C@H](OC[C@H]([NH3+])C([O-])=O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 XDMCWZFLLGVIID-SXPRBRBTSA-N 0.000 description 1
- 108091081548 Palindromic sequence Proteins 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 102000009339 Proliferating Cell Nuclear Antigen Human genes 0.000 description 1
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
- 101150002130 Rb1 gene Proteins 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 241000701033 Simian cytomegalovirus Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 102000006467 TATA-Box Binding Protein Human genes 0.000 description 1
- 108010044281 TATA-Box Binding Protein Proteins 0.000 description 1
- -1 Tax Proteins 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical class O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 102000006290 Transcription Factor TFIID Human genes 0.000 description 1
- 108010083268 Transcription Factor TFIID Proteins 0.000 description 1
- 108090000941 Transcription factor TFIIB Proteins 0.000 description 1
- 102000004408 Transcription factor TFIIB Human genes 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 102000011117 Transforming Growth Factor beta2 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- 101800000304 Transforming growth factor beta-2 Proteins 0.000 description 1
- 206010044696 Tropical spastic paresis Diseases 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000003081 coactivator Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000005918 in vitro anti-tumor Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 239000002799 interferon inducing agent Substances 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 108010052790 interleukin 1 precursor Proteins 0.000 description 1
- 230000019734 interleukin-12 production Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 230000009061 membrane transport Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- WIFGCZCFSNIILK-UHFFFAOYSA-N platinum;pyrimidine Chemical class [Pt].C1=CN=CN=C1 WIFGCZCFSNIILK-UHFFFAOYSA-N 0.000 description 1
- 230000004911 positive regulation of CREB transcription factor activity Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 108700004030 rev Genes Proteins 0.000 description 1
- 101150098213 rev gene Proteins 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 230000029069 type 2 immune response Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000006490 viral transcription Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- oligonucleotides Like DNA, oligodeoxyribonucleotides (ODNs) are able to enter cells in a saturable, sequence independent, and temperature and energy dependent fashion (reviewed in Jaroszewski, J. W., and J. S. Cohen. 1991.
- Lymphocyte ODN uptake has been shown to be regulated by cell activation.
- Spleen cells stimulated with the B cell mitogen LPS had dramatically enhanced ODN uptake in the B cell population, while spleen cells treated with the T cell mitogen Con A showed enhanced ODN uptake by T but not B cells (Krieg, A. M., F. Gmelig-Meyling, M. F. Gourley, W. J. Kisch, L. A. Chrisey, and A. D. Steinberg. 1991. “Uptake of oligodeoxyribonucleotides by lymphoid cells is heterogeneous and inducible”. Antisense Research and Development 1:161).
- poly (I,C) which is a potent inducer of IFN production as well as a macrophage activator and inducer of NK activity
- I,C a potent inducer of IFN production as well as a macrophage activator and inducer of NK activity
- Guanine ribonucleotides substituted at the C8 position with either a bromine or a thiol group are B cell mitogens and may replace “B cell differentiation factors” (Feldbush, T. L., and Z. K. Ballas. 1985. “Lymphokine-like activity of 8-mercaptoguanosine: induction of T and B cell differentiation”. J. Immunol. 134:3204; and Goodman, M. G. 1986. “Mechanism of synergy between T cell signals and C8-substituted guanine nucleosides in humoral immunity: B lymphotropic cytokines induce responsiveness to 8-mercaptoguanosine”. J. Immunol. 136:3335).
- 8-mercaptoguanosine and 8-bromoguanosine also can substitute for the cytokine requirement for the generation of MHC restricted CTL (Feldbush, T. L., 1985. cited supra), augment murine NK activity (Koo, G. C., M. E. Jewell, C. L. Manyak, N. H. Sigal, and L. S. Wicker. 1988. “Activation of murine natural killer cells and macrophages by 8-bromoguanosine”. J. Immunol. 140:3249), and synergize with IL-2 in inducing murine LAK generation (Thompson, R. A., and Z. K. Ballas. 1990. “Lymphokine-activated killer (LAK) cells.
- CREB cAMP response element binding protein
- ATF activating transcription factor
- CREB/ATF family of transcription factors is a ubiquitously expressed class of transcription factors of which 11 members have so far been cloned (reviewed in de Groot, R. P., and P. Sassone-Corsi: “Hormonal control of gene expression: Multiplicity and versatility of cyclic adenosine 3′,5′-monophosphate-responsive nuclear regulators”. Mol. Endocrin. 7:145, 1993; Lee, K. A. W., and N. Masson: “Transcriptional regulation by CREB and its relatives”. Biochim. Biophys. Acta 1174:221, 1993.).
- bZip basic region/leucine zipper
- All cells appear to express one or more CREB/ATF proteins, but the members expressed and the regulation of mRNA splicing appear to be tissue-specific. Differential splicing of activation domains can determine whether a particular CREB/ATF protein will be a transcriptional inhibitor or activator. Many CREB/ATF proteins activate viral transcription, but some splicing variants which lack the activation domain are inhibitory.
- CREB/ATF proteins can bind DNA as homo- or hetero-dimers through the cAMP response element, the CRE, the consensus form of which is the umethylated sequence TGACGTC (binding is abolished if the CpG is methylated) (Iguchi-Ariga, S. M. M., and W. Schaffner: “CpG methylation of the cAMP-responsive enhancer/promoter sequence TGACGTCA abolishes specific factor binding as well as transcriptional activation”. Genes & Develop. 3:612, 1989.).
- CREB/ATF proteins appear to regulate the expression of multiple genes through the CRE including immunologically important genes such as fos, jun B, Rb-1, IL-6, IL-1 (Tsukada, J., K. Saito, W. R. Waterman, A. C. Webb, and P. E. Auron: “Transcription factors NF-IL6 and CREB recognize a common essential site in the human prointerleukin 1 ⁇ gene”. Mol. Cell.
- Ehrlich “Binding of AP-1/CREB proteins and of MDBP to contiguous sites downstream of the human TGF-B1 gene”. Biochim. Biophys. Acta 1219:55, 1994.), TGF- ⁇ 2, class II MHC (Cox, P. M., and C. R. Goding: “An ATF/CREB binding motif is required for aberrant constitutive expression of the MHC class II DRa promoter and activation by SV40 T-antigen”. Nucl. Acids Res. 20:4881, 1992.), E-selectin, GM-CSF, CD-8 ⁇ , the germline Ig ⁇ constant region gene, the TCR V ⁇ gene, and the proliferating cell nuclear antigen (Huang, D., P. M.
- Activation of CREB through the cyclic AMP pathway requires protein kinase A (PKA), which phosphorylates CREB 341 on ser 133 and allows it to bind to a recently cloned protein, CBP (Kwok, R. P. S., J. R. Lundblad, J. C. Chrivia, J. P. Richards, H. P. Bachinger, R. G. Brennan, S. G. E. Roberts, M. R. Green, and R. H. Goodman: “Nuclear protein CBP is a coactivator for the transcription factor CREB”. Nature 370:223, 1994; Arias, J., A. S. Alberts, P. Brindle, F. X.
- PKA protein kinase A
- CBP basal transcription factor
- TFIIB basal transcription factor
- CREB also has been reported to interact with dTAFII 110, a TATA binding protein-associated factor whose binding may regulate transcription (Ferreri, K., G. Gill, and M. Montminy: “The cAMP-regulated transcription factor CREB interacts with a component of the TFIID complex”. Proc. Natl. Acad. Sci. USA 91:1210, 1994.).
- CREB/ATF proteins can specifically bind multiple other nuclear factors (Hoeffler, J. P., J. W. Lustbader, and C. -Y. Chen: “Identification of multiple nuclear factors that interact with cyclic adenosine 3′,5′-monophosphate response element-binding protein and activating transcription factor-2 by protein-protein interactions”. Mol. Endocrinol. 5:256, 1991) but the biologic significance of most of these interactions is unknown.
- CREB is normally thought to bind DNA either as a homodimer or as a heterodimer with several other proteins.
- CREB monomers constitutively activate transcription Krajewski, W., and K. A. W. Lee: “A monomeric derivative of the cellular transcription factor CREB functions as a constitutive activator”. Mol. Cell. Biol. 14:7204, 1994.).
- cytomegalovirus immediate early promoter one of the strongest known mammalian promoters, contains eleven copies of the CRE which are essential for promoter function (Chang, Y. -N., S. Crawford, J. Stall, D. R. Rawlins, K. -T. Jeang, and G. S. Hayward: “The palindromic series I repeats in the simian cytomegalovirus major immediate-early promoter behave as both strong basal enhancers and cyclic AMP response elements”. J. Virol.
- HTLV-1 Human T lymphotropic virus-I
- oligonucleotides do not include a GCG trinucleotide sequence at or near the 5′ and/or 3′ terminals and/or the consensus mitogenic CpG motif is not a palindrome.
- Prolonged immunostimulation can be obtained using stabilized oligonucleotides, particularly phosphorothioate stabilized oligonucleotides.
- the invention features useful therapies, which are based on the immunostimulatory activity of the nucleic acid molecules.
- the immunostimulatory nucleic acid molecules can be used to treat, prevent or ameliorate an immune system deficiency (e.g., a tumor or cancer or a viral, fungal, bacterial or parasitic infection in a subject).
- an immune system deficiency e.g., a tumor or cancer or a viral, fungal, bacterial or parasitic infection in a subject.
- immunostimulatory nucleic acid molecules can be administered to stimulate a subject's response to a vaccine.
- the instant claimed nucleic acid molecules can be administered to treat or prevent the symptoms of asthma.
- the instant claimed nucleic acid molecules can be administered in conjunction with a particular allergen to a subject as a type of desensitization therapy to treat or prevent the occurrence of an allergic reaction.
- immunostimulatory nucleic acid molecules to induce leukemic cells to enter the cell cycle supports the use of immunostimulatory nucleic acid molecules in treating leukemia by increasing the sensitivity of chronic leukemia cells and then administering conventional ablative chemotherapy, or combining the immunostimulatory nucleic acid molecules with another immunotherapy.
- FIG. 1A -C are graphs plotting dose-dependent IL-6 production in response to various DNA sequences in T cell depleted spleen cell cultures.
- ODN phosphodiester oligodeoxynucleotide
- SEQ ID NO:1 ATGGAAGGTCCAGTGTTCTC 3′
- CpG ODN 5′ ATCGACCTACGTGCGTTCTC 3′
- SEQ ID NO:3 5′ TCCATAACGTTCCTGATGCT 3′
- FIG. 2 is a graph plotting IL-6 production induced by CpG DNA in vivo as determined 1-8 hrs after injection. Data represent the mean from duplicate analyses of sera from two mice. BALB/c mice (two mice/group) were injected iv. with 100 ill of PBS ( ⁇ ) or 200 ⁇ g of CpG phosphorothioate ODN 5′ TCCATGACGTTCCTGATGCT 3′ (SEQ ID NO:7) ( ⁇ ) or non-CpG phosphorothioate ODN 5′ TCCATGAGCTTCCTGAGTCT 3′ (SEQ ID NO:8) ( ⁇ ).
- FIG. 3 is an autoradiograph showing IL-6 mRNA expression as determined by reverse transcription polymerase chain reaction in liver, spleen, and thymus at various time periods after in vivo stimulation of BALB/c mice (two mice/group) injected iv with 100 ⁇ l of PBS, 200 ⁇ g of CpG phosphorothioate ODN 5′ TCCATGACGTTCCTGATGCT 3′ (SEQ ID NO:7) or non-CpG phosphorothioate ODN 5′ TCCATGAGCTTCCTGAGTCT 3′ (SEQ ID NO:8).
- FIG. 4A is a graph plotting dose-dependent inhibition of CpG-induced IgM production by anti-IL-6.
- Splenic B-cells from DBA/2 mice were stimulated with CpG ODN 5′ TCCAAGACGTTCCTGATGCT 3′ (SEQ ID NO:9) in the presence of the indicated concentrations of neutralizing anti-IL-6 ( ⁇ ) or isotype control Ab ( ⁇ ) and IgM levels in culture supernatants determined by ELISA.
- ⁇ neutralizing anti-IL-6
- ⁇ isotype control Ab
- IgM levels in culture supernatants determined by ELISA.
- the anti-IL-6 Ab had no effect on IgM secretion ( ⁇ ).
- FIG. 4B is a graph plotting the stimulation index of CpG-induced splenic B cells cultured with anti-IL-6 and CpG S-ODN 5′ TCCATGACGTTCCTGATGCT 3′ (SEQ ID NO:7) ( ⁇ ) or anti-IL-6 antibody only ( ⁇ ). Data present the mean ⁇ standard deviation of triplicates.
- FIG. 5 is a bar graph plotting chloramphenicol acetyltransferase (CAT) activity in WEHI-231 cells transfected with a promoter-less CAT construct (pCAT), positive control plasmid (RSV), or IL-6 promoter-CAT construct alone or cultured with CpG 5′ TCCATGACGTTCCTGATGCT 3′ (SEQ ID NO:7) or non-CpG 5′ TCCATGAGCTTCCTGAGTCT 3′ (SEQ ID NO:8) phosphorothioate ODN at the indicated concentrations. Data present the mean of triplicates.
- FIG. 6 is a schematic overview of the immune effects of the immunostimulatory unmethylated CpG containing nucleic acids, which can directly activate both B cells and monocytic cells (including macrophages and dendritic cells) as shown.
- the immunostimulatory oligonucleotides do not directly activate purified NK cells, but render them competent to respond to IL-12 with a marked increase in their IFN- ⁇ production.
- the immunostimulatory nucleic acids promote a Th1 type immune response. No direct activation of proliferation of cytokine secretion by highly purified T cells has been found. However, the induction of Th1 cytokine secretion by the immunostimulatory oligonucleotides promotes the development of a cytotoxic lymphocyte response.
- FIG. 7 is an autoradiograph showing NF ⁇ B mRNA induction in monocytes treated with E. coli (EC) DNA (containing unmethylated CpG motifs), control (CT) DNA (containing no unmethylated CpG motifs) and lipopolysaccharide (LPS) at various measured times, 15 and 30 minutes after contact.
- E. coli E. coli
- CT control
- LPS lipopolysaccharide
- FIG. 8A shows the results from a flow cytometry study using mouse B cells with the dihydrorhodamine 123 dye to determine levels of reactive oxygen species.
- the dye only sample in Panel A of the figure shows the background level of cells positive for the dye at 28.6%.
- This level of reactive oxygen species was greatly increased to 80% in the cells treated for 20 minutes with PMA and ionomycin, a positive control (Panel B).
- the cells treated with the CpG oligo (TCCATGACGTTCCTGACGTT SEQ ID NO:10) also showed an increase in the level of reactive oxygen species such that more than 50% of the cells became positive (Panel D).
- FIG. 8B shows the results from a flow cytometry study using mouse B cells in the presence of chloroquine with the dihydrorhodamine 123 dye to determine levels of reactive oxygen species. Chloroquine slightly lowers the background level of reactive oxygen species in the cells such that the untreated cells in Panel A have only 4.3% that are positive. Chloroquine completely abolishes the induction of reactive oxygen species in the cells treated with CpG DNA (Panel B) but does not reduce the level of reactive oxygen species in the cells treated with PMA and ionomycin (Panel E).
- FIG. 9 is a graph plotting lung lavage cell count over time.
- the graph shows that when the mice are initially injected with Schistosoma mansoni eggs “egg”, which induces a Th2 immune response, and subsequently inhale Schistosoma mansoni egg antigen “SEA” (open circle), many inflammatory cells are present in the lungs.
- SEA Schistosoma mansoni egg antigen
Abstract
Description
- This application is a divisional of co-pending U.S. patent application Ser. No. 08/738,652, filed Oct. 30, 1996, which is a continuation-in-part of U.S. patent application Ser. No. 08/386,063, filed Feb. 7, 1995, now issued as U.S. Pat. No. 6,194,388, which is a continuation-in-part of U.S. patent application Ser. No. 08/276,358, filed Jul. 15, 1994, now abandoned.
- The work resulting in this invention was supported in part by National Institute of Health Grant No. R29-AR42556-01. The U.S. Government may therefore be entitled to certain rights in the invention.
- DNA binds to cell membranes and is internalized In the 1970's, several investigators reported the binding of high molecular weight DNA to cell membranes (Lerner, R. A., W. Meinke, and D. A. Goldstein. 1971. “Membrane-associated DNA in the cytoplasm of diploid human lymphocytes”. Proc. Natl. Acad. Sci. USA 68:1212; Agrawal, S. K., R. W. Wagner, P. K. McAllister, and B. Rosenberg. 1975. “Cell-surface-associated nucleic acid in tumorigenic cells made visible with platinum-pyrimidine complexes by electron microscopy”. Proc. Natl. Acad. Sci. USA 72:928). In 1985, Bennett et al. presented the first evidence that DNA binding to lymphocytes is similar to a ligand receptor interaction: binding is saturable, competitive, and leads to DNA endocytosis and degradation into oligonucleotides (Bennett, R. M., G. T. Gabor, and M. M. Merritt. 1985. “DNA binding to human leukocytes. Evidence for a receptor-mediated association, internalization, and degradation of DNA”. J. Clin. Invest. 76:2182). Like DNA, oligodeoxyribonucleotides (ODNs) are able to enter cells in a saturable, sequence independent, and temperature and energy dependent fashion (reviewed in Jaroszewski, J. W., and J. S. Cohen. 1991. “Cellular uptake of antisense oligodeoxynucleotides”. Advanced Drug Delivery Reviews 6:235; Akhtar, S., Y. Shoji, and R. L. Juliano. 1992. “Pharmaceutical aspects of the biological stability and membrane transport characteristics of antisense oligonucleotides”. In: Gene Regulation: Biology of Antisense RNA and DNA. R. P. Erickson, and J. G. Izant, eds. Raven Press, Ltd. New York, pp. 133; and Zhao, Q., T. Waldschmidt, E. Fisher, C. J. Herrera, and A. M. Krieg., 1994. “Stage specific oligonucleotide uptake in murine bone marrow B cell precursors”. Blood, 84:3660). No receptor for DNA or ODN uptake has yet been cloned, and it is not yet clear whether ODN binding and cell uptake occurs through the same or a different mechanism from that of high molecular weight DNA.
- Lymphocyte ODN uptake has been shown to be regulated by cell activation. Spleen cells stimulated with the B cell mitogen LPS had dramatically enhanced ODN uptake in the B cell population, while spleen cells treated with the T cell mitogen Con A showed enhanced ODN uptake by T but not B cells (Krieg, A. M., F. Gmelig-Meyling, M. F. Gourley, W. J. Kisch, L. A. Chrisey, and A. D. Steinberg. 1991. “Uptake of oligodeoxyribonucleotides by lymphoid cells is heterogeneous and inducible”. Antisense Research and Development 1:161).
- Immune Effects of Nucleic Acids
- Several polynucleotides have been extensively evaluated as biological response modifiers. Perhaps the best example is poly (I,C) which is a potent inducer of IFN production as well as a macrophage activator and inducer of NK activity (Talmadge, J. E., J. Adams, H. Phillips, M. Collins, B. Lenz, M. Schneider, E. Schlick, R. Ruffmann, R. H. Wiltrout, and M. A. Chirigos. 1985. “Immunomodulatory effects in mice of polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose”. Cancer Res. 45:1058; Wiltrout, R. H., R. R. Salup, T. A. Twilley, and J. E. Talmadge. 1985. “Immunomodulation of natural killer activity by polyribonucleotides”. J. Biol. Resp. Mod. 4:512; Krown, S. E. 1986. “Interferons and interferon inducers in cancer treatment”. Sem. Oncol. 13:207; and Ewel, C. H., S. J. Urba, W. C. Kopp, J. W. Smith II, R. G. Steis, J. L. Rossio, D. L. Longo, M. J. Jones, W. G. Alvord, C. M. Pinsky, J. M. Beveridge, K. L. McNitt, and S. P. Creekmore. 1992. “Polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose in combination with interleukin-2 in patients with cancer: clinical and immunological effects”. Canc. Res. 52:3005). It appears that this murine NK activation may be due solely to induction of IFN-β secretion (Ishikawa, R., and C. A. Biron. 1993. “IFN induction and associated changes in splenic leukocyte distribution”. J. Immunol. 150:3713). This activation was specific for the ribose sugar since deoxyribose was ineffective. Its potent in vitro antitumor activity led to several clinical trials using poly (I,C) complexed with poly-L-lysine and carboxymethylcellulose (to reduce degradation by RNAse) (Talmadge, J. E., et al., 1985. cited supra; Wiltrout, R. H., et al., 1985. cited supra); Krown, S. E., 1986. cited supra); and Ewel, C. H., et al., 1992. cited supra). Unfortunately, toxic side effects have thus far prevented poly (I,C) from becoming a useful therapeutic agent.
- Guanine ribonucleotides substituted at the C8 position with either a bromine or a thiol group are B cell mitogens and may replace “B cell differentiation factors” (Feldbush, T. L., and Z. K. Ballas. 1985. “Lymphokine-like activity of 8-mercaptoguanosine: induction of T and B cell differentiation”. J. Immunol. 134:3204; and Goodman, M. G. 1986. “Mechanism of synergy between T cell signals and C8-substituted guanine nucleosides in humoral immunity: B lymphotropic cytokines induce responsiveness to 8-mercaptoguanosine”. J. Immunol. 136:3335). 8-mercaptoguanosine and 8-bromoguanosine also can substitute for the cytokine requirement for the generation of MHC restricted CTL (Feldbush, T. L., 1985. cited supra), augment murine NK activity (Koo, G. C., M. E. Jewell, C. L. Manyak, N. H. Sigal, and L. S. Wicker. 1988. “Activation of murine natural killer cells and macrophages by 8-bromoguanosine”. J. Immunol. 140:3249), and synergize with IL-2 in inducing murine LAK generation (Thompson, R. A., and Z. K. Ballas. 1990. “Lymphokine-activated killer (LAK) cells. V. 8-Mercaptoguanosine as an IL-2-sparing agent in LAK generation”. J. Immunol. 145:3524). The NK and LAK augmenting activities of these C8-substituted guanosines appear to be due to their induction of IFN (Thompson, R. A., et al. 1990. cited supra). Recently, a 5′ triphosphorylated thymidine produced by a mycobacterium was found to be mitogenic for a subset of human γδ T cells (Constant, P., F. Davodeau, M. -A. Peyrat, Y. Poquet, G. Puzo, M. Bonneville, and J. -J. Foumie. 1994. “Stimulation of human γδ T cells by nonpeptidic mycobacterial ligands” Science 264:267). This report indicated the possibility that the immune system may have evolved ways to preferentially respond to microbial nucleic acids.
- Several observations suggest that certain DNA structures may also have the potential to activate lymphocytes. For example, Bell et al. reported that nucleosomal protein-DNA complexes (but not naked DNA) in spleen cell supernatants caused B cell proliferation and immunoglobulin secretion (Bell, D. A., B. Morrison, and P. VandenBygaart. 1990. “Immunogenic DNA-related factors”. J. Clin. Invest. 85:1487). In other cases, naked DNA has been reported to have immune effects. For example, Messina et al. have recently reported that 260 to 800 bp fragments of poly (dG)·(dC) and poly (dG·dC) were mitogenic for B cells (Messina, J. P., G. S. Gilkeson, and D. S. Pisetsky. 1993. “The influence of DNA structure on the in vitro stimulation of murine lymphocytes by natural and synthetic polynucleotide antigens”. Cell. Immunol. 147:148). Tokunaga, et al. have reported that dG·dC induces IFN-γ and NK activity (Tokunaga, S. Yamamoto, and K. Namba. 1988. “A synthetic single-stranded DNA, poly(dG,dC), induces interferon-α/β and -γ, augments natural killer activity, and suppresses tumor growth” Jpn. J Cancer Res. 79:682). Aside from such artificial homopolymer sequences, Pisetsky et al. reported that pure mammalian DNA has no detectable immune effects, but that DNA from certain bacteria induces B cell activation and immunoglobulin secretion (Messina, J. P., G. S. Gilkeson, and D. S. Pisetsky. 1991. “Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA”. J. Immunol. 147:1759). Assuming that these data did not result from some unusual contaminant, these studies suggested that a particular structure or other characteristic of bacterial DNA renders it capable of triggering B cell activation. Investigations of mycobacterial DNA sequences have demonstrated that ODN which contain certain palindrome sequences can activate NK cells (Yamamoto, S., T. Yamamoto, T. Kataoka, E. Kuramoto, O. Yano, and T. Tokunaga. 1992. “Unique palindromic sequences in synthetic oligonucleotides are required to induce INF and augment INF-mediated natural killer activity”. J. Immunol. 148:4072; Kuramoto, E., O. Yano, Y. Kimura, M. Baba, T. Makino, S. Yamamoto, T. Yamamoto, T. Kataoka, and T. Tokunaga. 1992. “Oligonucleotide sequences required for natural killer cell activation”. Jpn. J. Cancer Res. 83:1128).
- Several phosphorothioate modified ODN have been reported to induce in vitro or in vivo B cell stimulation (Tanaka, T., C. C. Chu, and W. E. Paul. 1992. “An antisense oligonucleotide complementary to a sequence in Iγ2b increases γ2b germline transcripts, stimulates B cell DNA synthesis, and inhibits immunoglobulin secretion”. J. Exp. Med. 175:597; Branda, R. F., A. L. Moore, L. Mathews, J. J. McCormack, and G. Zon. 1993. “Immune stimulation by an antisense oligomer complementary to the rev gene of HIV-1”. Biochem. Pharmacol. 45:2037; McIntyre, K. W., K. Lombard-Gillooly, J. R. Perez, C. Kunsch, U. M. Sarmiento, J. D. Larigan, K. T. Landreth, and R. Narayanan. 1993. “A sense phosphorothioate oligonucleotide directed to the initiation codon of transcription factor NFκB T65 causes sequence-specific immune stimulation”. Antisense Res. Develop. 3:309; and Pisetsky, D. S., and C. F. Reich. 1993. “Stimulation of murine lymphocyte proliferation by a phosphorothioate oligonucleotide with antisense activity for herpes simplex virus”. Life Sciences 54:101). These reports do not suggest a common structural motif or sequence element in these ODN that might explain their effects.
- The CREB/ATF Family of Transcription Factors and Their Role in Replication
- The cAMP response element binding protein (CREB) and activating transcription factor (ATF) or CREB/ATF family of transcription factors is a ubiquitously expressed class of transcription factors of which 11 members have so far been cloned (reviewed in de Groot, R. P., and P. Sassone-Corsi: “Hormonal control of gene expression: Multiplicity and versatility of
cyclic adenosine 3′,5′-monophosphate-responsive nuclear regulators”. Mol. Endocrin. 7:145, 1993; Lee, K. A. W., and N. Masson: “Transcriptional regulation by CREB and its relatives”. Biochim. Biophys. Acta 1174:221, 1993.). They all belong to the basic region/leucine zipper (bZip) class of proteins. All cells appear to express one or more CREB/ATF proteins, but the members expressed and the regulation of mRNA splicing appear to be tissue-specific. Differential splicing of activation domains can determine whether a particular CREB/ATF protein will be a transcriptional inhibitor or activator. Many CREB/ATF proteins activate viral transcription, but some splicing variants which lack the activation domain are inhibitory. CREB/ATF proteins can bind DNA as homo- or hetero-dimers through the cAMP response element, the CRE, the consensus form of which is the umethylated sequence TGACGTC (binding is abolished if the CpG is methylated) (Iguchi-Ariga, S. M. M., and W. Schaffner: “CpG methylation of the cAMP-responsive enhancer/promoter sequence TGACGTCA abolishes specific factor binding as well as transcriptional activation”. Genes & Develop. 3:612, 1989.). - The transcriptional activity of the CRE is increased during B cell activation (Xie, H. T. C. Chiles, and T. L. Rothstein: “Induction of CREB activity via the surface Ig receptor of B cells”. J. Immunol. 151:880, 1993.). CREB/ATF proteins appear to regulate the expression of multiple genes through the CRE including immunologically important genes such as fos, jun B, Rb-1, IL-6, IL-1 (Tsukada, J., K. Saito, W. R. Waterman, A. C. Webb, and P. E. Auron: “Transcription factors NF-IL6 and CREB recognize a common essential site in the human prointerleukin 1β gene”. Mol. Cell. Biol. 14:7285, 1994; Gray, G. D., O. M. Hernandez, D. Hebel, M. Root, J. M. Pow-Sang, and E. Wickstrom: “Antisense DNA inhibition of tumor growth induced by c-Ha-ras oncogene in nude mice”. Cancer Res. 53:577, 1993), IFN-β (Du, W., and T. Maniatis: “An ATF/CREB binding site protein is required for virus induction of the human interferon B gene”. Proc. Natl. Acad. Sci. USA 89:2150, 1992), TGF-β1 (Asiedu, C. K., L. Scott, R. K. Assoian, M. Ehrlich: “Binding of AP-1/CREB proteins and of MDBP to contiguous sites downstream of the human TGF-B1 gene”. Biochim. Biophys. Acta 1219:55, 1994.), TGF-β2, class II MHC (Cox, P. M., and C. R. Goding: “An ATF/CREB binding motif is required for aberrant constitutive expression of the MHC class II DRa promoter and activation by SV40 T-antigen”. Nucl. Acids Res. 20:4881, 1992.), E-selectin, GM-CSF, CD-8α, the germline Igα constant region gene, the TCR Vβ gene, and the proliferating cell nuclear antigen (Huang, D., P. M. Shipman-Appasamy, D. J. Orten, S. H. Hinrichs, and M. B. Prystowsky: “Promoter activity of the proliferating-cell nuclear antigen gene is associated with inducible CRE-binding proteins in interleukin 2-stimulated T lymphocytes”. Mol. Cell. Biol. 14:4233, 1994.). In addition to activation through the cAMP pathway, CREB can also mediate transcriptional responses to changes in intracellular Ca++ concentration (Sheng, M., G. McFadden, and M. E. Greenberg: “Membrane depolarization and calcium induce c-fos transcription via phosphorylation of transcription factor CREB”. Neuron 4:571, 1990).
- The role of protein-protein interactions in transcriptional activation by CREB/ATF proteins appears to be extremely important. There are several published studies reporting direct or indirect interactions between NFκB proteins and CREB/ATF proteins (Whitley, et. al., (1994) Mol. & Cell. Biol. 14:6464; Cogswell, et al., (1994) J. Immun. 153:712; Hines, et al., (1993) Oncogene 8:3189; and Du, et al., (1993) Cell 74:887. Activation of CREB through the cyclic AMP pathway requires protein kinase A (PKA), which phosphorylates CREB341 on ser133 and allows it to bind to a recently cloned protein, CBP (Kwok, R. P. S., J. R. Lundblad, J. C. Chrivia, J. P. Richards, H. P. Bachinger, R. G. Brennan, S. G. E. Roberts, M. R. Green, and R. H. Goodman: “Nuclear protein CBP is a coactivator for the transcription factor CREB”. Nature 370:223, 1994; Arias, J., A. S. Alberts, P. Brindle, F. X. Claret, T. Smea, M. Karin, J. Feramisco, and M. Montminy: “Activation of cAMP and mitogen responsive genes relies on a common nuclear factor”. Nature 370:226, 1994.). CBP in turn interacts with the basal transcription factor TFIIB causing increased transcription. CREB also has been reported to interact with
dTAFII 110, a TATA binding protein-associated factor whose binding may regulate transcription (Ferreri, K., G. Gill, and M. Montminy: “The cAMP-regulated transcription factor CREB interacts with a component of the TFIID complex”. Proc. Natl. Acad. Sci. USA 91:1210, 1994.). In addition to these interactions, CREB/ATF proteins can specifically bind multiple other nuclear factors (Hoeffler, J. P., J. W. Lustbader, and C. -Y. Chen: “Identification of multiple nuclear factors that interact withcyclic adenosine 3′,5′-monophosphate response element-binding protein and activating transcription factor-2 by protein-protein interactions”. Mol. Endocrinol. 5:256, 1991) but the biologic significance of most of these interactions is unknown. CREB is normally thought to bind DNA either as a homodimer or as a heterodimer with several other proteins. Surprisingly, CREB monomers constitutively activate transcription (Krajewski, W., and K. A. W. Lee: “A monomeric derivative of the cellular transcription factor CREB functions as a constitutive activator”. Mol. Cell. Biol. 14:7204, 1994.). - Aside from their critical role in regulating cellular transcription, it has recently been shown that CREB/ATF proteins are subverted by some infectious viruses and retroviruses, which require them for viral replication. For example, the cytomegalovirus immediate early promoter, one of the strongest known mammalian promoters, contains eleven copies of the CRE which are essential for promoter function (Chang, Y. -N., S. Crawford, J. Stall, D. R. Rawlins, K. -T. Jeang, and G. S. Hayward: “The palindromic series I repeats in the simian cytomegalovirus major immediate-early promoter behave as both strong basal enhancers and cyclic AMP response elements”. J. Virol. 64:264, 1990). At least some of the transcriptional activating effects of the adenovirus E1A protein, which induces many promoters, are due to its binding to the DNA binding domain of the CREB/ATF protein, ATF-2, which mediates E1A inducible transcription activation (Liu, F., and M. R. Green: “Promoter targeting by adenovirus E1a through interaction with different cellular DNA-binding domains”. Nature 368:520, 1994). It has also been suggested that E1A binds to the CREB-binding protein, CBP (Arany, Z., W. R. Sellers, D. M. Livingston, and R. Eckner: “E1A-associated p300 and CREB-associated CBP belong to a conserved family of coactivators”. Cell 77:799, 1994). Human T lymphotropic virus-I (HTLV-1), the retrovirus which causes human T cell leukemia and tropical spastic paresis, also requires CREB/ATF proteins for replication. In this case, the retrovirus produces a protein, Tax, oligonucleotides do not include a GCG trinucleotide sequence at or near the 5′ and/or 3′ terminals and/or the consensus mitogenic CpG motif is not a palindrome. Prolonged immunostimulation can be obtained using stabilized oligonucleotides, particularly phosphorothioate stabilized oligonucleotides.
- In a second aspect, the invention features useful therapies, which are based on the immunostimulatory activity of the nucleic acid molecules. For example, the immunostimulatory nucleic acid molecules can be used to treat, prevent or ameliorate an immune system deficiency (e.g., a tumor or cancer or a viral, fungal, bacterial or parasitic infection in a subject). In addition, immunostimulatory nucleic acid molecules can be administered to stimulate a subject's response to a vaccine.
- Further, by redirecting a subject's immune response from Th2 to Th1, the instant claimed nucleic acid molecules can be administered to treat or prevent the symptoms of asthma. In addition, the instant claimed nucleic acid molecules can be administered in conjunction with a particular allergen to a subject as a type of desensitization therapy to treat or prevent the occurrence of an allergic reaction.
- Further, the ability of immunostimulatory nucleic acid molecules to induce leukemic cells to enter the cell cycle supports the use of immunostimulatory nucleic acid molecules in treating leukemia by increasing the sensitivity of chronic leukemia cells and then administering conventional ablative chemotherapy, or combining the immunostimulatory nucleic acid molecules with another immunotherapy.
- Other features and advantages of the invention will become more apparent from the following detailed description and claims.
-
FIG. 1A -C are graphs plotting dose-dependent IL-6 production in response to various DNA sequences in T cell depleted spleen cell cultures. A. E. coli DNA (●) and calf thymus DNA (▪) sequences and LPS (at 10× the concentration of E. coli and calf thymus DNA) (♦). B. Control phosphodiester oligodeoxynucleotide (ODN) 5′ATGGAAGGTCCAGTGTTCTC3′ (SEQ ID NO:1) (▪) and two phosphodiester CpG ODN5′ATCGACCTACGTGCGTTCTC3′ (SEQ ID NO:2) (♦) and 5′TCCATAACGTTCCTGATGCT3′ (SEQ ID NO:3) (●). C. Control phosphorothioate ODN5′GCTAGATGTTAGCGT3′ (SEQ ID NO:4) (▪) and two phosphorothioate CpG ODN5′GAGAACGTCGACCTTCGAT3′ (SEQ ID NO:5) (♦) and 5′GCATGACGTTGAGCT3′ (SEQ ID NO:6) (●). Data present the mean±standard deviation of triplicates. -
FIG. 2 is a graph plotting IL-6 production induced by CpG DNA in vivo as determined 1-8 hrs after injection. Data represent the mean from duplicate analyses of sera from two mice. BALB/c mice (two mice/group) were injected iv. with 100 ill of PBS (□) or 200 μg ofCpG phosphorothioate ODN 5′TCCATGACGTTCCTGATGCT 3′ (SEQ ID NO:7) (ζ) ornon-CpG phosphorothioate ODN 5′TCCATGAGCTTCCTGAGTCT 3′ (SEQ ID NO:8) (♦). -
FIG. 3 is an autoradiograph showing IL-6 mRNA expression as determined by reverse transcription polymerase chain reaction in liver, spleen, and thymus at various time periods after in vivo stimulation of BALB/c mice (two mice/group) injected iv with 100 μl of PBS, 200 μg ofCpG phosphorothioate ODN 5′TCCATGACGTTCCTGATGCT 3′ (SEQ ID NO:7) ornon-CpG phosphorothioate ODN 5′TCCATGAGCTTCCTGAGTCT 3′ (SEQ ID NO:8). -
FIG. 4A is a graph plotting dose-dependent inhibition of CpG-induced IgM production by anti-IL-6. Splenic B-cells from DBA/2 mice were stimulated with CpG ODN5′TCCAAGACGTTCCTGATGCT3′ (SEQ ID NO:9) in the presence of the indicated concentrations of neutralizing anti-IL-6 (♦) or isotype control Ab (●) and IgM levels in culture supernatants determined by ELISA. In the absence of CpG ODN, the anti-IL-6 Ab had no effect on IgM secretion (▪). -
FIG. 4B is a graph plotting the stimulation index of CpG-induced splenic B cells cultured with anti-IL-6 and CpG S-ODN 5′TCCATGACGTTCCTGATGCT 3′ (SEQ ID NO:7) (♦) or anti-IL-6 antibody only (▪). Data present the mean±standard deviation of triplicates. -
FIG. 5 is a bar graph plotting chloramphenicol acetyltransferase (CAT) activity in WEHI-231 cells transfected with a promoter-less CAT construct (pCAT), positive control plasmid (RSV), or IL-6 promoter-CAT construct alone or cultured withCpG 5′TCCATGACGTTCCTGATGCT 3′ (SEQ ID NO:7) or non-CpG 5′TCCATGAGCTTCCTGAGTCT 3′ (SEQ ID NO:8) phosphorothioate ODN at the indicated concentrations. Data present the mean of triplicates. -
FIG. 6 is a schematic overview of the immune effects of the immunostimulatory unmethylated CpG containing nucleic acids, which can directly activate both B cells and monocytic cells (including macrophages and dendritic cells) as shown. The immunostimulatory oligonucleotides do not directly activate purified NK cells, but render them competent to respond to IL-12 with a marked increase in their IFN-γ production. By inducing IL-12 production and the subsequent increased IFN-γ secretion by NK cells, the immunostimulatory nucleic acids promote a Th1 type immune response. No direct activation of proliferation of cytokine secretion by highly purified T cells has been found. However, the induction of Th1 cytokine secretion by the immunostimulatory oligonucleotides promotes the development of a cytotoxic lymphocyte response. -
FIG. 7 is an autoradiograph showing NFκB mRNA induction in monocytes treated with E. coli (EC) DNA (containing unmethylated CpG motifs), control (CT) DNA (containing no unmethylated CpG motifs) and lipopolysaccharide (LPS) at various measured times, 15 and 30 minutes after contact. -
FIG. 8A shows the results from a flow cytometry study using mouse B cells with the dihydrorhodamine 123 dye to determine levels of reactive oxygen species. The dye only sample in Panel A of the figure shows the background level of cells positive for the dye at 28.6%. This level of reactive oxygen species was greatly increased to 80% in the cells treated for 20 minutes with PMA and ionomycin, a positive control (Panel B). The cells treated with the CpG oligo (TCCATGACGTTCCTGACGTT SEQ ID NO:10) also showed an increase in the level of reactive oxygen species such that more than 50% of the cells became positive (Panel D). However, cells treated with an oligonucleotide with the identical sequence except that the CpGs were switched (TCCATGAGCTTCCTGAGTGCT SEQ ID NO:11) did not show this significant increase in the level of reactive oxygen species (Panel E). -
FIG. 8B shows the results from a flow cytometry study using mouse B cells in the presence of chloroquine with the dihydrorhodamine 123 dye to determine levels of reactive oxygen species. Chloroquine slightly lowers the background level of reactive oxygen species in the cells such that the untreated cells in Panel A have only 4.3% that are positive. Chloroquine completely abolishes the induction of reactive oxygen species in the cells treated with CpG DNA (Panel B) but does not reduce the level of reactive oxygen species in the cells treated with PMA and ionomycin (Panel E). -
FIG. 9 is a graph plotting lung lavage cell count over time. The graph shows that when the mice are initially injected with Schistosoma mansoni eggs “egg”, which induces a Th2 immune response, and subsequently inhale Schistosoma mansoni egg antigen “SEA” (open circle), many inflammatory cells are present in the lungs. However, when the mice are initially given CpG oligo (SEQ ID NO:10) along with egg, the
Claims (16)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/888,449 US20050049215A1 (en) | 1994-07-15 | 2004-07-09 | Immunostimulatory nucleic acid molecules |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27635894A | 1994-07-15 | 1994-07-15 | |
US08/386,063 US6194388B1 (en) | 1994-07-15 | 1995-02-07 | Immunomodulatory oligonucleotides |
US08/738,652 US6207646B1 (en) | 1994-07-15 | 1996-10-30 | Immunostimulatory nucleic acid molecules |
US09/818,918 US20030050261A1 (en) | 1994-07-15 | 2001-03-27 | Immunostimulatory nucleic acid molecules |
US10/888,449 US20050049215A1 (en) | 1994-07-15 | 2004-07-09 | Immunostimulatory nucleic acid molecules |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/818,918 Continuation US20030050261A1 (en) | 1994-07-15 | 2001-03-27 | Immunostimulatory nucleic acid molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050049215A1 true US20050049215A1 (en) | 2005-03-03 |
Family
ID=24968901
Family Applications (32)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/738,652 Expired - Lifetime US6207646B1 (en) | 1994-07-15 | 1996-10-30 | Immunostimulatory nucleic acid molecules |
US09/818,918 Abandoned US20030050261A1 (en) | 1994-07-15 | 2001-03-27 | Immunostimulatory nucleic acid molecules |
US10/435,656 Abandoned US20050277604A1 (en) | 1994-07-15 | 2003-05-09 | Immunostimulatory nucleic acid molecules |
US10/613,916 Abandoned US20050070491A1 (en) | 1994-07-15 | 2003-07-03 | Immunostimulatory nucleic acid molecules |
US10/679,710 Abandoned US20040147468A1 (en) | 1994-07-15 | 2003-10-03 | Immunostimulatory nucleic acid molecules |
US10/743,625 Abandoned US20040132685A1 (en) | 1994-07-15 | 2003-12-22 | Immunostimulatory nucleic acid |
US10/769,282 Expired - Fee Related US7674777B2 (en) | 1994-07-15 | 2004-01-30 | Immunostimulatory nucleic acid molecules |
US10/817,165 Abandoned US20040198688A1 (en) | 1994-07-15 | 2004-04-02 | Immunostimulatory nucleic acid molecules |
US10/831,647 Expired - Fee Related US7402572B2 (en) | 1994-07-15 | 2004-04-23 | Immunostimulatory nucleic acid molecules |
US10/847,642 Abandoned US20050004061A1 (en) | 1994-07-15 | 2004-05-17 | Immunostimulatory nucleic acid molecules |
US10/877,407 Abandoned US20040229835A1 (en) | 1994-07-15 | 2004-06-24 | Immunostimulatory nucleic acid molecules |
US10/884,852 Abandoned US20050059625A1 (en) | 1994-07-15 | 2004-07-02 | Immunostimulatory nucleic acid molecules |
US10/888,785 Expired - Fee Related US7517861B2 (en) | 1994-07-15 | 2004-07-09 | Immunostimulatory nucleic acid molecules |
US10/888,449 Abandoned US20050049215A1 (en) | 1994-07-15 | 2004-07-09 | Immunostimulatory nucleic acid molecules |
US10/894,862 Expired - Fee Related US8058249B2 (en) | 1994-07-15 | 2004-07-16 | Immunostimulatory nucleic acid molecules |
US10/894,657 Abandoned US20050054602A1 (en) | 1994-07-15 | 2004-07-16 | Immunostimulatory nucleic acid molecules |
US10/928,762 Abandoned US20050123523A1 (en) | 1994-07-15 | 2004-08-26 | Immunostimulatory nucleic acid molecules |
US10/956,745 Abandoned US20050239732A1 (en) | 1994-07-15 | 2004-10-01 | Immunostimulatory nucleic acid molecules |
US10/956,494 Expired - Fee Related US7879810B2 (en) | 1994-07-15 | 2004-10-01 | Immunostimulatory nucleic acid molecules |
US10/972,301 Abandoned US20050215500A1 (en) | 1994-07-15 | 2004-10-22 | Immunostimulatory nucleic acid molecules |
US10/987,146 Abandoned US20050148537A1 (en) | 1994-07-15 | 2004-11-12 | Immunostimulatory nucleic acid molecules |
US11/031,460 Expired - Fee Related US8158592B2 (en) | 1994-07-15 | 2005-01-07 | Immunostimulatory nucleic acid molecules |
US11/036,527 Expired - Fee Related US7723022B2 (en) | 1994-07-15 | 2005-01-14 | Immunostimulatory nucleic acid molecules |
US11/067,587 Expired - Fee Related US8129351B2 (en) | 1994-07-15 | 2005-02-25 | Immunostimulatory nucleic acid molecules |
US11/134,918 Abandoned US20050267064A1 (en) | 1994-07-15 | 2005-05-23 | Immunostimulatory nucleic acid molecules |
US11/296,572 Abandoned US20060089326A1 (en) | 1994-07-15 | 2005-12-07 | Immunostimulatory nucleic acid molecules |
US11/503,483 Expired - Fee Related US7723500B2 (en) | 1994-07-15 | 2006-08-11 | Immunostimulatory nucleic acid molecules |
US11/526,197 Abandoned US20070078104A1 (en) | 1994-07-15 | 2006-09-22 | Immunostimulatory nucleic acid molecules |
US11/598,207 Expired - Fee Related US8258106B2 (en) | 1994-07-15 | 2006-11-10 | Immunostimulatory nucleic acid molecules |
US11/810,353 Abandoned US20080026011A1 (en) | 1994-07-15 | 2007-06-05 | Immunostimulatory nucleic acid molecules |
US12/248,493 Abandoned US20090202575A1 (en) | 1994-07-15 | 2008-10-09 | Immunostimulatory nucleic acid molecules |
US12/383,824 Expired - Fee Related US7888327B2 (en) | 1994-07-15 | 2009-03-25 | Methods of using immunostimulatory nucleic acid molecules to treat allergic conditions |
Family Applications Before (13)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/738,652 Expired - Lifetime US6207646B1 (en) | 1994-07-15 | 1996-10-30 | Immunostimulatory nucleic acid molecules |
US09/818,918 Abandoned US20030050261A1 (en) | 1994-07-15 | 2001-03-27 | Immunostimulatory nucleic acid molecules |
US10/435,656 Abandoned US20050277604A1 (en) | 1994-07-15 | 2003-05-09 | Immunostimulatory nucleic acid molecules |
US10/613,916 Abandoned US20050070491A1 (en) | 1994-07-15 | 2003-07-03 | Immunostimulatory nucleic acid molecules |
US10/679,710 Abandoned US20040147468A1 (en) | 1994-07-15 | 2003-10-03 | Immunostimulatory nucleic acid molecules |
US10/743,625 Abandoned US20040132685A1 (en) | 1994-07-15 | 2003-12-22 | Immunostimulatory nucleic acid |
US10/769,282 Expired - Fee Related US7674777B2 (en) | 1994-07-15 | 2004-01-30 | Immunostimulatory nucleic acid molecules |
US10/817,165 Abandoned US20040198688A1 (en) | 1994-07-15 | 2004-04-02 | Immunostimulatory nucleic acid molecules |
US10/831,647 Expired - Fee Related US7402572B2 (en) | 1994-07-15 | 2004-04-23 | Immunostimulatory nucleic acid molecules |
US10/847,642 Abandoned US20050004061A1 (en) | 1994-07-15 | 2004-05-17 | Immunostimulatory nucleic acid molecules |
US10/877,407 Abandoned US20040229835A1 (en) | 1994-07-15 | 2004-06-24 | Immunostimulatory nucleic acid molecules |
US10/884,852 Abandoned US20050059625A1 (en) | 1994-07-15 | 2004-07-02 | Immunostimulatory nucleic acid molecules |
US10/888,785 Expired - Fee Related US7517861B2 (en) | 1994-07-15 | 2004-07-09 | Immunostimulatory nucleic acid molecules |
Family Applications After (18)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/894,862 Expired - Fee Related US8058249B2 (en) | 1994-07-15 | 2004-07-16 | Immunostimulatory nucleic acid molecules |
US10/894,657 Abandoned US20050054602A1 (en) | 1994-07-15 | 2004-07-16 | Immunostimulatory nucleic acid molecules |
US10/928,762 Abandoned US20050123523A1 (en) | 1994-07-15 | 2004-08-26 | Immunostimulatory nucleic acid molecules |
US10/956,745 Abandoned US20050239732A1 (en) | 1994-07-15 | 2004-10-01 | Immunostimulatory nucleic acid molecules |
US10/956,494 Expired - Fee Related US7879810B2 (en) | 1994-07-15 | 2004-10-01 | Immunostimulatory nucleic acid molecules |
US10/972,301 Abandoned US20050215500A1 (en) | 1994-07-15 | 2004-10-22 | Immunostimulatory nucleic acid molecules |
US10/987,146 Abandoned US20050148537A1 (en) | 1994-07-15 | 2004-11-12 | Immunostimulatory nucleic acid molecules |
US11/031,460 Expired - Fee Related US8158592B2 (en) | 1994-07-15 | 2005-01-07 | Immunostimulatory nucleic acid molecules |
US11/036,527 Expired - Fee Related US7723022B2 (en) | 1994-07-15 | 2005-01-14 | Immunostimulatory nucleic acid molecules |
US11/067,587 Expired - Fee Related US8129351B2 (en) | 1994-07-15 | 2005-02-25 | Immunostimulatory nucleic acid molecules |
US11/134,918 Abandoned US20050267064A1 (en) | 1994-07-15 | 2005-05-23 | Immunostimulatory nucleic acid molecules |
US11/296,572 Abandoned US20060089326A1 (en) | 1994-07-15 | 2005-12-07 | Immunostimulatory nucleic acid molecules |
US11/503,483 Expired - Fee Related US7723500B2 (en) | 1994-07-15 | 2006-08-11 | Immunostimulatory nucleic acid molecules |
US11/526,197 Abandoned US20070078104A1 (en) | 1994-07-15 | 2006-09-22 | Immunostimulatory nucleic acid molecules |
US11/598,207 Expired - Fee Related US8258106B2 (en) | 1994-07-15 | 2006-11-10 | Immunostimulatory nucleic acid molecules |
US11/810,353 Abandoned US20080026011A1 (en) | 1994-07-15 | 2007-06-05 | Immunostimulatory nucleic acid molecules |
US12/248,493 Abandoned US20090202575A1 (en) | 1994-07-15 | 2008-10-09 | Immunostimulatory nucleic acid molecules |
US12/383,824 Expired - Fee Related US7888327B2 (en) | 1994-07-15 | 2009-03-25 | Methods of using immunostimulatory nucleic acid molecules to treat allergic conditions |
Country Status (14)
Country | Link |
---|---|
US (32) | US6207646B1 (en) |
EP (5) | EP1714969A3 (en) |
JP (5) | JP2001503267A (en) |
KR (1) | KR100689942B1 (en) |
CN (2) | CN100338086C (en) |
AT (1) | ATE332966T1 (en) |
AU (3) | AU5242498A (en) |
CA (1) | CA2270345C (en) |
DE (1) | DE69736331T2 (en) |
DK (1) | DK0948510T3 (en) |
ES (2) | ES2624859T3 (en) |
NZ (1) | NZ335397A (en) |
PT (1) | PT948510E (en) |
WO (1) | WO1998018810A1 (en) |
Cited By (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020164341A1 (en) * | 1997-03-10 | 2002-11-07 | Loeb Health Research Institute At The Ottawa Hospital | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
US20030026801A1 (en) * | 2000-06-22 | 2003-02-06 | George Weiner | Methods for enhancing antibody-induced cell lysis and treating cancer |
US20030139364A1 (en) * | 2001-10-12 | 2003-07-24 | University Of Iowa Research Foundation | Methods and products for enhancing immune responses using imidazoquinoline compounds |
US20030148976A1 (en) * | 2001-08-17 | 2003-08-07 | Krieg Arthur M. | Combination motif immune stimulatory oligonucleotides with improved activity |
US20030191079A1 (en) * | 1994-07-15 | 2003-10-09 | University Of Iowa Research Foundation | Methods for treating and preventing infectious disease |
US20030212026A1 (en) * | 1999-09-25 | 2003-11-13 | University Of Iowa Research Foundation | Immunostimulatory nucleic acids |
US20030232074A1 (en) * | 2002-04-04 | 2003-12-18 | Coley Pharmaceutical Gmbh | Immunostimulatory G, U-containing oligoribonucleotides |
US20040067905A1 (en) * | 2002-07-03 | 2004-04-08 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US20040092472A1 (en) * | 2002-07-03 | 2004-05-13 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US20040131628A1 (en) * | 2000-03-08 | 2004-07-08 | Bratzler Robert L. | Nucleic acids for the treatment of disorders associated with microorganisms |
US20040142469A1 (en) * | 1994-07-15 | 2004-07-22 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
US20040147468A1 (en) * | 1994-07-15 | 2004-07-29 | Krieg Arthur M | Immunostimulatory nucleic acid molecules |
US20040152649A1 (en) * | 2002-07-03 | 2004-08-05 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US20040157791A1 (en) * | 1998-06-25 | 2004-08-12 | Dow Steven W. | Systemic immune activation method using nucleic acid-lipid complexes |
US20040171571A1 (en) * | 2002-12-11 | 2004-09-02 | Coley Pharmaceutical Group, Inc. | 5' CpG nucleic acids and methods of use |
US20040198680A1 (en) * | 2002-07-03 | 2004-10-07 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US20040235778A1 (en) * | 1998-05-14 | 2004-11-25 | Coley Pharmaceutical Gmbh | Methods for regulating hematopoiesis using CpG-oligonucleotides |
US20040235774A1 (en) * | 2000-02-03 | 2004-11-25 | Bratzler Robert L. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
US20050013812A1 (en) * | 2003-07-14 | 2005-01-20 | Dow Steven W. | Vaccines using pattern recognition receptor-ligand:lipid complexes |
US20050054601A1 (en) * | 1997-01-23 | 2005-03-10 | Coley Pharmaceutical Gmbh | Pharmaceutical composition comprising a polynucleotide and optionally an antigen especially for vaccination |
US20050059619A1 (en) * | 2002-08-19 | 2005-03-17 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids |
US20050075302A1 (en) * | 1994-03-25 | 2005-04-07 | Coley Pharmaceutical Group, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US20050101557A1 (en) * | 1994-07-15 | 2005-05-12 | The University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20050100983A1 (en) * | 2003-11-06 | 2005-05-12 | Coley Pharmaceutical Gmbh | Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling |
US20050119273A1 (en) * | 2003-06-20 | 2005-06-02 | Coley Pharmaceutical Gmbh | Small molecule toll-like receptor (TLR) antagonists |
US20050130911A1 (en) * | 2003-09-25 | 2005-06-16 | Coley Pharmaceutical Group, Inc. | Nucleic acid-lipophilic conjugates |
US20050181422A1 (en) * | 2000-09-15 | 2005-08-18 | Coley Pharmaceutical Gmbh | Process for high throughput screening of CpG-based immuno-agonist/antagonist |
US20050197314A1 (en) * | 1998-04-03 | 2005-09-08 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
US20050239734A1 (en) * | 2003-10-30 | 2005-10-27 | Coley Pharmaceutical Gmbh | C-class oligonucleotide analogs with enhanced immunostimulatory potency |
US20050239733A1 (en) * | 2003-10-31 | 2005-10-27 | Coley Pharmaceutical Gmbh | Sequence requirements for inhibitory oligonucleotides |
US20050256073A1 (en) * | 2004-02-19 | 2005-11-17 | Coley Pharmaceutical Group, Inc. | Immunostimulatory viral RNA oligonucleotides |
US20060003962A1 (en) * | 2002-10-29 | 2006-01-05 | Coley Pharmaceutical Group, Ltd. | Methods and products related to treatment and prevention of hepatitis C virus infection |
US20060140875A1 (en) * | 2004-10-20 | 2006-06-29 | Coley Pharmaceutical Group, Inc. | Semi-soft C-class immunostimulatory oligonucleotides |
US20060211644A1 (en) * | 2005-02-24 | 2006-09-21 | Coley Pharmaceutical Group, Inc. | Immunostimulatory oligonucleotides |
US20060229271A1 (en) * | 2005-04-08 | 2006-10-12 | Coley Pharmaceutical Group, Inc. | Methods for treating infectious disease exacerbated asthma |
US20060241076A1 (en) * | 2005-04-26 | 2006-10-26 | Coley Pharmaceutical Gmbh | Modified oligoribonucleotide analogs with enhanced immunostimulatory activity |
US20060286070A1 (en) * | 1999-09-27 | 2006-12-21 | Coley Pharmaceutical Gmbh | Methods related to immunostimulatory nucleic acid-induced interferon |
US20070009710A1 (en) * | 2000-08-04 | 2007-01-11 | Toyo Boseki Kabushiki Kaisha | Flexible metal-clad laminate and method for producing the same |
US20070065467A1 (en) * | 1994-07-15 | 2007-03-22 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US20080026986A1 (en) * | 2006-06-05 | 2008-01-31 | Rong-Fu Wang | Reversal of the suppressive function of specific t cells via toll-like receptor 8 signaling |
US20080045473A1 (en) * | 2006-02-15 | 2008-02-21 | Coley Pharmaceutical Gmbh | Compositions and methods for oligonucleotide formulations |
US20080226649A1 (en) * | 2000-12-08 | 2008-09-18 | Coley Pharmaceutical Gmbh | CPG-like nucleic acids and methods of use thereof |
US20090117132A1 (en) * | 2005-07-07 | 2009-05-07 | Pfizer, Inc. | Anti-Ctla-4 Antibody and Cpg-Motif-Containing Synthetic Oligodeoxynucleotide Combination Therapy for Cancer Treatment |
US20090142362A1 (en) * | 2006-11-06 | 2009-06-04 | Avant Immunotherapeutics, Inc. | Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP) |
US20090214578A1 (en) * | 2005-09-16 | 2009-08-27 | Coley Pharmaceutical Gmbh | Immunostimulatory Single-Stranded Ribonucleic Acid with Phosphodiester Backbone |
US20090306177A1 (en) * | 2005-09-16 | 2009-12-10 | Coley Pharmaceutical Gmbh | Modulation of Immunostimulatory Properties of Short Interfering Ribonucleic Acid (Sirna) by Nucleotide Modification |
US20090311277A1 (en) * | 2002-07-03 | 2009-12-17 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7662949B2 (en) | 2005-11-25 | 2010-02-16 | Coley Pharmaceutical Gmbh | Immunostimulatory oligoribonucleotides |
US7741300B2 (en) | 1998-06-25 | 2010-06-22 | National Jewish Medical And Research Center | Methods of using nucleic acid vector-lipid complexes |
US7776343B1 (en) | 1999-02-17 | 2010-08-17 | Csl Limited | Immunogenic complexes and methods relating thereto |
US8574599B1 (en) | 1998-05-22 | 2013-11-05 | Ottawa Hospital Research Institute | Methods and products for inducing mucosal immunity |
US8580268B2 (en) | 2006-09-27 | 2013-11-12 | Coley Pharmaceutical Gmbh | CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity |
US8883174B2 (en) | 2009-03-25 | 2014-11-11 | The Board Of Regents, The University Of Texas System | Compositions for stimulation of mammalian innate immune resistance to pathogens |
US10286065B2 (en) | 2014-09-19 | 2019-05-14 | Board Of Regents, The University Of Texas System | Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds |
Families Citing this family (780)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL105325A (en) * | 1992-04-16 | 1996-11-14 | Minnesota Mining & Mfg | Immunogen/vaccine adjuvant composition |
US6498147B2 (en) * | 1992-05-22 | 2002-12-24 | The Scripps Research Institute | Suppression of nuclear factor-κb dependent processes using oligonucleotides |
CA2110946A1 (en) * | 1992-12-09 | 1994-06-10 | Elazar Rabbani | Induction of immunocompatibility by nucleic acid |
US20030109469A1 (en) * | 1993-08-26 | 2003-06-12 | Carson Dennis A. | Recombinant gene expression vectors and methods for use of same to enhance the immune response of a host to an antigen |
US5849719A (en) * | 1993-08-26 | 1998-12-15 | The Regents Of The University Of California | Method for treating allergic lung disease |
US6825174B2 (en) * | 1995-06-07 | 2004-11-30 | East Carolina University | Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation |
US5981501A (en) * | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
US7034007B1 (en) * | 1995-06-07 | 2006-04-25 | East Carolina University | Low adenosine anti-sense oligonucleotide, compositions, kit & method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) & surfactant depletion |
US7422902B1 (en) * | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
ATE355375T1 (en) | 1996-01-04 | 2006-03-15 | Novartis Vaccines & Diagnostic | BACTERIOFERRITIN FROM HELICOBACTER PYLORI |
ATE437943T1 (en) * | 1996-01-30 | 2009-08-15 | Univ California | EXPRESSION VECTORS THAT INDUCE AN ANTIGEN-SPECIFIC IMMUNE RESPONSE AND METHODS FOR THEIR USE. |
US20030078223A1 (en) * | 1996-01-30 | 2003-04-24 | Eyal Raz | Compositions and methods for modulating an immune response |
US5898031A (en) * | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
US20050119470A1 (en) * | 1996-06-06 | 2005-06-02 | Muthiah Manoharan | Conjugated oligomeric compounds and their use in gene modulation |
US20040171031A1 (en) * | 1996-06-06 | 2004-09-02 | Baker Brenda F. | Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
US7812149B2 (en) | 1996-06-06 | 2010-10-12 | Isis Pharmaceuticals, Inc. | 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations |
US9096636B2 (en) | 1996-06-06 | 2015-08-04 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
US20040147022A1 (en) * | 1996-06-06 | 2004-07-29 | Baker Brenda F. | 2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations |
ES2241042T3 (en) | 1996-10-11 | 2005-10-16 | The Regents Of The University Of California | IMMUNO STIMULATOR POLINUCLEOTIDE CONJUGATES / IMMUNOMODULATOR MOLECULA. |
ES2290969T3 (en) | 1996-10-25 | 2008-02-16 | Minnesota Mining And Manufacturing Company | AMENDING COMPOUNDS OF THE IMMUNE RESPONSE FOR THE TREATMENT OF DISEASES MEDIATED BY TH2 AND RELATED. |
US6884435B1 (en) * | 1997-01-30 | 2005-04-26 | Chiron Corporation | Microparticles with adsorbent surfaces, methods of making same, and uses thereof |
AU747577B2 (en) * | 1997-01-30 | 2002-05-16 | Novartis Vaccines And Diagnostics, Inc. | Use of microparticles with adsorbed antigen to stimulate immune responses |
US6214806B1 (en) * | 1997-02-28 | 2001-04-10 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CPC dinucleotide in the treatment of LPS-associated disorders |
WO1998040100A1 (en) * | 1997-03-10 | 1998-09-17 | Ottawa Civic Loeb Research Institute | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT |
US6426334B1 (en) | 1997-04-30 | 2002-07-30 | Hybridon, Inc. | Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal |
US20030104044A1 (en) * | 1997-05-14 | 2003-06-05 | Semple Sean C. | Compositions for stimulating cytokine secretion and inducing an immune response |
CA2289702C (en) | 1997-05-14 | 2008-02-19 | Inex Pharmaceuticals Corp. | High efficiency encapsulation of charged therapeutic agents in lipid vesicles |
AU7690898A (en) | 1997-05-20 | 1998-12-11 | Ottawa Civic Hospital Loeb Research Institute | Vectors and methods for immunization or therapeutic protocols |
EP1003850B1 (en) | 1997-06-06 | 2009-05-27 | The Regents of the University of California | Inhibitors of dna immunostimulatory sequence activity |
EP1374894A3 (en) * | 1997-06-06 | 2004-09-22 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
US6589940B1 (en) | 1997-06-06 | 2003-07-08 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
US20040006034A1 (en) * | 1998-06-05 | 2004-01-08 | Eyal Raz | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
EP1009440B1 (en) * | 1997-07-03 | 2008-09-17 | MacFarlane, Donald E. | Method for inhibiting immunostimulatory dna associated responses |
AU2003203948B2 (en) * | 1997-09-05 | 2005-12-22 | The Regents Of The University Of California | Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation |
AU757175B2 (en) * | 1997-09-05 | 2003-02-06 | Regents Of The University Of California, The | Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation |
AU3884199A (en) * | 1998-05-06 | 1999-11-23 | Ottawa Health Research Institute | Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides |
CN1307473A (en) | 1998-05-19 | 2001-08-08 | 研究发展基金会 | Triterpene compositions and methods for use thereof |
KR19990086271A (en) * | 1998-05-27 | 1999-12-15 | 손경식 | Novel endonucleases of immune cells and immunoadjuvant using the same |
US6562798B1 (en) | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
US20040247662A1 (en) * | 1998-06-25 | 2004-12-09 | Dow Steven W. | Systemic immune activation method using nucleic acid-lipid complexes |
JP2002521489A (en) * | 1998-07-27 | 2002-07-16 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | Stereoisomers of CpG oligonucleotides and related methods |
PT1104306E (en) | 1998-08-10 | 2006-05-31 | Antigenics Inc | CPG COMPOSITIONS AND SAPONIN ADJUVANTS AND THEIR METHODS |
WO2000016804A1 (en) * | 1998-09-18 | 2000-03-30 | Dynavax Technologies Corporation | METHODS OF TREATING IgE-ASSOCIATED DISORDERS AND COMPOSITIONS FOR USE THEREIN |
WO2000021556A1 (en) * | 1998-10-09 | 2000-04-20 | Dynavax Technologies Corporation | Anti hiv compositions comprising immunostimulatory polynucleotides and hiv antigens |
US6867289B1 (en) * | 1998-10-26 | 2005-03-15 | Board Of Regents, The University Of Texas Systems | Thio-modified aptamer synthetic methods and compositions |
AU770464B2 (en) * | 1998-12-22 | 2004-02-19 | Seer Pharmaceuticals, Llc | Treatment of skin lesions |
US6558951B1 (en) * | 1999-02-11 | 2003-05-06 | 3M Innovative Properties Company | Maturation of dendritic cells with immune response modifying compounds |
PT1154790E (en) * | 1999-02-26 | 2005-03-31 | Chiron Srl | REFORCO OF THE ACTIVITY BACTERICIDE OF ANTIGEN AGAINST NEISSERIA WITH OLIGONUCLEOTIDOS CONTAINING REASONS CG |
CA2689696C (en) | 1999-02-26 | 2013-08-06 | Novartis Vaccines And Diagnostics, Inc. | Microemulsions with adsorbed macromolecules and microparticles |
GB2348132B (en) * | 1999-03-02 | 2004-08-04 | Nedaa Abdul-Ghani Nasif | Asthma/allergy therapy that targets t-lymphocytes and/or eosinophils |
FR2790955B1 (en) | 1999-03-19 | 2003-01-17 | Assist Publ Hopitaux De Paris | USE OF STABILIZED OLIGONUCLEOTIDES AS ANTI-TUMOR ACTIVE INGREDIENT |
AU4343700A (en) * | 1999-04-12 | 2000-11-14 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Oligodeoxynucleotide and its use to induce an immune response |
US6977245B2 (en) | 1999-04-12 | 2005-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
WO2000062803A2 (en) * | 1999-04-15 | 2000-10-26 | Board Of Regents, The University Of Texas System | ppGpp AND pppGpp AS IMMUNOMODULATORY AGENTS |
US6558670B1 (en) | 1999-04-19 | 2003-05-06 | Smithkline Beechman Biologicals S.A. | Vaccine adjuvants |
BRPI0010612B8 (en) | 1999-04-19 | 2021-05-25 | Smithkline Beecham Biologicals S A | vaccines |
GB9908885D0 (en) * | 1999-04-19 | 1999-06-16 | Smithkline Beecham Biolog | Vccine |
CA2370708A1 (en) * | 1999-04-20 | 2000-10-26 | Smithkline Beecham Biologicals S.A. | Vaccine comprising rsv antigen and cpg oligonucleotide |
ES2250151T3 (en) * | 1999-06-29 | 2006-04-16 | Glaxosmithkline Biologicals S.A. | USE OF CPG AS A VACCINE ASSISTANT AGAINST HIV. |
US20050002958A1 (en) * | 1999-06-29 | 2005-01-06 | Smithkline Beecham Biologicals Sa | Vaccines |
US6514948B1 (en) | 1999-07-02 | 2003-02-04 | The Regents Of The University Of California | Method for enhancing an immune response |
FR2795963A1 (en) * | 1999-07-08 | 2001-01-12 | Pasteur Merieux Serums Vacc | New polynucleotides are useful as vaccines for humans |
DE19935756A1 (en) * | 1999-07-27 | 2001-02-08 | Mologen Forschungs Entwicklung | Covalently closed nucleic acid molecule for immune stimulation |
US20050226890A1 (en) * | 1999-08-12 | 2005-10-13 | Cohen David I | Tat-based vaccine compositions and methods of making and using same |
CA2784789A1 (en) * | 1999-08-13 | 2001-02-22 | Idera Pharmaceuticals, Inc. | Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides |
DE60041335D1 (en) | 1999-08-19 | 2009-02-26 | Dynavax Tech Corp | METHOD FOR MODULATING AN IMMUNE RESPONSE WITH IMMUNOSTIMULATING SEQUENCES AND COMPOSITIONS THEREFOR |
US20050249794A1 (en) * | 1999-08-27 | 2005-11-10 | Semple Sean C | Compositions for stimulating cytokine secretion and inducing an immune response |
CN100368020C (en) * | 1999-08-27 | 2008-02-13 | 不列颠哥伦比亚大学 | Compositions for stimulating cytokine secretion and inducing an immune response |
EP1688147A1 (en) * | 1999-09-27 | 2006-08-09 | Coley Pharmaceutical Group, Inc. | Methods Related to Immunostimulatory Nucleic Acid-Induced Interferon |
WO2001022990A2 (en) * | 1999-09-27 | 2001-04-05 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
ES2564463T3 (en) | 1999-10-29 | 2016-03-22 | Glaxosmithkline Biologicals S.A. | Neisserial antigenic peptides |
US7223398B1 (en) | 1999-11-15 | 2007-05-29 | Dynavax Technologies Corporation | Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof |
EP1322655B1 (en) * | 2000-01-14 | 2007-11-14 | The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services | Oligodeoxynucleotide and its use to induce an immune response |
US20010044416A1 (en) * | 2000-01-20 | 2001-11-22 | Mccluskie Michael J. | Immunostimulatory nucleic acids for inducing a Th2 immune response |
US6552006B2 (en) | 2000-01-31 | 2003-04-22 | The Regents Of The University Of California | Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen |
US20030130217A1 (en) * | 2000-02-23 | 2003-07-10 | Eyal Raz | Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
AU4175101A (en) | 2000-02-23 | 2001-09-03 | Univ California | Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
WO2001062092A1 (en) * | 2000-02-25 | 2001-08-30 | Thomas Jefferson University | Formulations and methods for using the same to elicit an immune response |
US7157437B2 (en) | 2000-03-10 | 2007-01-02 | Dynavax Technologies Corporation | Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences |
US7129222B2 (en) * | 2000-03-10 | 2006-10-31 | Dynavax Technologies Corporation | Immunomodulatory formulations and methods for use thereof |
US20030129251A1 (en) | 2000-03-10 | 2003-07-10 | Gary Van Nest | Biodegradable immunomodulatory formulations and methods for use thereof |
US20020098199A1 (en) | 2000-03-10 | 2002-07-25 | Gary Van Nest | Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences |
US20010046967A1 (en) | 2000-03-10 | 2001-11-29 | Gary Van Nest | Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide |
AU2001251407A1 (en) * | 2000-04-07 | 2001-10-23 | The Regents Of The University Of California | Synergistic improvements to polynucleotide vaccines |
PT1278761E (en) * | 2000-05-01 | 2005-08-31 | Hybridon Inc | MODULATION OF IMMUNITARY STIMULATION MEASURED BY OLGONUCLEOTIDES OF CPG, BY POSITIONAL MODIFICATION OF NUCLEOSIDOS |
US6696064B2 (en) * | 2000-06-20 | 2004-02-24 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of protecting vasculature from damage by diphtheria toxin-and pseudomonas toxin-based immunotoxins during therapy |
AU2001276831A1 (en) | 2000-06-22 | 2002-01-02 | Rxkinetix, Inc. | Delivery vehicle composition and methods for delivering antigens and other drugs |
BRPI0111830B8 (en) * | 2000-06-23 | 2021-05-25 | American Cyanamid Co | method of producing influenza virus-like particles (vlps), influenza vlps, chimeric vlps, immunogenic and pharmaceutical compositions, and uses of influenza vlps and chimeric vlps |
WO2002002172A1 (en) * | 2000-06-30 | 2002-01-10 | Univ Jefferson | Dna palindrome - oligoguanylic acid compositions and uses thereof |
WO2006033665A1 (en) * | 2004-03-16 | 2006-03-30 | Inist Inc. | Tat-based vaccine compositions and methods of making and using same |
WO2005090392A1 (en) * | 2004-03-16 | 2005-09-29 | Inist Inc. | Tat-based tolerogen compositions and methods of making and using same |
WO2002016549A2 (en) * | 2000-08-25 | 2002-02-28 | Yeda Research And Development Co. Ltd. | METHODS OF TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES WITH CpG-CONTAINING POLYNUCLEOTIDE |
ES2298269T3 (en) * | 2000-09-26 | 2008-05-16 | Idera Pharmaceuticals, Inc. | MODULATION OF THE IMMUNO-STIMULATING ACTIVITY OF OLIGONUCLEOTIDIC ANALOGS IMMUNO-STIMULANTS THROUGH POSITIONAL CHEMICAL CHANGES. |
IL154853A0 (en) | 2000-10-27 | 2003-10-31 | Chiron Spa | Nucleic acids and proteins from streptococcus groups a & b |
CA2598144A1 (en) * | 2000-12-08 | 2006-08-31 | 3M Innovative Properties Company | Compositions and methods for targeted delivery of immune response modifiers |
US6677347B2 (en) * | 2000-12-08 | 2004-01-13 | 3M Innovative Properties Company | Sulfonamido ether substituted imidazoquinolines |
CN1293192C (en) * | 2000-12-27 | 2007-01-03 | 戴纳瓦克斯技术公司 | Immunoregulation polynucleotide and using method thereof |
KR20030070101A (en) * | 2001-01-12 | 2003-08-27 | 아마토 세이야쿠 가부시키가이샤 | Preventives for Microbial Infections |
US7264810B2 (en) * | 2001-01-19 | 2007-09-04 | Cytos Biotechnology Ag | Molecular antigen array |
WO2002060476A2 (en) * | 2001-01-31 | 2002-08-08 | Mologen Forschungs-, Entwicklungs- Und Vertriebs Gmbh | Tumor vaccine |
US20030050268A1 (en) * | 2001-03-29 | 2003-03-13 | Krieg Arthur M. | Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases |
US20070128229A1 (en) * | 2002-04-12 | 2007-06-07 | Wyeth | Surface proteins of Streptococcus pyogenes |
CA2443493A1 (en) * | 2001-04-13 | 2002-10-24 | Wyeth | Surface proteins of streptococcus pyogenes |
EP1572868A4 (en) | 2001-04-16 | 2007-04-04 | Wyeth Corp | Novel streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof |
US7034140B2 (en) * | 2001-04-24 | 2006-04-25 | E.I. Du Pont De Nemours And Company | Genes involved in isoprenoid compound production |
CA2448031A1 (en) | 2001-05-21 | 2002-11-28 | Intercell Ag | Method for stabilising of nucleic acids |
US6818787B2 (en) * | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
US7785610B2 (en) * | 2001-06-21 | 2010-08-31 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same—III |
DK2423335T3 (en) | 2001-06-21 | 2014-08-18 | Dynavax Tech Corp | CHEMICAL IMMUNAL MODULATOR RELATIONS AND PROCEDURES FOR USE THEREOF |
NZ530632A (en) * | 2001-06-29 | 2007-04-27 | Chiron Corp | HCV E1E2 vaccine compositions comprising E1E2 antigens, submicron oil-in-water emulsions and/or CpG oligonucleotides |
GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
US7666674B2 (en) | 2001-07-27 | 2010-02-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo |
GB0121591D0 (en) | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
US20030148316A1 (en) * | 2001-08-01 | 2003-08-07 | Lipford Grayson B. | Methods and compositions relating to plasmacytoid dendritic cells |
WO2003025119A2 (en) * | 2001-08-03 | 2003-03-27 | Medarex, Inc. | Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance fc receptor-mediated immunotherapies |
AU2002326561B2 (en) * | 2001-08-07 | 2008-04-03 | Dynavax Technologies Corporation | Immunomodulatory compositions, formulations, and methods for use thereof |
WO2003020884A2 (en) * | 2001-08-14 | 2003-03-13 | The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services | Method for rapid generation of mature dendritic cells |
WO2003018611A2 (en) | 2001-08-24 | 2003-03-06 | University Of Victoria Innovation And Development Corporation | Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer |
MXPA04001972A (en) * | 2001-08-30 | 2005-02-17 | 3M Innovative Properties Co | Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules. |
WO2003022296A1 (en) * | 2001-09-07 | 2003-03-20 | The Trustees Of Boston University | Method and composition for treating immune complex associated disorders |
ATE447967T1 (en) | 2001-09-14 | 2009-11-15 | Cytos Biotechnology Ag | PACKAGING OF IMMUNO-STIMULATIVE CPG IN VIRUS-LIKE PARTICLES: PRODUCTION METHOD AND USE |
US20030091593A1 (en) * | 2001-09-14 | 2003-05-15 | Cytos Biotechnology Ag | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
AU2002353783A1 (en) | 2001-09-24 | 2003-04-07 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE |
US20030119774A1 (en) * | 2001-09-25 | 2003-06-26 | Marianna Foldvari | Compositions and methods for stimulating an immune response |
AR045702A1 (en) | 2001-10-03 | 2005-11-09 | Chiron Corp | COMPOSITIONS OF ASSISTANTS. |
KR20050034583A (en) * | 2001-10-05 | 2005-04-14 | 콜리 파마슈티칼 게엠베하 | Toll-like receptor 3 signaling agonists and antagonists |
WO2003030656A2 (en) | 2001-10-06 | 2003-04-17 | Merial Limited | Methods and compositions for promoting growth and innate immunity in young animals |
KR20050048539A (en) * | 2001-10-06 | 2005-05-24 | 메리얼엘엘씨 | CpG formulations and related methods |
MX339524B (en) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Novel immunogenic compositions for the prevention and treatment of meningococcal disease. |
US7276489B2 (en) * | 2002-10-24 | 2007-10-02 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends |
WO2003039595A2 (en) * | 2001-11-07 | 2003-05-15 | Inex Pharmaceuticals Corporation | Mucosal adjuvants comprising an oligonucleotide and a cationic lipid |
EP1441758A2 (en) * | 2001-11-09 | 2004-08-04 | MediGene Aktiengesellschaft | Allogenic vaccine that contains a costimulatory polypeptide-expressing tumor cell |
WO2003043572A2 (en) * | 2001-11-16 | 2003-05-30 | 3M Innovative Properties Company | Methods and compositions related to irm compounds and toll-like receptor pathways |
US7179798B2 (en) * | 2001-11-16 | 2007-02-20 | Russell R. Roby | Methods and compositions for the treatment of pain and other hormone-allergy-related symptoms using dilute hormone solutions |
AU2004220469B2 (en) * | 2001-11-29 | 2010-07-29 | 3M Innovative Properties Company | Methods of improving skin quality |
WO2003047602A1 (en) * | 2001-12-07 | 2003-06-12 | Intercell Ag | Immunostimulatory oligodeoxynucleotides |
AU2002366710A1 (en) | 2001-12-20 | 2003-07-09 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS |
CA2365732A1 (en) * | 2001-12-20 | 2003-06-20 | Ibm Canada Limited-Ibm Canada Limitee | Testing measurements |
US8466116B2 (en) | 2001-12-20 | 2013-06-18 | The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of CpG oligodeoxynucleotides to induce epithelial cell growth |
EP1467755A1 (en) * | 2001-12-21 | 2004-10-20 | Antigenics Inc. | Compositions comprising immunoreactive reagents and saponins, and methods of use thereof |
EP1474432A1 (en) | 2002-02-04 | 2004-11-10 | Biomira Inc. | Immunostimulatory, covalently lipidated oligonucleotides |
US8088388B2 (en) * | 2002-02-14 | 2012-01-03 | United Biomedical, Inc. | Stabilized synthetic immunogen delivery system |
JP4646516B2 (en) * | 2002-02-20 | 2011-03-09 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | Fine particles with adsorbed polypeptide-containing molecules |
MXPA04008023A (en) * | 2002-02-22 | 2004-11-26 | 3M Innovative Properties Co | Method of reducing and treating uvb-induced immunosuppression. |
US6923958B2 (en) * | 2002-03-02 | 2005-08-02 | The Scripps Research Institute | DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof |
EP2258712A3 (en) * | 2002-03-15 | 2011-05-04 | Multicell Immunotherapeutics, Inc. | Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs |
KR100981471B1 (en) * | 2002-03-15 | 2010-09-10 | 더 큐레이터스 오브 더 유니버시티 오브 미주리 | Mutants of the p4 protein of nontypable haemophilus influenzae with reduced enzymatic activity |
EP1485403A4 (en) * | 2002-03-15 | 2007-08-08 | Multicell Immunotherapeutics I | Compositions and methods to initiate or enhance antibody and major-histocompatibility class i or class ii-restricted t cell responses by using immunomodulatory, non-coding rna motifs |
US20030224013A1 (en) * | 2002-04-19 | 2003-12-04 | Cole Garry T. | Methods for protection against Coccidioides spp. infection using Coccidioides spp. urea amidohydrolase (Ure) protein |
US20040013649A1 (en) * | 2002-05-10 | 2004-01-22 | Inex Pharmaceuticals Corporation | Cancer vaccines and methods of using the same |
US20040009944A1 (en) * | 2002-05-10 | 2004-01-15 | Inex Pharmaceuticals Corporation | Methylated immunostimulatory oligonucleotides and methods of using the same |
US20040009943A1 (en) * | 2002-05-10 | 2004-01-15 | Inex Pharmaceuticals Corporation | Pathogen vaccines and methods for using the same |
US9045727B2 (en) | 2002-05-17 | 2015-06-02 | Emory University | Virus-like particles, methods of preparation, and immunogenic compositions |
US20060088909A1 (en) * | 2002-05-17 | 2006-04-27 | Compans Richard W | Virus-like particles, methods of preparation, and immunogenic compositions |
KR100456681B1 (en) * | 2002-05-22 | 2004-11-10 | 주식회사 대웅 | Immnune-stimulating and controlling Composition comprising bacterial chromosomal DNA fragments and detoxified lipopolysaccharides |
CA2388049A1 (en) | 2002-05-30 | 2003-11-30 | Immunotech S.A. | Immunostimulatory oligonucleotides and uses thereof |
WO2003103586A2 (en) * | 2002-06-05 | 2003-12-18 | Coley Pharmaceutical Group, Inc. | Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids |
BR0311995A (en) * | 2002-06-20 | 2005-04-05 | Cytos Biotechnology Ag | Virus-like particles packaged for use as adjuvants: Method of preparation and use |
JP2005532067A (en) * | 2002-07-03 | 2005-10-27 | コーリー ファーマシューティカル グループ,インコーポレイテッド | Nucleic acid composition for stimulating immune response |
AU2003255969A1 (en) * | 2002-07-17 | 2004-02-02 | Coley Pharmaceutical Gmbh | Use of cpg nucleic acids in prion-disease |
US20060270620A1 (en) * | 2002-07-23 | 2006-11-30 | University Of South Florida | Method of Enhancing Therapeutic Effect of Nucleic Acids |
WO2004011650A2 (en) | 2002-07-24 | 2004-02-05 | Intercell Ag | Antigens encoded by alternative reading frame from pathogenic viruses |
EP1575504A4 (en) | 2002-08-01 | 2009-11-04 | Us Gov Health & Human Serv | Method of treating inflammatory arthropathies with suppressors of cpg oligonucleotides |
DE60335010D1 (en) | 2002-08-15 | 2010-12-30 | 3M Innovative Properties Co | IMMUNOSTIMULATORY COMPOSITIONS AND METHOD FOR STIMULATING AN IMMUNE RESPONSE |
GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
US7785608B2 (en) * | 2002-08-30 | 2010-08-31 | Wyeth Holdings Corporation | Immunogenic compositions for the prevention and treatment of meningococcal disease |
US7595303B1 (en) * | 2002-09-05 | 2009-09-29 | University Of South Florida | Genetic adjuvants for immunotherapy |
US20050196382A1 (en) * | 2002-09-13 | 2005-09-08 | Replicor, Inc. | Antiviral oligonucleotides targeting viral families |
WO2004024182A2 (en) | 2002-09-13 | 2004-03-25 | Intercell Ag | Method for isolating hepatitis c virus peptides |
BR0314236A (en) * | 2002-09-13 | 2005-08-09 | Replicor Inc | Oligonucleotide formulation, pharmaceutical composition, kit, antiviral compound, preparation of oligonucleotide and methods for selection of an antiviral oligonucleotide for use as an antiviral agent, for prophylaxis or treatment of a viral infection in a patient, for prophylactic treatment of cancer caused by oncoviruses. for identifying a compound that alters the binding of an oligonucleotide to at least one viral component, for purifying oligonucleotide binding to at least one viral component and for enriching oligonucleotides from an oligonucleotide cluster |
US8263091B2 (en) * | 2002-09-18 | 2012-09-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides |
US7301554B2 (en) * | 2002-09-20 | 2007-11-27 | Ricoh Company, Ltd. | Light scanning device, scanning line adjusting method, scanning line adjusting control method, image forming apparatus, and image forming method |
WO2004031382A1 (en) * | 2002-10-02 | 2004-04-15 | Mochida Pharmaceutical Co., Ltd. | Novel method of constructing monoclonal antibody |
US8043622B2 (en) | 2002-10-08 | 2011-10-25 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides |
EP2351579B1 (en) | 2002-10-11 | 2016-09-21 | Novartis Vaccines and Diagnostics S.r.l. | Polypeptide vaccines for broad protection against hypervirulent meningococcal lineages |
EP1578459A3 (en) * | 2002-10-25 | 2005-11-23 | University of Connecticut Health Center | Apparatus and method for immunotherapy of a cancer through controlled cell lysis |
JP4976653B2 (en) * | 2002-11-01 | 2012-07-18 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシス | Method for preventing infections caused by bioterrorism pathogens using immunostimulatory CpG oligonucleotides |
WO2004044136A2 (en) * | 2002-11-05 | 2004-05-27 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2’-modified nucleosides for use in gene modulation |
EP2279746B1 (en) | 2002-11-15 | 2013-10-02 | Novartis Vaccines and Diagnostics S.r.l. | Surface proteins in neisseria meningitidis |
US7811813B2 (en) * | 2002-11-21 | 2010-10-12 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and immune modulatory nucleic acid compositions for preventing and treating disease |
US8853376B2 (en) | 2002-11-21 | 2014-10-07 | Archemix Llc | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
US20050124565A1 (en) * | 2002-11-21 | 2005-06-09 | Diener John L. | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
US8039443B2 (en) * | 2002-11-21 | 2011-10-18 | Archemix Corporation | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
US10100316B2 (en) * | 2002-11-21 | 2018-10-16 | Archemix Llc | Aptamers comprising CPG motifs |
GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
AU2003300831A1 (en) * | 2002-12-11 | 2004-06-30 | Hawaii Biotech, Inc. | Recombinant vaccine against flavivirus infection |
AU2003287316A1 (en) * | 2002-12-11 | 2004-06-30 | 3M Innovative Properties Company | Assays relating to toll-like receptor activity |
WO2004053057A2 (en) * | 2002-12-11 | 2004-06-24 | 3M Innovative Properties Company | Gene expression systems and recombinant cell lines |
NZ541027A (en) | 2002-12-23 | 2008-04-30 | Dynavax Tech Corp | Immunostimulatory sequence oligonucleotides and methods of using the same |
WO2004058159A2 (en) * | 2002-12-23 | 2004-07-15 | Dynavax Technologies Corporation | Branched immunomodulatory compounds and methods of using the same |
US8158768B2 (en) * | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
EP2263687B1 (en) | 2002-12-27 | 2015-03-25 | Novartis Vaccines and Diagnostics, Inc. | Immunogenic compositions containing phospholipid |
JP2006512391A (en) | 2002-12-30 | 2006-04-13 | スリーエム イノベイティブ プロパティズ カンパニー | Combination immunostimulant |
ATE552844T1 (en) | 2003-01-30 | 2012-04-15 | Novartis Ag | INJECTABLE VACCINE AGAINST MULTIPLE MENINGOCOCC SEROGROUPES |
US7354907B2 (en) * | 2003-02-07 | 2008-04-08 | Idera Pharmaceuticals, Inc. | Short immunomodulatory oligonucleotides |
JP2006517974A (en) * | 2003-02-13 | 2006-08-03 | スリーエム イノベイティブ プロパティズ カンパニー | Methods and compositions for IRM compounds and Toll-like receptor 8 |
JP4976848B2 (en) | 2003-02-20 | 2012-07-18 | ユニバーシティー オブ コネティカット ヘルス センター | Methods and compositions for the treatment of cancer and infectious diseases using alpha (2) macroglobulin-antigen molecule complexes |
GB2398783A (en) | 2003-02-26 | 2004-09-01 | Antonio Lanzavecchia | A method for producing immortalised human B memory lymphocytes |
EP1599726A4 (en) * | 2003-02-27 | 2009-07-22 | 3M Innovative Properties Co | Selective modulation of tlr-mediated biological activity |
JP2006519866A (en) | 2003-03-04 | 2006-08-31 | スリーエム イノベイティブ プロパティズ カンパニー | Prophylactic treatment of UV-induced epidermal neoplasia |
CN100439386C (en) * | 2003-03-05 | 2008-12-03 | 长春华普生物技术有限公司 | Deoxyoligonucleotide containing CpG single strand for strengthening immunological effect of Protein vaccine |
AU2004220465A1 (en) | 2003-03-13 | 2004-09-23 | 3M Innovative Properties Company | Method of tattoo removal |
DE602004029657D1 (en) | 2003-03-24 | 2010-12-02 | Intercell Ag | IMPROVED VACCINES |
US20040192585A1 (en) * | 2003-03-25 | 2004-09-30 | 3M Innovative Properties Company | Treatment for basal cell carcinoma |
NZ542323A (en) * | 2003-03-26 | 2008-07-31 | Cytos Biotechnology Ag | Melan-A peptide analogue-virus-like-particle conjugates |
US7537767B2 (en) | 2003-03-26 | 2009-05-26 | Cytis Biotechnology Ag | Melan-A- carrier conjugates |
CA2520181A1 (en) * | 2003-03-26 | 2004-10-14 | Astral Inc. | Selected rna motifs to include cell death and/or apoptosis |
US20060210588A1 (en) * | 2003-03-26 | 2006-09-21 | Cytos Biotechnology Ag | Hiv-peptide-carrier-conjugates |
EP1608403A2 (en) * | 2003-04-02 | 2005-12-28 | Coley Pharmaceutical Group, Ltd. | Immunostimulatory nucleic acid oil-in-water formulations for topical application |
US7923560B2 (en) * | 2003-04-10 | 2011-04-12 | 3M Innovative Properties Company | Delivery of immune response modifier compounds |
NZ543467A (en) | 2003-04-10 | 2008-07-31 | Novartis Vaccines & Diagnostic | The severe acute respiratory syndrome coronavirus |
US20040265351A1 (en) * | 2003-04-10 | 2004-12-30 | Miller Richard L. | Methods and compositions for enhancing immune response |
AU2004232848A1 (en) | 2003-04-21 | 2004-11-04 | Archemix Corp. | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
JP4673217B2 (en) * | 2003-04-23 | 2011-04-20 | 由紀夫 佐藤 | Methylated CpG polynucleotide |
US20050250106A1 (en) * | 2003-04-24 | 2005-11-10 | David Epstein | Gene knock-down by intracellular expression of aptamers |
WO2004096136A2 (en) * | 2003-04-25 | 2004-11-11 | Chiron Corporation | Compositions comprising cationic microparticles and hcv e1e2 dna and methods of use thereof |
WO2004096144A2 (en) * | 2003-04-28 | 2004-11-11 | 3M Innovative Properties Company | Compositions and methods for induction of opioid receptors |
WO2004100965A1 (en) * | 2003-05-15 | 2004-11-25 | Japan Science And Technology Agency | Immunostimulant |
US8080642B2 (en) | 2003-05-16 | 2011-12-20 | Vical Incorporated | Severe acute respiratory syndrome DNA compositions and methods of use |
ES2596553T3 (en) | 2003-06-02 | 2017-01-10 | Glaxosmithkline Biologicals Sa | Immunogenic compositions based on microparticles comprising adsorbed toxoid and an antigen containing a polysaccharide |
US7803386B2 (en) | 2003-06-05 | 2010-09-28 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli |
KR101137572B1 (en) * | 2003-06-11 | 2012-05-30 | 이데라 파마슈티칼즈, 인코포레이티드 | Stabilized immunomodulatory oligonucleotides |
WO2005004907A1 (en) * | 2003-07-10 | 2005-01-20 | Cytos Biotechnology Ag | Packaged virus-like particles |
CA2534042A1 (en) * | 2003-07-31 | 2005-02-10 | 3M Innovative Properties Company | Compositions for encapsulation and controlled release |
CN1852711A (en) * | 2003-08-05 | 2006-10-25 | 3M创新有限公司 | Infection prophylaxis using immune response modifier compounds |
TW200524927A (en) * | 2003-08-12 | 2005-08-01 | 3M Innovative Properties Co | Hydroxylamine substituted imidazo-containing compounds |
US20060035242A1 (en) | 2004-08-13 | 2006-02-16 | Michelitsch Melissa D | Prion-specific peptide reagents |
US20050065136A1 (en) * | 2003-08-13 | 2005-03-24 | Roby Russell R. | Methods and compositions for the treatment of infertility using dilute hormone solutions |
WO2005020902A2 (en) * | 2003-08-21 | 2005-03-10 | Cytokine Pharmasciences, Inc. | Compositions and methods for treating and diagnosing irritable bowel syndrome |
EP1658035A4 (en) * | 2003-08-25 | 2007-08-22 | 3M Innovative Properties Co | Delivery of immune response modifier compounds |
AU2004266162A1 (en) * | 2003-08-25 | 2005-03-03 | 3M Innovative Properties Company | Immunostimulatory combinations and treatments |
WO2005020999A1 (en) * | 2003-08-27 | 2005-03-10 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted imidazoquinolines |
MXPA06002408A (en) * | 2003-09-02 | 2006-06-20 | 3M Innovative Properties Co | Methods related to the treatment of mucosal associated conditions. |
JP2007504269A (en) * | 2003-09-05 | 2007-03-01 | スリーエム イノベイティブ プロパティズ カンパニー | Method for treating CD5 + B cell lymphoma |
EP1670507A4 (en) | 2003-09-12 | 2007-10-17 | Antigenics Inc | Vaccine for treatment and prevention of herpes simplex virus infection |
GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
BR122017002991B1 (en) | 2003-10-02 | 2023-01-10 | Novartis Vaccines And Diagnostics S.R.L. | AQUEOUS IMMUNOGENIC COMPOSITIONS FOR MULTIPLE MENINGOCOCCAL SEROGROUPS |
KR101154101B1 (en) * | 2003-10-03 | 2012-06-11 | 쓰리엠 이노베이티브 프로퍼티즈 컴파니 | Alkoxy substituted imidazoquinolines |
US20090075980A1 (en) * | 2003-10-03 | 2009-03-19 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and Analogs Thereof |
US7544697B2 (en) * | 2003-10-03 | 2009-06-09 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridines and analogs thereof |
AU2004280143A1 (en) * | 2003-10-11 | 2005-04-21 | Tekmira Pharmaceuticals Corporation | Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity |
GB0323965D0 (en) * | 2003-10-13 | 2003-11-19 | Glaxosmithkline Biolog Sa | Immunogenic compositions |
CA2543685A1 (en) * | 2003-10-31 | 2005-05-12 | 3M Innovative Properties Company | Neutrophil activation by immune response modifier compounds |
CN1906192A (en) * | 2003-11-14 | 2007-01-31 | 3M创新有限公司 | Hydroxylamine substituted imidazo ring compounds |
US7897767B2 (en) | 2003-11-14 | 2011-03-01 | 3M Innovative Properties Company | Oxime substituted imidazoquinolines |
CA2547020C (en) * | 2003-11-25 | 2014-03-25 | 3M Innovative Properties Company | 1h-imidazo[4,5-c]pyridine-4-amine derivatives as immune response modifier |
US20050277127A1 (en) * | 2003-11-26 | 2005-12-15 | Epitomics, Inc. | High-throughput method of DNA immunogen preparation and immunization |
US20050287118A1 (en) * | 2003-11-26 | 2005-12-29 | Epitomics, Inc. | Bacterial plasmid with immunological adjuvant function and uses thereof |
JP2007513165A (en) * | 2003-12-02 | 2007-05-24 | スリーエム イノベイティブ プロパティズ カンパニー | Concomitant drugs containing IRM compounds and methods of treatment |
US20050226878A1 (en) * | 2003-12-02 | 2005-10-13 | 3M Innovative Properties Company | Therapeutic combinations and methods including IRM compounds |
US9090673B2 (en) * | 2003-12-12 | 2015-07-28 | City Of Hope | Synthetic conjugate of CpG DNA and T-help/CTL peptide |
BRPI0417689A8 (en) | 2003-12-17 | 2017-04-25 | Elan Pharm Inc | METHOD FOR CONJUGATING A PEPTIDE IMMOGEN, COMPOSITION, CONJUGATE, IMMUNOGENIC COMPOSITION, METHOD FOR INDUCING AN IMMUNE RESPONSE IN A MAMMAL INDIVIDUAL, AND, USE OF THE CONJUGATE |
WO2005058940A2 (en) | 2003-12-17 | 2005-06-30 | Wyeth | Immunogenic peptide carrier conjugates and methods of producing same |
JP4817599B2 (en) * | 2003-12-25 | 2011-11-16 | 独立行政法人科学技術振興機構 | Immune activity enhancer and method for enhancing immune activity using the same |
WO2005066170A1 (en) * | 2003-12-29 | 2005-07-21 | 3M Innovative Properties Company | Arylalkenyl and arylalkynyl substituted imidazoquinolines |
EP1699788A2 (en) * | 2003-12-30 | 2006-09-13 | 3M Innovative Properties Company | Imidazoquinolinyl, imidazopyridinyl and imidazonaphthyridinyl sulfonamides |
US20050239735A1 (en) * | 2003-12-30 | 2005-10-27 | 3M Innovative Properties Company | Enhancement of immune responses |
KR100558851B1 (en) * | 2004-01-08 | 2006-03-10 | 학교법인연세대학교 | Modified CpG oligodeoxynucleotide with improved immunoregulatory function |
WO2005072290A2 (en) * | 2004-01-23 | 2005-08-11 | Joslin Diabetes Center | Methods of treating, reducing, or preventing autoimmune conditions |
US20050181035A1 (en) * | 2004-02-17 | 2005-08-18 | Dow Steven W. | Systemic immune activation method using non CpG nucleic acids |
CN1918293A (en) * | 2004-02-20 | 2007-02-21 | 莫洛根股份公司 | Substituted non-coding nucleic acid molecule for therapeutic or prophylaxis immunological stimulus for human and higher animal |
US20060193821A1 (en) * | 2004-03-05 | 2006-08-31 | Diener John L | Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics |
CA2559371C (en) | 2004-03-09 | 2014-07-08 | Chiron Corporation | Influenza virus vaccines |
US8569474B2 (en) | 2004-03-09 | 2013-10-29 | Isis Pharmaceuticals, Inc. | Double stranded constructs comprising one or more short strands hybridized to a longer strand |
US7820175B2 (en) | 2004-03-19 | 2010-10-26 | Herbal Spring, Llc | Herbal therapy for the treatment of food allergy |
TW200612932A (en) * | 2004-03-24 | 2006-05-01 | 3M Innovative Properties Co | Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
TWI235440B (en) * | 2004-03-31 | 2005-07-01 | Advanced Semiconductor Eng | Method for making leadless semiconductor package |
US20060019916A1 (en) * | 2004-04-02 | 2006-01-26 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for inducing IL-10 responses |
US20050260755A1 (en) * | 2004-04-06 | 2005-11-24 | Isis Pharmaceuticals, Inc. | Sequential delivery of oligomeric compounds |
WO2005105106A2 (en) * | 2004-04-21 | 2005-11-10 | Roby Russell R | Hormone treatment of macular degeneration |
WO2005105107A2 (en) * | 2004-04-21 | 2005-11-10 | Roby Russell R | Hormone treatment of multiple sclerosis |
US7579450B2 (en) * | 2004-04-26 | 2009-08-25 | Archemix Corp. | Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics |
BRPI0510430A (en) * | 2004-04-28 | 2007-10-30 | 3M Innovative Properties Co | compositions and methods for mucosal vaccination |
GB0500787D0 (en) | 2005-01-14 | 2005-02-23 | Chiron Srl | Integration of meningococcal conjugate vaccination |
WO2005105140A2 (en) | 2004-04-30 | 2005-11-10 | Chiron Srl | Meningococcal conjugate vaccination |
GB0409745D0 (en) | 2004-04-30 | 2004-06-09 | Chiron Srl | Compositions including unconjugated carrier proteins |
AU2005247341B2 (en) * | 2004-05-06 | 2008-05-08 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods and compositions for the treatment of uveitis |
GB0410220D0 (en) | 2004-05-07 | 2004-06-09 | Kirkham Lea Ann | Mutant pneumolysin proteins |
GB0410866D0 (en) | 2004-05-14 | 2004-06-16 | Chiron Srl | Haemophilius influenzae |
CN1296378C (en) * | 2004-05-17 | 2007-01-24 | 中国人民解放军第三军医大学 | CpG-N ODN gene sequence with high immunological activity CpG-S ODN and antagonism CpG-N ODN and use thereof |
CA2566355C (en) * | 2004-05-18 | 2014-04-15 | Vical Incorporated | Influenza virus vaccine composition and methods of use |
MXPA06013448A (en) | 2004-05-21 | 2007-01-23 | Wyeth Corp | Altered fibronectin-binding protein of staphylococcus aureus. |
EP2811027A1 (en) | 2004-05-21 | 2014-12-10 | Novartis Vaccines and Diagnostics, Inc. | Alphavirus vectors for RSV and PIV vaccines |
US20050267145A1 (en) * | 2004-05-28 | 2005-12-01 | Merrill Bryon A | Treatment for lung cancer |
EP3001990A1 (en) | 2004-05-28 | 2016-04-06 | Oryxe | A mixture for transdermal delivery of low& and high molecular weight compounds |
US8394947B2 (en) | 2004-06-03 | 2013-03-12 | Isis Pharmaceuticals, Inc. | Positionally modified siRNA constructs |
JP2008501693A (en) * | 2004-06-03 | 2008-01-24 | アイシス ファーマシューティカルズ、インク. | Double-stranded composition with individually regulated strands for use in gene regulation |
CA2567789A1 (en) * | 2004-06-08 | 2006-08-03 | Coley Pharmaceutical Gmbh | Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist |
US8017779B2 (en) * | 2004-06-15 | 2011-09-13 | 3M Innovative Properties Company | Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines |
TW200613554A (en) | 2004-06-17 | 2006-05-01 | Wyeth Corp | Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV |
WO2006009832A1 (en) * | 2004-06-18 | 2006-01-26 | 3M Innovative Properties Company | Substituted imidazo ring systems and methods |
US8026366B2 (en) * | 2004-06-18 | 2011-09-27 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines |
WO2006038923A2 (en) * | 2004-06-18 | 2006-04-13 | 3M Innovative Properties Company | Aryl substituted imidazonaphthyridines |
US7915281B2 (en) * | 2004-06-18 | 2011-03-29 | 3M Innovative Properties Company | Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method |
US7482158B2 (en) * | 2004-07-01 | 2009-01-27 | Mathison Brian H | Composite polynucleic acid therapeutics |
EP1781325A2 (en) * | 2004-07-18 | 2007-05-09 | CSL Limited | Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses |
US20060025390A1 (en) * | 2004-07-28 | 2006-02-02 | Roby Russell R | Treatment of hormone allergy and related symptoms and disorders |
WO2006078318A2 (en) | 2004-07-29 | 2006-07-27 | Novartis Vaccines And Diagnostics Inc. | Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae |
DK1773884T3 (en) | 2004-08-03 | 2012-05-21 | Innate Pharma | THERAPEUTIC AND DIAGNOSTIC PROCEDURES AND COMPOSITIONS FOR TARGETING 4IG-B7-H3 AND ITS SIMILAR NK CELL RECEPTOR |
EP1786450A4 (en) * | 2004-08-27 | 2009-11-11 | 3M Innovative Properties Co | Hiv immunostimulatory compositions |
US20090270443A1 (en) * | 2004-09-02 | 2009-10-29 | Doris Stoermer | 1-amino imidazo-containing compounds and methods |
US7884086B2 (en) * | 2004-09-08 | 2011-02-08 | Isis Pharmaceuticals, Inc. | Conjugates for use in hepatocyte free uptake assays |
EP1791858B1 (en) | 2004-09-24 | 2010-04-21 | Intercell AG | Modified vp1-capsid protein of parvovirus b19 |
JP2008000001A (en) * | 2004-09-30 | 2008-01-10 | Osaka Univ | Immune stimulating oligonucleotide and use in pharmaceutical |
ES2531734T3 (en) | 2004-10-06 | 2015-03-18 | Medimmune, Llc | Flu vaccine compositions stable at refrigerator temperatures |
AU2005294129B2 (en) | 2004-10-08 | 2010-12-23 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Modulation of replicative fitness by using less frequently used synonymous codons |
US20070243215A1 (en) * | 2004-10-08 | 2007-10-18 | Miller Richard L | Adjuvant for Dna Vaccines |
EP1802335A2 (en) | 2004-10-21 | 2007-07-04 | Wyeth a Corporation of the State of Delaware | Immunogenic compositions of staphylococcus epidermidis polypeptide and polynucleotide antigens |
GB0424092D0 (en) | 2004-10-29 | 2004-12-01 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
EP3034089A1 (en) | 2004-11-02 | 2016-06-22 | Archemix LLC | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
US7332324B2 (en) | 2004-12-03 | 2008-02-19 | University Of Toledo | Attenuated vaccine useful for immunizations against Coccidioides spp. infections |
EP1819364A4 (en) * | 2004-12-08 | 2010-12-29 | 3M Innovative Properties Co | Immunomodulatory compositions, combinations and methods |
WO2006065751A2 (en) * | 2004-12-13 | 2006-06-22 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Cpg oligonucleotide prodrugs, compositions thereof and associated therapeutic methods |
US8197817B2 (en) | 2004-12-17 | 2012-06-12 | Dana-Farber Cancer Institute, Inc. | Regulation of mink in thymocytes and T lymphocytes |
CA2592922A1 (en) * | 2004-12-29 | 2006-07-06 | Mannkind Corporation | Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs |
JP5543068B2 (en) * | 2004-12-30 | 2014-07-09 | スリーエム イノベイティブ プロパティズ カンパニー | Chiral fused [1,2] imidazo [4,5-c] cyclic compound |
AU2005321912B2 (en) * | 2004-12-30 | 2012-04-05 | 3M Innovative Properties Company | Treatment for cutaneous metastases |
CA2594674C (en) | 2004-12-30 | 2016-05-17 | 3M Innovative Properties Company | Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds |
CN101107007B (en) | 2005-01-27 | 2011-08-17 | 奥克兰儿童医院及研究中心 | GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis |
CN100485034C (en) * | 2005-01-28 | 2009-05-06 | 权滢周 | Oligonucleotides extracted from mycobacteria for stimulating immune function, treating immune-related diseases, allergic dermatitis and/or protecting normal immune cells |
GB0502095D0 (en) | 2005-02-01 | 2005-03-09 | Chiron Srl | Conjugation of streptococcal capsular saccharides |
WO2006084251A2 (en) | 2005-02-04 | 2006-08-10 | Coley Pharmaceutical Group, Inc. | Aqueous gel formulations containing immune reponse modifiers |
WO2006086634A2 (en) | 2005-02-11 | 2006-08-17 | Coley Pharmaceutical Group, Inc. | Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods |
ATE552267T1 (en) | 2005-02-18 | 2012-04-15 | Novartis Vaccines & Diagnostic | IMMUGENES OF UROPATHOGENS ESCHERICHIA COLI |
DK1858920T3 (en) | 2005-02-18 | 2016-02-29 | Glaxosmithkline Biolog Sa | PROTEINS AND NUCLEIC ACIDS FROM MENINGITIS / SEPSIS-ASSOCIATED ESCHERICHIA COLI |
CN101171033A (en) | 2005-03-04 | 2008-04-30 | 戴纳瓦克斯技术公司 | Vaccines comprising oligonucleotides having immunostimulatory sequences (ISS) wherein the ISS are conjugated to antigens and stabilized by buffer conditions and further excipients |
US8101345B1 (en) | 2005-03-25 | 2012-01-24 | Isis Pharmaceuticals, Inc. | Proinflammatory nucleic acids |
CA2602590A1 (en) | 2005-04-01 | 2006-10-12 | Coley Pharmaceutical Group, Inc. | 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases |
AU2006232377A1 (en) | 2005-04-01 | 2006-10-12 | Coley Pharmaceutical Group, Inc. | Pyrazolopyridine-1,4-diamines and analogs thereof |
US7709001B2 (en) | 2005-04-08 | 2010-05-04 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
EP2425855A1 (en) | 2005-04-08 | 2012-03-07 | Wyeth LLC | Multivalent pneumococcal polysaccharide-protein conjugate composition |
JP2008535862A (en) * | 2005-04-08 | 2008-09-04 | キメリクス,インコーポレイテッド | Compounds, compositions and methods for the treatment of poxvirus infections |
US20070003608A1 (en) * | 2005-04-08 | 2007-01-04 | Almond Merrick R | Compounds, compositions and methods for the treatment of viral infections and other medical disorders |
CA2604683C (en) | 2005-04-12 | 2019-04-30 | Duke University | Method of inducing neutralizing antibodies to human immunodeficiency virus |
EP1871411A4 (en) | 2005-04-18 | 2010-07-21 | Novartis Vaccines & Diagnostic | Expressing hepatitis b virus surface antigen for vaccine preparation |
JP2008539252A (en) * | 2005-04-25 | 2008-11-13 | スリーエム イノベイティブ プロパティズ カンパニー | Immune activation composition |
DE602006020867D1 (en) | 2005-06-14 | 2011-05-05 | Protox Therapeutics Inc | PROCESS FOR TREATING OR PREVENTING PROPER PROSTATE HYPERPLASIA USING MODIFIED PORENE PROTEINS |
MX2007016561A (en) | 2005-06-30 | 2008-03-10 | Archemix Corp | Materials and methods for the generation of fully 2'-modified nucleic acid transcripts. |
US8101385B2 (en) | 2005-06-30 | 2012-01-24 | Archemix Corp. | Materials and methods for the generation of transcripts comprising modified nucleotides |
EP2179737B1 (en) | 2005-07-01 | 2013-08-14 | Index Pharmaceuticals AB | Modulating responsiveness to steroids |
CA2612162C (en) | 2005-07-01 | 2016-05-17 | Index Pharmaceuticals Ab | Use of oligonucleotides in steroid refractory or steroid dependent inflammatory conditions |
WO2007008904A2 (en) | 2005-07-08 | 2007-01-18 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Targeting poly-gamma-glutamic acid to treat staphylococcus epidermidis and related infections |
JP2009501546A (en) | 2005-07-18 | 2009-01-22 | ノバルティス アーゲー | A small animal model for HCV replication |
WO2007012285A1 (en) * | 2005-07-28 | 2007-02-01 | Changchun Huapu Biotechnology Co., Ltd. | Viral infection resistent single strand deoxynucleosides |
US20070081972A1 (en) * | 2005-09-30 | 2007-04-12 | The University Of Iowa Research Foundation | Polymer-based delivery system for immunotherapy of cancer |
EP2357000A1 (en) | 2005-10-18 | 2011-08-17 | Novartis Vaccines and Diagnostics, Inc. | Mucosal and systemic immunizations with alphavirus replicon particles |
AU2006306805A1 (en) | 2005-10-28 | 2007-05-03 | Index Pharmaceuticals Ab | Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease |
JP2009514850A (en) | 2005-11-04 | 2009-04-09 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant |
ES2792398T3 (en) | 2005-11-04 | 2020-11-11 | Seqirus Uk Ltd | Non-virion antigen-adjuvanted vaccines prepared from influenza viruses grown in cell culture |
EP1951299B1 (en) | 2005-11-04 | 2012-01-04 | Novartis Vaccines and Diagnostics S.r.l. | Influenza vaccines including combinations of particulate adjuvants and immunopotentiators |
JP2009514839A (en) | 2005-11-04 | 2009-04-09 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | Adjuvant influenza vaccine containing cytokine inducer |
CN102864152B (en) * | 2005-11-07 | 2015-11-18 | 艾德拉药物股份有限公司 | Comprise the immunostimulatory properties of the compound based on oligonucleotide of modified immunostimulating dinucleotides |
EP1969001A2 (en) | 2005-11-22 | 2008-09-17 | Novartis Vaccines and Diagnostics, Inc. | Norovirus and sapovirus antigens |
GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
US20070184068A1 (en) | 2005-12-14 | 2007-08-09 | Cytos Biotechnology Ag | Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity |
WO2007085969A2 (en) | 2006-01-27 | 2007-08-02 | Novartis Vaccines And Diagnostics Gmbh & Co Kg | Influenza vaccines containing hemagglutinin and matrix proteins |
WO2007100634A2 (en) | 2006-02-22 | 2007-09-07 | 3M Innovative Properties Company | Immune response modifier conjugates |
EP2397855A3 (en) | 2006-03-14 | 2012-03-14 | Oregon Health and Science University | Methods for detecting a mycobacterium tuberculosis infection |
EP2357184B1 (en) | 2006-03-23 | 2015-02-25 | Novartis AG | Imidazoquinoxaline compounds as immunomodulators |
WO2007109812A2 (en) * | 2006-03-23 | 2007-09-27 | Novartis Ag | Immunopotentiating compounds |
EP2004226A1 (en) | 2006-03-24 | 2008-12-24 | Novartis Vaccines and Diagnostics GmbH & Co. KG | Storage of influenza vaccines without refrigeration |
SG173336A1 (en) | 2006-03-31 | 2011-08-29 | Novartis Ag | Combined mucosal and parenteral immunization against hiv |
WO2007119815A1 (en) | 2006-04-14 | 2007-10-25 | Kyowa Hakko Kirin Co., Ltd. | Toll-like receptor 9 agonists |
TW200806315A (en) | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
DK2034015T3 (en) * | 2006-05-31 | 2012-10-15 | Toray Industries | Immunostimulatory oligonucleotide and its pharmaceutical use |
ATE522541T1 (en) | 2006-06-09 | 2011-09-15 | Novartis Ag | BACTERIAL ADHESIN CONFORMERS |
MX2008015529A (en) | 2006-06-12 | 2009-01-13 | Cytos Biotechnology Ag | Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages. |
KR101141333B1 (en) | 2006-06-20 | 2012-05-23 | 트랜스진 에스.에이. | Recombinant Viral Vaccine |
US8128921B2 (en) * | 2006-07-11 | 2012-03-06 | University Of Connecticut | Use of conditional plasmodium strains lacking nutrient transporters in malaria vaccination |
US8153116B2 (en) | 2006-07-11 | 2012-04-10 | University Of Connecticut | Use of conditional plasmodium strains lacking an essential gene in malaria vaccination |
US7906506B2 (en) * | 2006-07-12 | 2011-03-15 | 3M Innovative Properties Company | Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods |
GB0614460D0 (en) | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
CA2659552A1 (en) | 2006-08-16 | 2008-02-21 | Novartis Ag | Immunogens from uropathogenic escherichia coli |
US20100010199A1 (en) | 2006-09-11 | 2010-01-14 | Novartis Ag | Making influenza virus vaccines without using eggs |
DE102006050655A1 (en) * | 2006-10-24 | 2008-04-30 | Halmon Beheer B.V. | Pharmaceutical composition useful for treating allergic diseases comprises RNA and an allergen |
AU2007353120A1 (en) * | 2006-10-26 | 2008-11-20 | Coley Pharmaceutical Gmbh | Oligoribonucleotides and uses thereof |
EP3029461B1 (en) | 2006-11-01 | 2017-12-20 | Ventana Medical Systems, Inc. | Haptens, hapten conjugates, compositions thereof and method for their preparation and use |
CN104857512A (en) | 2006-11-09 | 2015-08-26 | 戴纳瓦克斯技术公司 | Long Term Disease Modification Using Immunostimulatory Oligonucleotides |
US20090285819A1 (en) * | 2006-11-15 | 2009-11-19 | Functional Genetics, Inc. | Methods and compositions for treating influenza |
WO2008068631A2 (en) | 2006-12-06 | 2008-06-12 | Novartis Ag | Vaccines including antigen from four strains of influenza virus |
AR064642A1 (en) | 2006-12-22 | 2009-04-15 | Wyeth Corp | POLINUCLEOTIDE VECTOR THAT INCLUDES IT RECOMBINATING CELL THAT UNDERSTANDS THE VECTOR POLYPEPTIDE, ANTIBODY, COMPOSITION THAT UNDERSTANDS THE POLINUCLEOTIDE, VECTOR, RECOMBINATING CELL POLYPEPTIDE OR ANTIBODY, USE OF THE COMPOSITION AND A COMPOSITION AND A METHOD |
US20080149123A1 (en) * | 2006-12-22 | 2008-06-26 | Mckay William D | Particulate material dispensing hairbrush with combination bristles |
GB0700562D0 (en) | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides |
EP2444410A3 (en) | 2007-02-28 | 2012-08-08 | The Govt. Of U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services | Brachyury polypeptides and methods for use |
EP2139516A4 (en) * | 2007-04-13 | 2011-06-29 | Univ Duke | Method of inducing neutralizing antibodies to human immunodeficiency virus |
US8518903B2 (en) | 2007-04-19 | 2013-08-27 | University of Pittsburgh—of the Commonwealth System of Higher Education | Use of toll-like receptor-9 agonists |
US20100322949A1 (en) | 2007-04-26 | 2010-12-23 | Ludwig Institute For Cancer Research Ltd. | Methods for diagnosing and treating astrocytomas |
WO2008134077A1 (en) * | 2007-04-30 | 2008-11-06 | Archemix Corp. | Metabolic profile directed aptamer medicinal chemistry |
AU2008252577A1 (en) * | 2007-05-17 | 2008-11-27 | Coley Pharmaceutical Gmbh | Class A oligonucleotides with immunostimulatory potency |
WO2008142513A2 (en) * | 2007-05-18 | 2008-11-27 | Coley Pharmaceutical Gmbh | Phosphate-modified oligonucleotide analogs with immunostimulatory activity |
AU2008262489B2 (en) | 2007-05-23 | 2013-11-28 | Ventana Medical Systems, Inc. | Polymeric carriers for immunohistochemistry and in situ hybridization |
AR066676A1 (en) * | 2007-05-24 | 2009-09-02 | Glaxosmithkline Biolog Sa | ANTIGENIC LIOFILIZED COMPOSITION CONTAINING A TOLL TYPE RECEIVER AGONIST |
PL2185191T3 (en) | 2007-06-27 | 2013-02-28 | Novartis Ag | Low-additive influenza vaccines |
GB0713880D0 (en) | 2007-07-17 | 2007-08-29 | Novartis Ag | Conjugate purification |
GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
US7879812B2 (en) | 2007-08-06 | 2011-02-01 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides and methods of use therefor |
CA2697049A1 (en) * | 2007-08-21 | 2009-02-26 | Dynavax Technologies Corporation | Composition and methods of making and using influenza proteins |
JP5653215B2 (en) | 2007-09-12 | 2015-01-14 | ノバルティス アーゲー | GAS57 mutant antigen and GAS57 antibody |
RU2010112771A (en) * | 2007-10-09 | 2011-11-20 | Коули Фармасьютикал ГмбХ (DE) | IMMUNITY MULATING ANALOGUES OF OLIGONUCLEOTIDES CONTAINING MODIFIED SUGAR GROUPS |
US20110014231A1 (en) * | 2007-11-05 | 2011-01-20 | Mor Research Applications Ltd | Anti-measles cancer immunotherapy |
US8415361B2 (en) | 2007-11-09 | 2013-04-09 | The Salk Institute For Biological Studies | Use of TAM receptor inhibitors as antimicrobials |
GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
WO2009076158A1 (en) | 2007-12-07 | 2009-06-18 | Novartis Ag | Compositions for inducing immune responses |
GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
US20090175906A1 (en) * | 2007-12-21 | 2009-07-09 | Wyeth | Genetically Modified Attenuated Vesicular Stomatitis Virus, Compositions and Methods of use Thereof |
BRPI0821240B8 (en) | 2007-12-21 | 2022-10-04 | Novartis Ag | mutant forms of streptolysin o |
MX2010008148A (en) * | 2008-01-25 | 2010-10-20 | Chimerix Inc | Methods of treating viral infections. |
PT2176408E (en) * | 2008-01-31 | 2015-04-23 | Curevac Gmbh | Nucleic acids comprising formula (nugixmgnnv)a and derivatives thereof as an immunostimulating agents /adjuvants |
EP2886551A3 (en) | 2008-02-21 | 2015-09-23 | Novartis AG | Meningococcal fhbp polypeptides |
ES2557282T3 (en) | 2008-03-10 | 2016-01-25 | Children's Hospital & Research Center At Oakland | Chimeric H-factor binding proteins (fHBP) containing a heterologous B domain, and methods of use |
NZ587798A (en) | 2008-03-18 | 2013-06-28 | Novartis Ag | Improvements in the preparation of influenza virus vaccine antigens utilising a phosphate buffer |
AU2009246169B2 (en) | 2008-05-15 | 2015-01-22 | Dynavax Technologies Corporation | Long term disease modification using immunostimulatory oligonucleotides |
US8222225B2 (en) | 2008-05-21 | 2012-07-17 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating pneumoconiosis with oligodeoxynucleotides |
CA2979353C (en) | 2008-06-05 | 2020-06-30 | Ventana Medical Systems, Inc. | Compositions comprising nanomaterials and method for using such compositions for histochemical processes |
EP2650014A2 (en) | 2008-06-20 | 2013-10-16 | Wyeth LLC | Compositions and methods of use of ORF1358 from beta-hemolytic streptococcal strains |
EP3552625A1 (en) | 2008-06-27 | 2019-10-16 | Zoetis Services LLC | Novel adjuvant compositions |
TWI351288B (en) * | 2008-07-04 | 2011-11-01 | Univ Nat Pingtung Sci & Tech | Cpg dna adjuvant in avian vaccines |
US20110136897A1 (en) * | 2008-08-14 | 2011-06-09 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Toll-like receptor 9 agonists for the treatment of anxiety-related disorders and inflammatory disorders |
WO2010027818A2 (en) | 2008-08-25 | 2010-03-11 | Dana-Farber Cancer Institute, Inc. | Conserved hemagglutinin epitope, antibodies to the epitope, and methods of use |
AU2009294318B2 (en) | 2008-09-18 | 2014-04-24 | Novartis Ag | Vaccine adjuvant combinations |
CA2732750A1 (en) | 2008-09-22 | 2010-03-25 | The Government Of The United States Of America D.B.A.The Department Of V Eterans Affairs | Methods for detecting a mycobacterium tuberculosis infection |
NZ591925A (en) * | 2008-10-16 | 2012-09-28 | Internat Vaccine Inst | Adjuvant composition comprising a host defense peptide, an immunostimulatory sequence and a polyanionic polymer |
US8691502B2 (en) | 2008-10-31 | 2014-04-08 | Tremrx, Inc. | T-cell vaccination with viral vectors via mechanical epidermal disruption |
CN102203122A (en) | 2008-11-05 | 2011-09-28 | 惠氏有限责任公司 | Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (bhs) disease |
EP2346529B1 (en) | 2008-11-12 | 2016-02-10 | Theraclone Sciences, Inc. | Human m2e peptide immunogens |
ES2616051T3 (en) | 2008-12-02 | 2017-06-09 | Wave Life Sciences Japan, Inc. | Method for the synthesis of modified nucleic acids in the phosphorus atom |
US8552165B2 (en) * | 2008-12-09 | 2013-10-08 | Heather Davis | Immunostimulatory oligonucleotides |
SI2759306T1 (en) | 2008-12-09 | 2016-05-31 | Coley Pharmaceutical Group, Inc. | Immunostimulatory oligonucleotides |
CN102245198B (en) | 2008-12-09 | 2016-08-17 | 辉瑞疫苗有限责任公司 | IgE CH3 peptide vaccine |
US8585505B2 (en) | 2008-12-15 | 2013-11-19 | Tetris Online, Inc. | Inter-game interactive hybrid asynchronous computer game infrastructure |
BRPI1005670A8 (en) | 2009-01-05 | 2017-12-26 | Epitogenesis Inc | adjuvant compositions and processes of use. |
US20100233270A1 (en) | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
US8465751B2 (en) | 2009-01-12 | 2013-06-18 | Novartis Ag | Cna—B domain antigens in vaccines against gram positive bacteria |
US8664183B2 (en) | 2009-02-27 | 2014-03-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | SPANX-B polypeptides and their use |
JP2012519482A (en) | 2009-03-06 | 2012-08-30 | ノバルティス アーゲー | Chlamydia antigen |
BRPI1009215B1 (en) | 2009-03-23 | 2019-10-29 | Nanirx Inc | a pharmaceutical composition comprising a modified amino acid sequence of the human immunodeficiency virus (hiv) transcriptional activating protein (tat) and use of a tat-derived polypeptide to treat cancer |
CA2756522C (en) | 2009-03-24 | 2018-06-26 | Novartis Ag | Adjuvanting meningococcal factor h binding protein |
RU2015117604A (en) | 2009-04-03 | 2015-10-27 | Эйдженус Инк. | METHODS FOR PRODUCING AND USING MULTI-CHAPERON-ANTIGENIC COMPLEXES |
JP2013505201A (en) | 2009-04-03 | 2013-02-14 | デューク ユニバーシティー | Formulations for inducing broadly reactive neutralizing anti-HIV antibodies |
EP2419129A2 (en) | 2009-04-14 | 2012-02-22 | Novartis AG | Compositions for immunising against staphylococcus aerus |
WO2010123569A2 (en) * | 2009-04-21 | 2010-10-28 | Selecta Biosciences, Inc. | Immunonanotherapeutics providing a th1-biased response |
CA2757620C (en) | 2009-04-30 | 2016-04-26 | Coley Pharmaceutical Group, Inc. | Pneumococcal vaccine and uses thereof |
EP2435094A2 (en) | 2009-05-27 | 2012-04-04 | Selecta Biosciences, Inc. | Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents |
US9526778B2 (en) | 2009-06-15 | 2016-12-27 | Institut Pasteur De Lille | Influenza vaccine, composition, and methods of use |
TW201544119A (en) | 2009-06-22 | 2015-12-01 | Wyeth Llc | Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions |
PE20110023A1 (en) | 2009-06-22 | 2011-01-31 | Wyeth Llc | IMMUNOGENIC COMPOSITIONS OF STAPHYLOCOCCUS AUREUS ANTIGENS |
AU2010270714B2 (en) | 2009-07-06 | 2015-08-13 | Wave Life Sciences Ltd. | Novel nucleic acid prodrugs and methods use thereof |
AR077757A1 (en) | 2009-07-15 | 2011-09-21 | Novartis Ag | COMPOSITIONS OF FUSION PROTEINS OF RESPIRATORY SINCICIAL VIRUS (RSV) AND METHODS FOR PREPARATION |
EP2464658B1 (en) | 2009-07-16 | 2014-10-01 | Novartis AG | Detoxified escherichia coli immunogens |
WO2011007961A2 (en) | 2009-07-17 | 2011-01-20 | Industry Academic Cooperation Foundation, Hallym University | Immunostimulatory compositions comprising liposome-encapsulated oligonucleotides and epitpoes |
US8614200B2 (en) | 2009-07-21 | 2013-12-24 | Chimerix, Inc. | Compounds, compositions and methods for treating ocular conditions |
CA2768346A1 (en) | 2009-07-30 | 2011-02-03 | Pfizer Vaccines Llc | Antigenic tau peptides and uses thereof |
US20110033515A1 (en) * | 2009-08-04 | 2011-02-10 | Rst Implanted Cell Technology | Tissue contacting material |
AU2010284329B2 (en) * | 2009-08-18 | 2015-04-16 | Takeda Pharmaceutical Company Limited | Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics |
US8598327B2 (en) | 2009-08-18 | 2013-12-03 | Baxter International Inc. | Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics |
WO2011031298A1 (en) | 2009-08-26 | 2011-03-17 | Selecta Biosciences, Inc. | Compositions that induce t cell help |
CA2772104A1 (en) | 2009-08-27 | 2011-03-03 | Novartis Ag | Hybrid polypeptides including meningococcal fhbp sequences |
BR112012004276A2 (en) | 2009-08-27 | 2017-10-24 | Novartis Ag | adjuvant comprising aluminum, oligonucleotide and polycation |
WO2011026111A1 (en) | 2009-08-31 | 2011-03-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Oral delivery of a vaccine to the large intestine to induce mucosal immunity |
HUE037416T2 (en) | 2009-09-03 | 2018-08-28 | Pfizer Vaccines Llc | Pcsk9 vaccine |
BR112012008338A2 (en) | 2009-09-10 | 2019-09-24 | Novartis Ag | combination of vaccines against respiratory tract diseases. |
GB0917003D0 (en) | 2009-09-28 | 2009-11-11 | Novartis Vaccines Inst For Global Health Srl | Purification of bacterial vesicles |
GB0917002D0 (en) | 2009-09-28 | 2009-11-11 | Novartis Vaccines Inst For Global Health Srl | Improved shigella blebs |
AU2010302344A1 (en) | 2009-09-30 | 2012-04-26 | Novartis Ag | Expression of meningococcal fhbp polypeptides |
ES2812523T3 (en) | 2009-09-30 | 2021-03-17 | Glaxosmithkline Biologicals Sa | Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides |
CN102782138A (en) | 2009-10-07 | 2012-11-14 | Uvic工业合伙公司 | Vaccines comprising heat-sensitive transgenes |
US9181306B2 (en) | 2009-10-16 | 2015-11-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Insertion of foreign genes in rubella virus and their stable expression in a live, attenuated viral vaccine |
GB0918392D0 (en) | 2009-10-20 | 2009-12-02 | Novartis Ag | Diagnostic and therapeutic methods |
MX2012004850A (en) | 2009-10-27 | 2012-05-22 | Novartis Ag | Modified meningococcal fhbp polypeptides. |
GB0919690D0 (en) | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
EP3263124A1 (en) | 2009-11-20 | 2018-01-03 | Oregon Health&Science University | Methods for producing an immune response to tuberculosis |
CN102762224A (en) | 2009-12-22 | 2012-10-31 | 塞尔德克斯医疗公司 | Vaccine compositions |
EP3216789A1 (en) | 2010-02-12 | 2017-09-13 | Chimerix, Inc. | Methods of treating viral infection |
GB201003333D0 (en) | 2010-02-26 | 2010-04-14 | Novartis Ag | Immunogenic proteins and compositions |
US8685416B2 (en) | 2010-03-02 | 2014-04-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for the treatment of cancer |
EA201290876A1 (en) | 2010-03-05 | 2013-03-29 | Президент Энд Феллоуз Оф Гарвард Колледж | COMPOSITIONS OF INDUCED DENDRITIC CELLS AND THEIR USE |
WO2011112599A2 (en) | 2010-03-12 | 2011-09-15 | The United States Of America, As Represented By The Secretary. Department Of Health & Human Services | Immunogenic pote peptides and methods of use |
CA2793510A1 (en) | 2010-03-18 | 2012-02-16 | Novartis Ag | Adjuvanted vaccines for serogroup b meningococcus |
BR122021020829B8 (en) | 2010-03-30 | 2022-12-27 | Children´S Hospital & Res Center At Oakland | NON-NATURALLY OCCURRING FACTOR H-BINDING PROTEIN (FHBP), COMPOSITION, AND GENETICALLY MODIFIED NEISSERIA MENINGITIDIS HOST CELL |
GB201005625D0 (en) | 2010-04-01 | 2010-05-19 | Novartis Ag | Immunogenic proteins and compositions |
EP2556151A1 (en) | 2010-04-07 | 2013-02-13 | Novartis AG | Method for generating a parvovirus b19 virus-like particle |
US9597326B2 (en) | 2010-04-13 | 2017-03-21 | Glaxosmithkline Biologicals Sa | Benzonapthyridine compositions and uses thereof |
EP2563367A4 (en) | 2010-04-26 | 2013-12-04 | Chimerix Inc | Methods of treating retroviral infections and related dosage regimes |
DK2569436T3 (en) | 2010-05-14 | 2018-03-05 | Univ Oregon Health & Science | RECOMBINANT HCMV AND RHCMV VECTORS AND APPLICATIONS THEREOF |
BR112012029912A2 (en) | 2010-05-26 | 2016-11-16 | Selecta Biosciences Inc | Synthetic Nanotransport Combination Vaccines |
BR112012030337B1 (en) | 2010-05-28 | 2021-04-27 | Coley Pharmaceutical Group, Inc | VACCINE UNDERSTANDING ONE OR MORE INSULATED CPG OLIGONUCLEOTIDE (S) OR A TLR AND CHOLESTEROL AGONIST, AND USE OF THE SAME |
MX342405B (en) | 2010-06-03 | 2016-09-28 | Pharmacyclics Inc | The use of inhibitors of bruton's tyrosine kinase (btk). |
CN102933229A (en) | 2010-06-04 | 2013-02-13 | 惠氏有限责任公司 | Vaccine formulations |
CA2800774A1 (en) | 2010-06-07 | 2011-12-15 | Pfizer Vaccines Llc | Ige ch3 peptide vaccine |
GB201009861D0 (en) | 2010-06-11 | 2010-07-21 | Novartis Ag | OMV vaccines |
WO2011161653A1 (en) | 2010-06-25 | 2011-12-29 | Novartis Ag | Combinations of meningococcal factor h binding proteins |
US9192661B2 (en) | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
EP3153578A1 (en) | 2010-07-06 | 2017-04-12 | Novartis Ag | Norovirus derived immunogenic compositions and methods |
CN103189071A (en) | 2010-08-23 | 2013-07-03 | 惠氏有限责任公司 | Stable formulations of neisseria meningitidis rLP2086 antigens |
WO2012032489A1 (en) | 2010-09-10 | 2012-03-15 | Wyeth Llc | Non-lipidated variants of neisseria meningitidis orf2086 antigens |
US8883171B2 (en) | 2010-09-14 | 2014-11-11 | University of Pittsburgh—of the Commonwealth System of Higher Education | Computationally optimized broadly reactive antigens for influenza |
GB201101665D0 (en) | 2011-01-31 | 2011-03-16 | Novartis Ag | Immunogenic compositions |
US10668092B2 (en) | 2010-09-24 | 2020-06-02 | The John Hopkins University | Compositions and methods for treatment of inflammatory disorders |
US10428019B2 (en) | 2010-09-24 | 2019-10-01 | Wave Life Sciences Ltd. | Chiral auxiliaries |
US9072760B2 (en) | 2010-09-24 | 2015-07-07 | University of Pittsburgh—of the Commonwealth System of Higher Education | TLR4 inhibitors for the treatment of human infectious and inflammatory disorders |
GB201017519D0 (en) | 2010-10-15 | 2010-12-01 | Novartis Vaccines Inst For Global Health S R L | Vaccines |
EP2640190A4 (en) | 2010-11-05 | 2016-05-11 | Selecta Biosciences Inc | Modified nicotinic compounds and related methods |
WO2012072769A1 (en) | 2010-12-01 | 2012-06-07 | Novartis Ag | Pneumococcal rrgb epitopes and clade combinations |
EP2468866A1 (en) * | 2010-12-21 | 2012-06-27 | Index Pharmaceuticals AB | Biologically active oligonucleotides capable of modulating the immune system |
ES2722204T3 (en) | 2010-12-22 | 2019-08-08 | Bayer Ip Gmbh | Enhanced immune response in bovine species |
MX350170B (en) | 2010-12-22 | 2017-08-28 | Wyeth Llc | Stable immunogenic compositions of staphylococcus aureus antigens. |
WO2012088425A2 (en) | 2010-12-22 | 2012-06-28 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Gap junction-enhancing agents for treatment of necrotizing enterocolitis and inflammatory bowel disease |
GB201021867D0 (en) | 2010-12-23 | 2011-02-02 | Mologen Ag | Non-coding immunomodulatory DNA construct |
WO2012085668A2 (en) | 2010-12-24 | 2012-06-28 | Novartis Ag | Compounds |
EP2471926A3 (en) * | 2010-12-30 | 2012-07-11 | Intervet International BV | Immunostimulatory oligodeoxynucleotides |
EP4144368A1 (en) | 2011-01-26 | 2023-03-08 | GlaxoSmithKline Biologicals S.A. | Rsv immunization regimen |
EP2673364A1 (en) | 2011-02-11 | 2013-12-18 | Baxter International Inc | Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics |
EP2680883B1 (en) | 2011-03-02 | 2018-09-05 | Pfizer Inc | Pcsk9 vaccine |
MX350795B (en) | 2011-04-08 | 2017-09-19 | Inmune Design Corp | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses. |
US9452212B2 (en) | 2011-04-14 | 2016-09-27 | Dynavax Technologies Corporation | Methods and compositions for eliciting an immune response against hepatitis B virus |
US20120288515A1 (en) | 2011-04-27 | 2012-11-15 | Immune Design Corp. | Synthetic long peptide (slp)-based vaccines |
ES2782119T3 (en) | 2011-05-13 | 2020-09-10 | Glaxosmithkline Biologicals Sa | RSV prefusion F antigens |
FR2975600B1 (en) | 2011-05-24 | 2013-07-05 | Assist Publ Hopitaux De Paris | AGENTS FOR THE TREATMENT OF TUMORS |
BR112013029966A2 (en) * | 2011-05-26 | 2017-01-31 | Intervet Int Bv | unmethylated immunostimulatory oligodeoxynucleotide, vector, and vaccine to prevent or combat an infectious disease |
WO2012167053A1 (en) | 2011-06-01 | 2012-12-06 | Janus Biotherapeutics, Inc. | Novel immune system modulators |
AU2012262014B2 (en) | 2011-06-01 | 2016-07-14 | Janus Biotherapeutics, Inc. | Novel immune system modulators |
CA2838158C (en) | 2011-06-03 | 2019-07-16 | 3M Innovative Properties Company | Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom |
MX355623B (en) | 2011-06-03 | 2018-04-25 | 3M Innovative Properties Co | Hydrazino 1h-imidazoquinolin-4-amines and conjugates made therefrom. |
US8697085B2 (en) | 2011-06-17 | 2014-04-15 | University Of Tennessee Research Foundation | Group A Streptococcus multivalent vaccine |
KR20140047069A (en) | 2011-06-20 | 2014-04-21 | 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | Computationally optimized broadly reactive antigens for h1n1 influenza |
ITMI20111182A1 (en) | 2011-06-28 | 2012-12-29 | Canio Buonavoglia | VACCINE FOR CORONAVIRUS CANINO |
CA2841047A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic compositions and uses thereof |
CA2840989A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic combination compositions and uses thereof |
CN103764171B (en) | 2011-07-08 | 2016-08-17 | 诺华股份有限公司 | Tyrosine method of attachment |
WO2013007703A1 (en) * | 2011-07-08 | 2013-01-17 | Universität Zürich | CLASS A CpG OLIGONUCLEOTIDES FOR PREVENTION OF VIRAL INFECTION IN CATS |
EP2734208B1 (en) | 2011-07-19 | 2017-03-01 | Wave Life Sciences Ltd. | Methods for the synthesis of functionalized nucleic acids |
US20130023736A1 (en) | 2011-07-21 | 2013-01-24 | Stanley Dale Harpstead | Systems for drug delivery and monitoring |
EP2736921B1 (en) | 2011-07-25 | 2018-06-27 | GlaxoSmithKline Biologicals SA | Compositions and methods for assessing functional immunogenicity of parvovirus vaccines |
WO2013019669A2 (en) | 2011-07-29 | 2013-02-07 | Selecta Biosciences, Inc. | Synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte (ctl) immune responses |
GB201114923D0 (en) | 2011-08-30 | 2011-10-12 | Novartis Ag | Immunogenic proteins and compositions |
WO2013039792A1 (en) | 2011-09-12 | 2013-03-21 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Immunogens based on an hiv-1 gp120 v1v2 epitope |
ES2732708T3 (en) | 2011-09-14 | 2019-11-25 | Glaxosmithkline Biologicals Sa | Manufacturing procedures of saccharide-protein glucoconjugates |
EP2755994A2 (en) | 2011-09-14 | 2014-07-23 | Novartis AG | Escherichia coli vaccine combination |
US20140234360A1 (en) | 2011-09-30 | 2014-08-21 | The United States of America, as represented by the Secretary, Dept.of Health and Human Services | Influenza vaccine |
EP2763677B1 (en) | 2011-10-04 | 2020-02-26 | Janus Biotherapeutics, Inc. | Novel imidazole quinoline-based immune system modulators |
EP3269728B1 (en) | 2011-10-20 | 2020-12-16 | The Government of The United States of America as represented by The Secretary, Department of Health and Human Services | Dengue virus e-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes |
AU2012335208B2 (en) | 2011-11-07 | 2017-08-31 | Glaxosmithkline Biologicals S.A. | Carrier molecule comprising a spr0096 and a spr2021 antigen |
BR112014013876A2 (en) | 2011-12-08 | 2019-09-24 | Novartis Ag | clostridium difficile toxin-based vaccine |
NZ625592A (en) | 2012-01-16 | 2016-09-30 | Elizabeth Mckenna | Compositions and methods for the treatment of hepatic diseases and disorders |
WO2013108272A2 (en) | 2012-01-20 | 2013-07-25 | International Centre For Genetic Engineering And Biotechnology | Blood stage malaria vaccine |
US9234008B2 (en) | 2012-02-07 | 2016-01-12 | University of Pittsburgh—of the Commonwealth System of Higher Education | Computationally optimized broadly reactive antigens for H3N2, H2N2, and B influenza viruses |
CA2863949C (en) | 2012-02-13 | 2021-06-29 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Computationally optimized broadly reactive antigens for human and avian h5n1 influenza |
WO2013124473A1 (en) | 2012-02-24 | 2013-08-29 | Novartis Ag | Pilus proteins and compositions |
AU2013229063B2 (en) | 2012-03-09 | 2016-10-06 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
SA115360586B1 (en) | 2012-03-09 | 2017-04-12 | فايزر انك | Neisseria meningitidis compositions and methods thereof |
CA2866185C (en) | 2012-03-23 | 2021-04-06 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pathogenic phlebovirus isolates and compositions and methods of use |
WO2013163176A1 (en) | 2012-04-23 | 2013-10-31 | Allertein Therapeutics, Llc | Nanoparticles for treatment of allergy |
US10279026B2 (en) | 2012-04-26 | 2019-05-07 | Glaxosmithkline Biologicals Sa | Antigens and antigen combinations |
CN108671228A (en) | 2012-04-26 | 2018-10-19 | 诺华股份有限公司 | antigen and antigen combination |
WO2013162828A1 (en) | 2012-04-27 | 2013-10-31 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Use of cpg oligonucleotides co-formulated with an antibiotic to accelarate wound healing |
SG11201406592QA (en) | 2012-05-04 | 2014-11-27 | Pfizer | Prostate-associated antigens and vaccine-based immunotherapy regimens |
CA2874210A1 (en) | 2012-05-22 | 2013-11-28 | Novartis Ag | Meningococcus serogroup x conjugate |
WO2013177291A1 (en) | 2012-05-23 | 2013-11-28 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Salmonella typhi ty21a expressing yersinia pestis f1-v fusion protein and uses thereof |
CN104428008B (en) | 2012-05-24 | 2020-10-09 | 美国政府(由卫生和人类服务部的部长所代表) | Multivalent meningococcal conjugates and methods of making conjugates |
WO2013192144A2 (en) | 2012-06-19 | 2013-12-27 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Rift valley fever virus replicon particles and use thereof |
CN104428494B (en) | 2012-06-19 | 2019-03-22 | 沃尔沃拉斯特瓦格纳公司 | For controlling the device of air-flow, exhaust after treatment system and system for promoting vehicle |
KR102057217B1 (en) | 2012-06-20 | 2020-01-22 | 에스케이바이오사이언스 주식회사 | Multivalent pneumococcal polysaccharide-protein conjugate composition |
JP2015522580A (en) | 2012-07-06 | 2015-08-06 | ノバルティス アーゲー | Immunological compositions and uses thereof |
MX2015000577A (en) | 2012-07-13 | 2015-08-14 | Wave Life Sciences Pte Ltd | Chiral control. |
JP6246121B2 (en) * | 2012-07-13 | 2017-12-13 | 株式会社新日本科学 | Chiral nucleic acid adjuvant |
CN107011400B (en) | 2012-07-13 | 2021-05-25 | 波涛生命科学有限公司 | Asymmetric auxiliary group |
MX2015000789A (en) | 2012-07-19 | 2015-05-07 | Zoetis Llc | Bovine influenza c virus compositions. |
AU2013293087B2 (en) | 2012-07-24 | 2017-08-31 | Pharmacyclics Llc | Mutations associated with resistance to inhibitors of Bruton's tyrosine kinase (BTK) |
WO2014018724A1 (en) | 2012-07-27 | 2014-01-30 | Zoetis Llc | Tick toxin compositions |
HUE049531T2 (en) | 2012-08-16 | 2020-10-28 | Pfizer | Glycoconjugation processes and compositions |
EP3639851A1 (en) | 2012-09-04 | 2020-04-22 | Bavarian Nordic A/S | Methods and compositions for enhancing vaccine immune responses |
WO2014043535A1 (en) | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions for the treatment of cancer |
US20150224181A1 (en) | 2012-09-14 | 2015-08-13 | The United States Of America As Represented By The Secretary Department Of Health And Human Se | Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use |
CA2882382A1 (en) | 2012-09-18 | 2014-03-27 | Novartis Ag | Outer membrane vesicles |
WO2014047588A1 (en) | 2012-09-21 | 2014-03-27 | Elizabeth Mckenna | Naturally occurring cpg oligonucleotide compositions and therapeutic applications thereof |
WO2014052453A1 (en) * | 2012-09-25 | 2014-04-03 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Oral therapy of necrotizing enterocolitis |
EP2903638B1 (en) | 2012-10-03 | 2019-12-18 | GlaxoSmithKline Biologicals SA | Immunogenic composition |
KR20150080592A (en) | 2012-11-02 | 2015-07-09 | 파마시클릭스, 인코포레이티드 | Tec family kinase inhibitor adjuvant therapy |
WO2014074785A1 (en) | 2012-11-08 | 2014-05-15 | Ludwig Institute For Cancer Research Ltd. | Methods of predicting outcome and treating breast cancer |
KR20140075196A (en) | 2012-12-11 | 2014-06-19 | 에스케이케미칼주식회사 | Multivalent pneumococcal polysaccharide-protein conjugate composition |
KR20140075201A (en) | 2012-12-11 | 2014-06-19 | 에스케이케미칼주식회사 | Multivalent pneumococcal polysaccharide-protein conjugate composition |
TWI465241B (en) | 2012-12-19 | 2014-12-21 | Ind Tech Res Inst | Use of an extract of juniperus chinensis or lignan for manufacturing a medicament for inhibiting angiogenesis |
WO2014097099A2 (en) | 2012-12-20 | 2014-06-26 | Pfizer Inc. | Glycoconjugation process |
JP2016507520A (en) | 2013-01-23 | 2016-03-10 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Stabilized hepatitis B core polypeptide |
JP6494527B2 (en) | 2013-02-07 | 2019-04-03 | ザ チルドレンズ メディカル センター コーポレーション | Protein antigens that provide protection from pneumococcal colonization and / or disease |
CA2903716C (en) | 2013-03-08 | 2019-04-09 | Pfizer Inc. | Immunogenic fusion polypeptides |
AU2014236340B2 (en) | 2013-03-14 | 2019-01-17 | Massachusetts Institute Of Technology | Nanoparticle-based compositions |
JP2016512841A (en) | 2013-03-15 | 2016-05-09 | ゾエティス・サービシーズ・エルエルシー | B. Multivalent vaccine Interference effect of cattle on trehaloci infection |
DE102013004595A1 (en) | 2013-03-15 | 2014-09-18 | Emergent Product Development Germany Gmbh | RSV vaccines |
KR102233251B1 (en) | 2013-04-03 | 2021-03-26 | 엔-폴드 엘엘씨 | Novel nanoparticle compositions |
EP2986717A1 (en) | 2013-04-19 | 2016-02-24 | The Regents of The University of California | Lone star virus |
AR095882A1 (en) | 2013-04-22 | 2015-11-18 | Hoffmann La Roche | ANTIBODY COMBINATION THERAPY AGAINST HUMAN CSF-1R WITH A TLR9 AGONIST |
CN103550783A (en) * | 2013-04-27 | 2014-02-05 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | Nucleic acid drug targeting delivery system and preparation method thereof |
CA2909586C (en) | 2013-05-15 | 2021-08-31 | The Governors Of The University Of Alberta | E1e2 hcv vaccines and methods of use |
WO2014201245A1 (en) | 2013-06-12 | 2014-12-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Tlr-9 agonist with tlr-7 and/or tlr-8 agonist for treating tumors |
TWI535451B (en) * | 2013-07-19 | 2016-06-01 | 財團法人國家衛生研究院 | Cpg-oligodeoxynucleotide, immunogenic composition comprising the same, and use of preparation of medicament for treatment in stimulating immune response |
CA2919268C (en) | 2013-07-25 | 2023-09-05 | Exicure, Inc. | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
EP3632458A1 (en) | 2013-07-26 | 2020-04-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of bacterial infections |
KR102199096B1 (en) | 2013-09-08 | 2021-01-06 | 화이자 인코포레이티드 | Neisseria meningitidis compositions and methods thereof |
AR097584A1 (en) | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | ANTIBODY COMBINATION THERAPY AGAINST HUMAN CSF-1R AND ANTIBODIES AGAINST HUMAN PD-L1 |
EP3049105B1 (en) | 2013-09-19 | 2020-12-30 | Moredun Research Institute | Vaccine |
WO2015048635A1 (en) | 2013-09-27 | 2015-04-02 | Duke University | Mper-liposome conjugates and uses thereof |
WO2015048785A2 (en) | 2013-09-30 | 2015-04-02 | Los Alamos National Security, Llc | Mosaic conserved region hiv immunogenic polypeptides |
CA2926221A1 (en) | 2013-10-04 | 2015-04-09 | Pin Pharma, Inc. | Immunostimulatory hiv tat derivative polypeptides for use in cancer treatment |
CA2928908C (en) | 2013-11-01 | 2021-01-12 | Pfizer Inc. | Vectors for expression of prostate-associated antigens |
EP2870974A1 (en) | 2013-11-08 | 2015-05-13 | Novartis AG | Salmonella conjugate vaccines |
HUE056105T2 (en) | 2013-11-28 | 2022-01-28 | Bavarian Nordic As | Compositions and methods for inducing an enhanced immune response using poxvirus vectors |
CN105939699B (en) | 2013-12-03 | 2020-10-02 | 西北大学 | Liposomal particles, method for preparing same and uses thereof |
AU2014361788B2 (en) | 2013-12-13 | 2019-10-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Multi-epitope TARP peptide vaccine and uses thereof |
WO2015095868A1 (en) | 2013-12-20 | 2015-06-25 | Wake Forest University Health Sciences | Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines |
US10149905B2 (en) | 2014-01-15 | 2018-12-11 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having antitumor effect and antitumor agent |
US10144933B2 (en) | 2014-01-15 | 2018-12-04 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
US10322173B2 (en) | 2014-01-15 | 2019-06-18 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
KR102423317B1 (en) | 2014-01-16 | 2022-07-22 | 웨이브 라이프 사이언시스 리미티드 | Chiral design |
CR20160369A (en) | 2014-01-21 | 2016-10-05 | Immune Desing Corp | COMPOSITIONS FOR USE IN THE TREATMENT OF ALLERGIC AFFECTIONS |
BR112016015525A2 (en) | 2014-01-21 | 2017-10-24 | Pfizer | immunogenic compositions comprising conjugated capsular saccharide antigens and use |
KR20210032013A (en) | 2014-01-21 | 2021-03-23 | 화이자 인코포레이티드 | Streptococcus pneumoniae capsular polysaccharides and conjugates thereof |
EP3096783B1 (en) | 2014-01-21 | 2021-07-07 | Pfizer Inc. | Streptococcus pneumoniae capsular polysaccharides and conjugates thereof |
US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
WO2016130569A1 (en) | 2015-02-09 | 2016-08-18 | Mj Biologics, Inc. | A composition comprising pedv antigens and methods for making and using the composition |
EP3104877B1 (en) | 2014-02-11 | 2020-01-22 | The USA, as represented by The Secretary, Department of Health and Human Services | Pcsk9 vaccine and methods of using the same |
EP3443983B1 (en) | 2014-02-14 | 2022-07-20 | Pfizer Inc. | Immunogenic glycoprotein conjugates |
GB2523187A (en) | 2014-02-18 | 2015-08-19 | Mologen Ag | Covalently closed non-coding immunomodulatory DNA construct |
WO2015130584A2 (en) | 2014-02-25 | 2015-09-03 | Merck Sharp & Dohme Corp. | Lipid nanoparticle vaccine adjuvants and antigen delivery systems |
BR112016019837A2 (en) | 2014-02-28 | 2017-10-17 | Bayer Animal Health Gmbh | immunostimulatory plasmids |
CN106535930A (en) | 2014-03-11 | 2017-03-22 | 明尼苏达大学董事会 | Porcine epidemic diarrhea virus vaccines and methods of use thereof |
WO2015143400A1 (en) | 2014-03-20 | 2015-09-24 | Pharmacyclics, Inc. | Phospholipase c gamma 2 and resistance associated mutations |
EA037818B1 (en) | 2014-03-26 | 2021-05-25 | Глаксосмитклайн Байолоджикалс С.А. | Mutant staphylococcal antigens |
US9549914B2 (en) | 2014-04-03 | 2017-01-24 | The Johns Hopkins University | Treatment of human cytomegalovirus by modulating Wnt |
WO2015164798A1 (en) | 2014-04-25 | 2015-10-29 | Tria Bioscience Corp. | Synthetic hapten carrier compositions and methods |
EP3145495A4 (en) * | 2014-05-23 | 2018-01-17 | Cauchon, Gregory | Coating method and materials |
US20170121373A1 (en) | 2014-05-30 | 2017-05-04 | Sanofi Pasteur Inc. | Expression and conformational analysis of engineered influenza hemagglutinin |
TR201908550T4 (en) | 2014-06-04 | 2019-07-22 | Exicure Inc | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications. |
EA201692512A1 (en) | 2014-06-25 | 2017-07-31 | Селекта Байосайенсиз, Инк. | METHODS AND COMPOSITIONS FOR THE TREATMENT BY SYNTHETIC NANOSEMS AND INHIBITORS OF THE IMMUNE CONTROL POINT |
EP3169352A1 (en) | 2014-07-15 | 2017-05-24 | Immune Design Corp. | Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector |
EP3183251A4 (en) | 2014-08-22 | 2017-12-27 | Janus Biotherapeutics, Inc. | Novel n2, n4, n7, 6-tetrasubstituted pteridine-2,4,7-triamine and 2, 4, 6, 7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof |
MX2017004448A (en) | 2014-10-06 | 2017-10-23 | Exicure Inc | Anti-tnf compounds. |
US20160129097A1 (en) * | 2014-11-06 | 2016-05-12 | Jeremy Delk | Method of processing a veterinary tumor vaccine and a veterinary tumor vaccine processing kit |
JP2017537619A (en) | 2014-11-21 | 2017-12-21 | ノースウェスタン ユニバーシティ | Sequence-specific intracellular uptake of spherical nucleic acid nanoparticle complexes |
JP6536964B2 (en) * | 2014-12-26 | 2019-07-03 | 国立研究開発法人医薬基盤・健康・栄養研究所 | Application of nucleic acid polysaccharide complex having immunostimulatory activity as antitumor agent |
PT3240801T (en) | 2014-12-31 | 2021-02-18 | Checkmate Pharmaceuticals Inc | Combination tumor immunotherapy |
DK3244917T3 (en) | 2015-01-15 | 2023-05-22 | Pfizer | Immunogenic compositions for use in pneumococcal vaccines |
CN114699518A (en) | 2015-01-16 | 2022-07-05 | 硕腾服务有限责任公司 | Foot and mouth disease vaccine |
US20180036334A1 (en) | 2015-02-13 | 2018-02-08 | Icahn School Of Medicine At Mount Sinai | Rna containing compositions and methods of their use |
RU2723045C2 (en) | 2015-02-19 | 2020-06-08 | Пфайзер Инк. | Compositions of neisseria meningitidis and methods for preparation thereof |
ES2711893T3 (en) | 2015-03-12 | 2019-05-08 | Zoetis Services Llc | Procedures and compositions of pyrrolysin |
NZ736238A (en) | 2015-05-04 | 2022-07-01 | Pfizer | Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof |
WO2016180852A1 (en) | 2015-05-12 | 2016-11-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for preparing antigen-specific t cells from an umbilical cord blood sample |
WO2016183371A1 (en) | 2015-05-13 | 2016-11-17 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for the treatment or prevention of ischemic tissue damage |
IL293135A (en) | 2015-05-13 | 2022-07-01 | Agenus Inc | Composition comprising at least two different complexes of a purified stress protein bound to an antigenic peptide |
CA2987939A1 (en) | 2015-06-02 | 2016-12-08 | Sanofi Pasteur Inc. | Engineered influenza antigenic polypeptides and immunogenic compositions thereof |
EP3650043A3 (en) | 2015-06-09 | 2020-07-29 | The Board of Regents of the University of Oklahoma | Compositions and treatments for haemophilus influenzae |
WO2016201224A1 (en) | 2015-06-10 | 2016-12-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Processes for production and purification of nucleic acid-containing compositions |
EP3313439A2 (en) | 2015-06-26 | 2018-05-02 | Seqirus UK Limited | Antigenically matched influenza vaccines |
US10449212B2 (en) | 2015-07-09 | 2019-10-22 | National Institute For Materials Science | Immunostimulating oligonucleotide complex |
IL303998A (en) | 2015-07-21 | 2023-08-01 | Pfizer | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
AU2016302436B2 (en) | 2015-07-31 | 2022-03-03 | Bayer Animal Health Gmbh | Enhanced immune response in porcine species |
CA2995101A1 (en) | 2015-08-14 | 2017-02-23 | Zoetis Services Llc | Mycoplasma bovis compositions |
WO2017040885A1 (en) | 2015-09-03 | 2017-03-09 | The Board Of Regents Of The University Of Oklahoma | Peptide inhibitors of clostridium difficile tcdb toxin |
LU92821B1 (en) | 2015-09-09 | 2017-03-20 | Mologen Ag | Combination comprising immunostimulatory oligonucleotides |
US11260018B2 (en) | 2015-09-17 | 2022-03-01 | Jrx Biotechnology, Inc. | Approaches for improving skin hydration and moisturization |
GB2542425A (en) | 2015-09-21 | 2017-03-22 | Mologen Ag | Means for the treatment of HIV |
WO2017059280A1 (en) | 2015-10-02 | 2017-04-06 | The University Of North Carolina At Chapel Hill | Novel pan-tam inhibitors and mer/axl dual inhibitors |
US10548970B2 (en) | 2015-10-05 | 2020-02-04 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Human rotavirus G9P[6] strain and use as a vaccine |
CA3002685A1 (en) | 2015-10-30 | 2017-05-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions and methods for the treatment of her2-expressing solid tumors |
EP3377098A1 (en) | 2015-11-20 | 2018-09-26 | Pfizer Inc | Immunogenic compositions for use in pneumococcal vaccines |
CA3006779A1 (en) | 2015-12-09 | 2017-06-15 | Admedus Vaccines Pty Ltd | Immunomodulating composition for treatment |
EP3402878A1 (en) | 2016-01-11 | 2018-11-21 | Zoetis Services LLC | Novel cross protective vaccine compositions for porcine epidemic diarrhea virus |
CA3009928A1 (en) | 2016-01-29 | 2017-08-03 | Bavarian Nordic A/S | Recombinant modified vaccinia virus ankara (mva) equine encephalitis virus vaccine |
WO2017189448A1 (en) | 2016-04-25 | 2017-11-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bivalent immunogenic conjugate for malaria and typhoid |
WO2017192874A1 (en) | 2016-05-04 | 2017-11-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Albumin-binding immunomodulatory compositions and methods of use thereof |
WO2017201390A1 (en) | 2016-05-19 | 2017-11-23 | The Regents Of The University Of Michigan | Novel adjuvant compositions |
US11033615B2 (en) | 2016-05-31 | 2021-06-15 | The Government of the United States, As Represented by the Secretary of the Army Fort Detrick, Maryland | Zika virus vaccine and methods of production |
CA3026096A1 (en) | 2016-06-02 | 2017-12-07 | Sanofi Pasteur Inc. | Engineered influenza antigenic polypeptides and immunogenic compositions thereof |
SG11201810758WA (en) | 2016-06-03 | 2018-12-28 | Sanofi Pasteur Inc | Modification of engineered influenza hemagglutinin polypeptides |
BR112018075513A2 (en) | 2016-06-13 | 2019-10-01 | Us Health | nucleic acids encoding Zika virus-like particles and their use in vaccines and Zika virus diagnostic testing |
WO2017220753A1 (en) | 2016-06-22 | 2017-12-28 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Pneumococcal polysaccharide-protein conjugate composition |
EP3269385A1 (en) | 2016-07-12 | 2018-01-17 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Pneumococcal polysaccharide-protein conjugate composition |
WO2018009604A1 (en) | 2016-07-08 | 2018-01-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric dengue/zika viruses live-attenuated zika virus vaccines |
US10632185B2 (en) | 2016-07-08 | 2020-04-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric west nile/zika viruses and methods of use |
MX2019001342A (en) | 2016-08-05 | 2019-07-04 | Sanofi Pasteur Inc | Multivalent pneumococcal polysaccharide-protein conjugate composition. |
EA039427B1 (en) | 2016-08-05 | 2022-01-26 | Санофи Пастер Инк. | Multivalent pneumococcal polysaccharide-protein conjugate composition |
US10182146B2 (en) * | 2016-08-22 | 2019-01-15 | Nice Ltd. | System and method for dynamic redundant call recording |
WO2018039629A2 (en) | 2016-08-25 | 2018-03-01 | Northwestern University | Micellar spherical nucleic acids from thermoresponsive, traceless templates |
JP7138094B2 (en) | 2016-08-25 | 2022-09-15 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Intermittent administration of anti-CSF-1R antibody in combination with macrophage activator |
US10172933B2 (en) | 2016-10-31 | 2019-01-08 | The United States Of America, As Represented By The Secretary Of Agriculture | Mosaic vaccines for serotype a foot-and-mouth disease virus |
US10751402B2 (en) | 2016-11-09 | 2020-08-25 | Pfizer Inc. | Immunogenic compositions and uses thereof |
JP7304287B2 (en) | 2016-12-22 | 2023-07-06 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Treatment of tumors with anti-CSF-1R antibodies in combination with anti-PD-L1 antibodies after unsuccessful anti-PD-L1/PD1 therapy |
EP3570879B1 (en) | 2017-01-20 | 2022-03-30 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
CN110225757A (en) | 2017-01-31 | 2019-09-10 | 默沙东公司 | By the method for S. pneumoniae serotypes 19F production capsular polysaccharide protein conjugate |
US10183070B2 (en) | 2017-01-31 | 2019-01-22 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
US11623945B2 (en) | 2017-02-06 | 2023-04-11 | The United States Of America, As Represented By The Secretary Of Agriculture | Immunostimulating compositions and uses therefore |
GB201703529D0 (en) | 2017-03-06 | 2017-04-19 | Cambridge Entpr Ltd | Vaccine composition |
WO2018183666A1 (en) | 2017-03-31 | 2018-10-04 | Boston Medical Center Corporation | Methods and compositions using highly converved pneumococcal surface proteins |
WO2018201090A1 (en) | 2017-04-28 | 2018-11-01 | Exicure, Inc. | Synthesis of spherical nucleic acids using lipophilic moieties |
CA3066915A1 (en) | 2017-06-11 | 2018-12-20 | Molecular Express, Inc. | Methods and compositions for substance use disorder vaccine formulations and uses thereof |
JP2020525540A (en) | 2017-06-23 | 2020-08-27 | ノソコミアル ヴァクスィーン コーポレイション | Immunogenic composition |
BR112020001255A2 (en) | 2017-07-21 | 2020-07-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | immunogenic compositions of neisseria meningitidis |
JP7438102B2 (en) | 2017-09-07 | 2024-02-26 | メルク・シャープ・アンド・ドーム・エルエルシー | Pneumococcal polysaccharide and its use in immunogenic polysaccharide-carrier protein conjugates |
CA3075219A1 (en) | 2017-09-08 | 2019-03-14 | Mina Therapeutics Limited | Hnf4a sarna compositions and methods of use |
EP3690030A4 (en) | 2017-09-28 | 2021-06-23 | Industry-Academic Cooperation Foundation, Yonsei University | Method for producing myeloid-derived suppressor cells, myeloid-derived suppressor cells produced thereby, and uses thereof |
WO2019090138A2 (en) | 2017-11-04 | 2019-05-09 | Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno | Immunogenic conjugates and methods of use thereof |
AR114154A1 (en) | 2017-12-06 | 2020-07-29 | Merck Sharp & Dohme | COMPOSITIONS INCLUDING STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE CONJUGATES WITH PROTEIN AND METHODS OF USE OF THESE |
WO2019126197A1 (en) | 2017-12-18 | 2019-06-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bacterial polysaccharide-conjugated carrier proteins and use thereof |
KR20200101954A (en) | 2017-12-19 | 2020-08-28 | 메사추세츠 인스티튜트 오브 테크놀로지 | Antigen-adjuvant coupling reagents and methods of use |
WO2019143955A1 (en) | 2018-01-22 | 2019-07-25 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Broadly protective inactivated influenza virus vaccine |
RU2020128440A (en) | 2018-02-28 | 2022-03-28 | Пфайзер Инк. | IL-15 OPTIONS AND THEIR APPLICATIONS |
MX2020009149A (en) * | 2018-03-02 | 2021-01-15 | Elicio Therapeutics Inc | Compounds including a mutant kras sequence and a lipid and uses thereof. |
US11633471B2 (en) | 2018-03-06 | 2023-04-25 | Unm Rainforest Innovations | Compositions and methods for reducing serum triglycerides |
CN112189019A (en) | 2018-03-28 | 2021-01-05 | 圣诺菲·帕斯图尔公司 | Method for producing broadly protective vaccine compositions comprising hemagglutinin |
JP2021519598A (en) | 2018-04-03 | 2021-08-12 | サノフイSanofi | Antigenic Epstein-Barr virus polypeptide |
CA3095174A1 (en) | 2018-04-03 | 2019-10-10 | Sanofi | Antigenic ospa polypeptides |
KR20210018206A (en) | 2018-04-03 | 2021-02-17 | 사노피 | Antigenic respiratory syncytial virus polypeptide |
JP2021519600A (en) | 2018-04-03 | 2021-08-12 | サノフイSanofi | Antigenic influenza-ferritin polypeptide |
CN112512564A (en) | 2018-04-03 | 2021-03-16 | 赛诺菲 | Ferritin proteins |
TWI816396B (en) | 2018-05-23 | 2023-09-21 | 美商輝瑞大藥廠 | Antibodies specific for gucy2c and uses thereof |
JP7384835B2 (en) | 2018-05-23 | 2023-11-21 | ファイザー・インク | Antibodies specific to CD3 and their uses |
EP3574915A1 (en) | 2018-05-29 | 2019-12-04 | Neovacs | Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity |
CN110004150B (en) * | 2018-08-01 | 2023-03-10 | 中国农业科学院兰州兽医研究所 | CpG oligonucleotide sequence with immune enhancement activity and application thereof |
US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
CN113454100A (en) | 2018-12-04 | 2021-09-28 | 洛克菲勒大学 | HIV vaccine immunogens |
CA3120922A1 (en) | 2018-12-12 | 2020-06-18 | Pfizer Inc. | Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof |
US20220023413A1 (en) | 2018-12-12 | 2022-01-27 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Recombinant mumps virus vaccine expressing genotype g fusion and hemagglutinin-neuraminidase proteins |
WO2020123989A1 (en) | 2018-12-14 | 2020-06-18 | University Of Georgia Research Foundation, Inc. | Crimean-congo hemorrhagic fever virus replicon particles and use thereof |
US11642406B2 (en) | 2018-12-19 | 2023-05-09 | Merck Sharp & Dohme Llc | Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
WO2020128893A1 (en) | 2018-12-21 | 2020-06-25 | Pfizer Inc. | Combination treatments of cancer comprising a tlr agonist |
CN114957407A (en) | 2019-04-02 | 2022-08-30 | 赛诺菲 | Antigenic multimeric respiratory syncytial virus polypeptides |
CA3136278A1 (en) | 2019-04-10 | 2020-10-15 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
EP3966331A4 (en) * | 2019-05-10 | 2023-07-05 | Microbio (Shanghai) Co., Ltd. | Dimeric cpg oligonucleotides for use in modulating immune responses |
EP3982983A4 (en) * | 2019-06-14 | 2023-11-15 | G Tech Bio LLC | Activated lymphocytic cells and methods of using the same to treat cancer and infectious conditions |
WO2021015987A1 (en) | 2019-07-19 | 2021-01-28 | Merck Sharp & Dohme Corp. | Antigenic glycoprotein e polypeptides, compositions, and methods of use thereof |
KR20220041142A (en) | 2019-07-30 | 2022-03-31 | 피브로 애니멀 헬스 코포레이션 | Composition for mucosal administration to birds |
AU2020323498A1 (en) | 2019-07-31 | 2022-03-03 | Sk Bioscience Co., Ltd. | Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same |
WO2021042022A1 (en) | 2019-08-30 | 2021-03-04 | University Of Rochester | Septin inhibitors for treatment of cancers |
CN110646557A (en) * | 2019-10-12 | 2020-01-03 | 北京航空航天大学 | Urine metabolic marker of glioblastoma patient carrying IDH gene mutation and application thereof |
AU2020375214B2 (en) | 2019-11-01 | 2024-02-08 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
EP4077387A1 (en) | 2019-12-17 | 2022-10-26 | Pfizer Inc. | Antibodies specific for cd47, pd-l1, and uses thereof |
US20230039456A1 (en) | 2019-12-17 | 2023-02-09 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Live attenuated leishmania parasite vaccines with enhanced safety characteristics |
US20230241196A1 (en) | 2020-01-27 | 2023-08-03 | Oregon State University | Gonorrhea subunit vaccine |
BR112022015994A2 (en) | 2020-02-13 | 2022-10-11 | Univ Illinois | MULTIVALENT IMMUNOGENIC COMPOSITION, RECOMBINANT VECTOR, RECOMBINANT HOST CELL, AND, METHODS FOR INDUCING A PROTECTIVE IMMUNE RESPONSE AND FOR IMMUNIZING AN ANIMAL AGAINST DIROPHILARIOSIS |
CN115605498A (en) | 2020-02-23 | 2023-01-13 | 辉瑞公司(Us) | Escherichia coli composition and method thereof |
JP2023515829A (en) | 2020-02-28 | 2023-04-14 | サノフィ パスツール インコーポレイテッド | High-dose influenza vaccine for pediatric subjects |
US11213482B1 (en) | 2020-03-05 | 2022-01-04 | University of Pittsburgh—Of the Commonwealth System of Higher Educat | SARS-CoV-2 subunit vaccine and microneedle array delivery system |
WO2021211279A1 (en) | 2020-04-17 | 2021-10-21 | Regents Of The University Of Minnesota | SARS-CoV-2 SPIKE RECEPTOR BINDING DOMAIN AND COMPOSITIONS AND METHODS THEREOF |
EP3900739A1 (en) | 2020-04-21 | 2021-10-27 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Synthetic streptococcus pneumoniae saccharide conjugates to conserved membrane protein |
EP4149440A1 (en) | 2020-05-11 | 2023-03-22 | Erytech Pharma | Red cell extracellular vesicles (rcevs) containing cargoes and methods of use and production thereof |
PE20231565A1 (en) | 2020-07-17 | 2023-10-04 | Pfizer | THERAPEUTIC ANTIBODIES AND THEIR USES |
EP4203995A1 (en) | 2020-08-26 | 2023-07-05 | Pfizer Inc. | Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof |
WO2022058571A1 (en) | 2020-09-17 | 2022-03-24 | Neovacs | IMMUNOGENIC PRODUCT COMPRISING AN IgE FRAGMENT FOR TREATING IgE-MEDIATED INFLAMMATORY DISORDERS |
WO2022066965A2 (en) | 2020-09-24 | 2022-03-31 | Fred Hutchinson Cancer Research Center | Immunotherapy targeting sox2 antigens |
WO2022066973A1 (en) | 2020-09-24 | 2022-03-31 | Fred Hutchinson Cancer Research Center | Immunotherapy targeting pbk or oip5 antigens |
KR20230096033A (en) | 2020-10-27 | 2023-06-29 | 화이자 인코포레이티드 | Escherichia coli composition and method thereof |
MX2023005221A (en) | 2020-11-04 | 2023-05-16 | Pfizer | Immunogenic compositions for use in pneumococcal vaccines. |
JP2023549736A (en) | 2020-11-10 | 2023-11-29 | ファイザー・インク | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
US20220202923A1 (en) | 2020-12-23 | 2022-06-30 | Pfizer Inc. | E. coli fimh mutants and uses thereof |
WO2022147373A1 (en) | 2020-12-31 | 2022-07-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins |
WO2022169835A1 (en) | 2021-02-03 | 2022-08-11 | The Board Of Trustees Of The University Of Illinois | Vaccine and methods for preventing filariasis and dirofilariasis |
CA3221075A1 (en) | 2021-05-28 | 2022-12-01 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
WO2022249106A2 (en) | 2021-05-28 | 2022-12-01 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
WO2022261251A1 (en) | 2021-06-08 | 2022-12-15 | Glyde Bio Inc. | Immunogenic compositions comprising tumour-associated antigen |
EP4104830A1 (en) | 2021-06-16 | 2022-12-21 | Burghardt Wittig | Sequential innate and adaptive immune modulation for cancer treatment |
AU2022311955A1 (en) | 2021-07-16 | 2024-01-18 | The Board Of Trustees Of The University Of Illinois | Universal vaccine for influenza virus based on tetrameric m2 protein incorporated into nanodiscs |
WO2023018817A1 (en) | 2021-08-11 | 2023-02-16 | Sanofi Pasteur Inc. | Truncated influenza neuraminidase and methods of using the same |
TW202333778A (en) | 2021-10-08 | 2023-09-01 | 美商賽諾菲巴斯德公司 | Multivalent influenza vaccines |
US20230302112A1 (en) | 2021-11-05 | 2023-09-28 | Sanofi | Respiratory synctial virus rna vaccine |
WO2023081798A1 (en) | 2021-11-05 | 2023-05-11 | Sanofi Pasteur Inc. | Multivalent influenza vaccines comprising recombinant hemagglutinin and neuraminidase and methods of using the same |
WO2023079113A1 (en) | 2021-11-05 | 2023-05-11 | Sanofi | Hybrid multivalent influenza vaccines comprising hemagglutinin and neuraminidase and methods of using the same |
WO2023102373A1 (en) | 2021-11-30 | 2023-06-08 | Sanofi Pasteur Inc. | Human metapneumovirus vaccines |
WO2023102388A1 (en) | 2021-11-30 | 2023-06-08 | Sanofi Pasteur Inc. | Human metapneumovirus viral vector-based vaccines |
WO2023111262A1 (en) | 2021-12-17 | 2023-06-22 | Sanofi | Lyme disease rna vaccine |
WO2023135515A1 (en) | 2022-01-13 | 2023-07-20 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
WO2023144206A1 (en) | 2022-01-27 | 2023-08-03 | Sanofi Pasteur | Modified vero cells and methods of using the same for virus production |
WO2023161817A1 (en) | 2022-02-25 | 2023-08-31 | Pfizer Inc. | Methods for incorporating azido groups in bacterial capsular polysaccharides |
WO2023177577A1 (en) | 2022-03-14 | 2023-09-21 | Sanofi Pasteur Inc. | Machine-learning techniques in protein design for vaccine generation |
WO2023201109A1 (en) | 2022-04-15 | 2023-10-19 | Yale University | Exatecan formulation |
WO2023214082A2 (en) | 2022-05-06 | 2023-11-09 | Sanofi | Signal sequences for nucleic acid vaccines |
WO2023218322A1 (en) | 2022-05-11 | 2023-11-16 | Pfizer Inc. | Process for producing of vaccine formulations with preservatives |
WO2024003239A1 (en) | 2022-06-29 | 2024-01-04 | Bavarian Nordic A/S | RECOMBINANT MODIFIED saRNA (VRP) AND VACCINIA VIRUS ANKARA (MVA) PRIME-BOOST REGIMEN |
WO2024069420A2 (en) | 2022-09-29 | 2024-04-04 | Pfizer Inc. | Immunogenic compositions comprising an rsv f protein trimer |
Citations (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4452775A (en) * | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
US4981684A (en) * | 1989-10-24 | 1991-01-01 | Coopers Animal Health Limited | Formation of adjuvant complexes |
US5023243A (en) * | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
US5178860A (en) * | 1989-09-01 | 1993-01-12 | Coopers Animal Health Limited | Adjuvant complexes and vaccine made therefrom |
US5514577A (en) * | 1990-02-26 | 1996-05-07 | Isis Pharmaceuticals, Inc. | Oligonucleotide therapies for modulating the effects of herpes viruses |
US5527899A (en) * | 1989-10-23 | 1996-06-18 | Gilead Sciences, Inc. | Oligonucleotides with inverted polarity |
US5594122A (en) * | 1993-06-23 | 1997-01-14 | Genesys Pharma Inc. | Antisense oligonucleotides targeted against human immunodeficiency virus |
US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
US5705385A (en) * | 1995-06-07 | 1998-01-06 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
US5723335A (en) * | 1994-03-25 | 1998-03-03 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US5728518A (en) * | 1994-01-12 | 1998-03-17 | The Immune Response Corporation | Antiviral poly-and oligonucleotides |
US5736152A (en) * | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
US5753613A (en) * | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
US5766920A (en) * | 1982-08-11 | 1998-06-16 | Cellcor, Inc. | Ex vivo activation of immune cells |
US5858987A (en) * | 1995-05-05 | 1999-01-12 | Mitotix, Inc. | E6AP antisense constructs and methods of use |
US6027732A (en) * | 1996-02-21 | 2000-02-22 | Morein; Bror | Iscom or iscom-matrix comprising hydrophobic receptor molecules for antigenic substances |
US6027726A (en) * | 1994-09-30 | 2000-02-22 | Inex Phamaceuticals Corp. | Glycosylated protein-liposome conjugates and methods for their preparation |
US6030955A (en) * | 1996-03-21 | 2000-02-29 | The Trustees Of Columbia University In The City Of New York And Imclone Systems, Inc. | Methods of affecting intracellular phosphorylation of tyrosine using phosphorothioate oligonucleotides, and antiangiogenic and antiproliferative uses thereof |
US6030954A (en) * | 1991-09-05 | 2000-02-29 | University Of Connecticut | Targeted delivery of poly- or oligonucleotides to cells |
US6031086A (en) * | 1994-03-18 | 2000-02-29 | The Regents Of The University Of California | Antisense oligonucleitide containing compositions and method of forming duplexes |
US6174872B1 (en) * | 1996-10-04 | 2001-01-16 | The Regents Of The University Of California | Method for treating allergic lung disease |
US6184369B1 (en) * | 1993-04-23 | 2001-02-06 | Aronex Pharmaceuticals, Inc. | Anti-viral guanosine-rich oligonucleotides |
US6191257B1 (en) * | 1993-04-27 | 2001-02-20 | Baylor College Of Medicine | Natural or recombinant DNA binding proteins as carriers for gene transfer or gene therapy |
US6194388B1 (en) * | 1994-07-15 | 2001-02-27 | The University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6214806B1 (en) * | 1997-02-28 | 2001-04-10 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CPC dinucleotide in the treatment of LPS-associated disorders |
US6218371B1 (en) * | 1998-04-03 | 2001-04-17 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
US6221882B1 (en) * | 1997-07-03 | 2001-04-24 | University Of Iowa Research Foundation | Methods for inhibiting immunostimulatory DNA associated responses |
US6225292B1 (en) * | 1997-06-06 | 2001-05-01 | The Regents Of The University Of California | Inhibitors of DNA immunostimulatory sequence activity |
US6239116B1 (en) * | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6339068B1 (en) * | 1997-05-20 | 2002-01-15 | University Of Iowa Research Foundation | Vectors and methods for immunization or therapeutic protocols |
US6348312B1 (en) * | 1993-11-12 | 2002-02-19 | Hoescht Aktiengesellschaft | Stabilized oligonucleotides and their use |
US20020055477A1 (en) * | 2000-03-10 | 2002-05-09 | Nest Gary Van | Immunomodulatory formulations and methods for use thereof |
US6503533B1 (en) * | 1994-07-28 | 2003-01-07 | Georgetown University | Antisense ogligonucleotides against Hepatitis B viral replication |
US20030022852A1 (en) * | 2000-03-10 | 2003-01-30 | Nest Gary Van | Biodegradable immunomodulatory formulations and methods for use thereof |
US20030026801A1 (en) * | 2000-06-22 | 2003-02-06 | George Weiner | Methods for enhancing antibody-induced cell lysis and treating cancer |
US20030029783A1 (en) * | 2001-07-13 | 2003-02-13 | Donald Hubbard H. | Aerobic treatment plant with filter pipe |
US20030050263A1 (en) * | 1994-07-15 | 2003-03-13 | The University Of Iowa Research Foundation | Methods and products for treating HIV infection |
US20030049266A1 (en) * | 2000-12-27 | 2003-03-13 | Fearon Karen L. | Immunomodulatory polynucleotides and methods of using the same |
US20030050268A1 (en) * | 2001-03-29 | 2003-03-13 | Krieg Arthur M. | Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases |
US20030055014A1 (en) * | 2000-12-14 | 2003-03-20 | Bratzler Robert L. | Inhibition of angiogenesis by nucleic acids |
US20030078223A1 (en) * | 1996-01-30 | 2003-04-24 | Eyal Raz | Compositions and methods for modulating an immune response |
US20030091599A1 (en) * | 1997-03-10 | 2003-05-15 | Coley Pharmaceutical Gmbh | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
US20030092663A1 (en) * | 1997-09-05 | 2003-05-15 | Eyal Raz | Immunization-free methods for treating antigen-stimulated inflammation in a mammalian host and shifting the host's antigen immune responsiveness to a Th1 phenotype |
US20030100527A1 (en) * | 1994-07-15 | 2003-05-29 | The University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US20040006034A1 (en) * | 1998-06-05 | 2004-01-08 | Eyal Raz | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
US20040009949A1 (en) * | 2002-06-05 | 2004-01-15 | Coley Pharmaceutical Group, Inc. | Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory CpG nucleic acids |
US20040030118A1 (en) * | 1998-05-14 | 2004-02-12 | Hermann Wagner | Methods for regulating hematopoiesis using CpG-oligonucleotides |
US20040053882A1 (en) * | 2000-05-18 | 2004-03-18 | Smith Mark Peart | Combination chemotherapy |
US20040067905A1 (en) * | 2002-07-03 | 2004-04-08 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US20040067902A9 (en) * | 2000-02-03 | 2004-04-08 | Bratzler Robert L. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
US6727230B1 (en) * | 1994-03-25 | 2004-04-27 | Coley Pharmaceutical Group, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US20040087534A1 (en) * | 1994-07-15 | 2004-05-06 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
US20040092472A1 (en) * | 2002-07-03 | 2004-05-13 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US20050054601A1 (en) * | 1997-01-23 | 2005-03-10 | Coley Pharmaceutical Gmbh | Pharmaceutical composition comprising a polynucleotide and optionally an antigen especially for vaccination |
US20050059619A1 (en) * | 2002-08-19 | 2005-03-17 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids |
US20050101557A1 (en) * | 1994-07-15 | 2005-05-12 | The University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20050100983A1 (en) * | 2003-11-06 | 2005-05-12 | Coley Pharmaceutical Gmbh | Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling |
US20060003962A1 (en) * | 2002-10-29 | 2006-01-05 | Coley Pharmaceutical Group, Ltd. | Methods and products related to treatment and prevention of hepatitis C virus infection |
US20060019923A1 (en) * | 2004-07-18 | 2006-01-26 | Coley Pharmaceutical Group, Ltd. | Methods and compositions for inducing innate immune responses |
US20060019916A1 (en) * | 2004-04-02 | 2006-01-26 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for inducing IL-10 responses |
US7157437B2 (en) * | 2000-03-10 | 2007-01-02 | Dynavax Technologies Corporation | Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences |
US20070006010A1 (en) * | 2005-06-30 | 2007-01-04 | Paul Wallner | Synchronous signal generator |
US20070066554A1 (en) * | 1999-09-25 | 2007-03-22 | Coley Pharmaceutical Gmbh | Immunostimulatory nucleic acids |
US7214380B1 (en) * | 1998-06-23 | 2007-05-08 | The Board Of Trustees Of The Leland Stanford Junior University | Adjuvant therapy |
Family Cites Families (459)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2003A (en) * | 1841-03-12 | Improvement in horizontal windivhlls | ||
US2004A (en) * | 1841-03-12 | Improvement in the manner of constructing and propelling steam-vessels | ||
US2010A (en) * | 1841-03-18 | Machine foe | ||
US2002A (en) * | 1841-03-12 | Tor and planter for plowing | ||
US2005A (en) * | 1841-03-16 | Improvement in the manner of constructing molds for casting butt-hinges | ||
US3521637A (en) * | 1967-11-28 | 1970-07-28 | Nelson J Waterbury | Tampon or similar sanitary napkin containing vitamin a |
US3627874A (en) | 1969-07-16 | 1971-12-14 | Merck & Co Inc | Vaccine preparation |
US3761585A (en) | 1971-04-05 | 1973-09-25 | Beecham Group Ltd | Vaccines containing modified allergenic material |
US3906092A (en) | 1971-11-26 | 1975-09-16 | Merck & Co Inc | Stimulation of antibody response |
DE2643213C2 (en) | 1976-09-25 | 1985-02-21 | Bayer Ag, 5090 Leverkusen | Process for attenuating or inactivating microorganisms |
US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
WO1983001451A1 (en) | 1981-10-23 | 1983-04-28 | Molecular Biosystems Inc | Oligonucleotide therapeutic agent and methods of making same |
ES507187A0 (en) | 1981-11-16 | 1983-01-01 | Union Ind Y Agro Ganader S A U | PROCEDURE FOR OBTAINING AN ADDITIONAL HUMANIZED MILK OF NUCLEOTIDES FOR CHILD FEEDING. |
SE8205892D0 (en) | 1982-10-18 | 1982-10-18 | Bror Morein | IMMUNOGENT MEMBRANE PROTEIN COMPLEX, SET FOR PREPARATION AND USE THEREOF |
SE8405493D0 (en) | 1984-11-01 | 1984-11-01 | Bror Morein | IMMUNOGENT COMPLEX AND KITCHEN FOR PREPARING IT AND USING IT AS IMMUNOSTIMENTING AGENTS |
US5308626A (en) * | 1985-06-28 | 1994-05-03 | Toni N. Mariani | Lymphokine activated effector cells for antibody-dependent cellular cytotoxicity (ADCC) treatment of cancer and other diseases |
EP0231039B1 (en) | 1986-01-14 | 1992-01-08 | De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur | Process for preparing immunological complexes and pharmaceutical composition containing these complexes |
US5194428A (en) | 1986-05-23 | 1993-03-16 | Worcester Foundation For Experimental Biology | Inhibition of influenza virus replication by oligonucleotide phosphorothioates |
US4806463A (en) | 1986-05-23 | 1989-02-21 | Worcester Foundation For Experimental Biology | Inhibition of HTLV-III by exogenous oligonucleotides |
US5059519A (en) | 1986-07-01 | 1991-10-22 | University Of Massachusetts Medical School | Oligonucleotide probes for the determination of the proclivity for development of autoimmune diseases |
US5075109A (en) * | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
US5264423A (en) | 1987-03-25 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
US5276019A (en) | 1987-03-25 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
ES2007350A6 (en) | 1987-05-29 | 1989-06-16 | Ganadera Union Ind Agro | Food products enriched with nucleosides and/or nucleotides and preparation thereof. |
CA1339596C (en) | 1987-08-07 | 1997-12-23 | New England Medical Center Hospitals, Inc. | Viral expression inhibitors |
NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
US5004810A (en) | 1988-09-30 | 1991-04-02 | Schering Corporation | Antiviral oligomers |
US5087617A (en) * | 1989-02-15 | 1992-02-11 | Board Of Regents, The University Of Texas System | Methods and compositions for treatment of cancer using oligonucleotides |
US5112605A (en) * | 1989-03-17 | 1992-05-12 | Genentech, Inc. | Temporal gamma-interferon administration for allergies |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5693622A (en) | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
US5629158A (en) * | 1989-03-22 | 1997-05-13 | Cemu Bitecknik Ab | Solid phase diagnosis of medical conditions |
US4958013A (en) | 1989-06-06 | 1990-09-18 | Northwestern University | Cholesteryl modified oligonucleotides |
US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
US5676954A (en) | 1989-11-03 | 1997-10-14 | Vanderbilt University | Method of in vivo delivery of functioning foreign genes |
US5786189A (en) | 1989-11-29 | 1998-07-28 | Smithkline Beecham Biologicals (S.A.) | Vaccine |
US5457189A (en) | 1989-12-04 | 1995-10-10 | Isis Pharmaceuticals | Antisense oligonucleotide inhibition of papillomavirus |
US5514788A (en) * | 1993-05-17 | 1996-05-07 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of cell adhesion |
US5587361A (en) | 1991-10-15 | 1996-12-24 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
US5248670A (en) * | 1990-02-26 | 1993-09-28 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides for inhibiting herpesviruses |
US5166195A (en) | 1990-05-11 | 1992-11-24 | Isis Pharmaceuticals, Inc. | Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides |
DE69128350T2 (en) | 1990-06-11 | 1998-03-26 | Nexstar Pharmaceuticals Inc | NUCLEIC ACID LIGANDS |
EP0468520A3 (en) | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
US5245022A (en) * | 1990-08-03 | 1993-09-14 | Sterling Drug, Inc. | Exonuclease resistant terminally substituted oligonucleotides |
WO1992003456A1 (en) | 1990-08-16 | 1992-03-05 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating the effects of cytomegalovirus infections |
US6042838A (en) * | 1991-02-15 | 2000-03-28 | Uab Research Foundation | immunogenic compositions for mucosal administration of pneumococcal surface protein A (PspA) |
WO1992016192A1 (en) * | 1991-03-15 | 1992-10-01 | Amgen Inc. | Pulmonary administration of granulocyte colony stimulating factor |
EP0580754A1 (en) | 1991-04-18 | 1994-02-02 | The Salk Institute For Biological Studies | Oligodeoxynucleotides and oligonucleotides useful as decoys for proteins which selectively bind to defined dna sequences |
US5498410A (en) * | 1991-04-22 | 1996-03-12 | Gleich; Gerald J. | Method for the treatment of eosinophil-associated conditions with anionic polymers |
US5681555A (en) | 1991-04-22 | 1997-10-28 | Gleich; Gerald J. | Method for the treatment of bronchial asthma by parenteral administration of anionic polymers |
WO1994008003A1 (en) | 1991-06-14 | 1994-04-14 | Isis Pharmaceuticals, Inc. | ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE |
WO1992021353A1 (en) | 1991-05-31 | 1992-12-10 | Genta Incorporated | Compositions and delivery systems for transdermal administration of neutral oligomers |
US5582986A (en) | 1991-06-14 | 1996-12-10 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide inhibition of the ras gene |
US5576302A (en) | 1991-10-15 | 1996-11-19 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity |
WO1993009789A1 (en) | 1991-11-15 | 1993-05-27 | Temple University - Of The Commonwealth System Of Higher Education | Treatment of melanoma with antisense oligonucleotides to c-myb proto-oncogene |
WO1993010138A1 (en) | 1991-11-18 | 1993-05-27 | Tanox Biosystems, Inc. | Anti-sense oligonucleotides for isotype-specific suppression of immunoglobulin production |
US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
PT625204E (en) | 1992-02-04 | 2002-10-31 | Chiron Corp | HEPATITIS THERAPEUTICS |
US5643578A (en) | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
US6498147B2 (en) | 1992-05-22 | 2002-12-24 | The Scripps Research Institute | Suppression of nuclear factor-κb dependent processes using oligonucleotides |
WO1993024640A2 (en) | 1992-06-04 | 1993-12-09 | The Regents Of The University Of California | Methods and compositions for in vivo gene therapy |
US5726518A (en) * | 1992-07-22 | 1998-03-10 | Nikon Corporation | Supporting device of relative moving element of vibration actuator or vibration motor |
US5585479A (en) | 1992-07-24 | 1996-12-17 | The United States Of America As Represented By The Secretary Of The Navy | Antisense oligonucleotides directed against human ELAM-I RNA |
RU95104940A (en) | 1992-07-27 | 1997-01-10 | Хайбрайдон | Method of incorporation of alkylphosphonothioate or arylphosphonothioate internucleotide linkage in oligonucleotide, method of oligonucleotide synthesis, method of gene expression inhibition, treatment method |
US6107062A (en) * | 1992-07-30 | 2000-08-22 | Inpax, Inc. | Antisense viruses and antisense-ribozyme viruses |
WO1994004196A1 (en) | 1992-08-14 | 1994-03-03 | Imperial Cancer Research Technology Limited | Tumour therapy |
US5429199A (en) * | 1992-08-26 | 1995-07-04 | Kennametal Inc. | Cutting bit and cutting insert |
JPH08504570A (en) | 1992-10-05 | 1996-05-21 | ハイブライドン インコーポレイテッド | Therapeutic anti-HIV oligonucleotides and drugs |
US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
ATE209887T1 (en) | 1993-04-02 | 2001-12-15 | Anticancer Inc | METHOD FOR ADMINISTRATION OF BENEFICIAL COMPOSITIONS TO HAIR FOLLICLES |
US5840497A (en) | 1993-06-11 | 1998-11-24 | The Commonwealth Of Australia Commonwealth Scientific And Industrial Research Organization | Method for specific silencing of genes by DNA methylation |
KR960704033A (en) | 1993-07-19 | 1996-08-31 | 다니엘 엘. 캐시앙 | Oligonucleotides with Activity against Humand Immunodeficiency Virus |
US6004534A (en) | 1993-07-23 | 1999-12-21 | Massachusetts Institute Of Technology | Targeted polymerized liposomes for improved drug delivery |
US6605708B1 (en) | 1993-07-28 | 2003-08-12 | Hybridon, Inc. | Building blocks with carbamate internucleoside linkages and oligonucleotides derived therefrom |
US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
US5830877A (en) | 1993-08-26 | 1998-11-03 | The Regents Of The University Of California | Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory |
EP0714308A4 (en) | 1993-08-26 | 1998-07-29 | Univ California | Method, compositions and devices for administration of naked polynucleotides which encode biologically active peptides |
US5985847A (en) | 1993-08-26 | 1999-11-16 | The Regents Of The University Of California | Devices for administration of naked polynucleotides which encode biologically active peptides |
US20030109469A1 (en) * | 1993-08-26 | 2003-06-12 | Carson Dennis A. | Recombinant gene expression vectors and methods for use of same to enhance the immune response of a host to an antigen |
US5804566A (en) | 1993-08-26 | 1998-09-08 | The Regents Of The University Of California | Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides |
FR2711670B1 (en) * | 1993-10-22 | 1996-01-12 | Pasteur Institut | Nucleotide vector, composition containing it and vaccine for immunization against hepatitis. |
JPH09506770A (en) | 1993-12-23 | 1997-07-08 | バイオグノステック・ゲゼルシャフト・フュア・バイオモレキュラーレ・ダイアグノスティック・ミット・ベシュレンクテル・ハフツング | Antisense nucleic acid for preventing and treating diseases associated with the expression of c-erbB |
US5712384A (en) | 1994-01-05 | 1998-01-27 | Gene Shears Pty Ltd. | Ribozymes targeting retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs |
US5646126A (en) | 1994-02-28 | 1997-07-08 | Epoch Pharmaceuticals | Sterol modified oligonucleotide duplexes having anticancer activity |
AU710504B2 (en) | 1994-03-15 | 1999-09-23 | Brown University Research Foundation | Polymeric gene delivery system |
US5451569A (en) | 1994-04-19 | 1995-09-19 | Hong Kong University Of Science And Technology R & D Corporation Limited | Pulmonary drug delivery system |
US5696248A (en) | 1994-06-15 | 1997-12-09 | Hoechst Aktiengesellschaft | 3'-modified oligonucleotide derivatives |
US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
US5543152A (en) | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
WO1996002560A1 (en) | 1994-07-18 | 1996-02-01 | University Of North Carolina At Chapel Hill | Oligonucleoside compounds and methods for inhibiting tumor growth, invasion and metastasis |
US5785992A (en) * | 1994-09-30 | 1998-07-28 | Inex Pharmaceuticals Corp. | Compositions for the introduction of polyanionic materials into cells |
WO1996012008A1 (en) | 1994-10-13 | 1996-04-25 | Merck & Co., Inc. | Synthesis of methylase-resistant genes |
US6630455B1 (en) | 1995-01-13 | 2003-10-07 | Vanderbilt University | Methods for inducing mucosal immune responses |
US6008202A (en) * | 1995-01-23 | 1999-12-28 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
US5795587A (en) * | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
US5674483A (en) * | 1995-01-31 | 1997-10-07 | National Jewish Medical And Research Center | Treatment for diseases involving inflammation |
DE19502912A1 (en) | 1995-01-31 | 1996-08-01 | Hoechst Ag | G-Cap Stabilized Oligonucleotides |
US5932556A (en) | 1995-09-17 | 1999-08-03 | Tam; Robert C | Methods and compositions for regulation of CD28 expression |
HUP9801629A3 (en) | 1995-02-09 | 2000-10-30 | Icn Pharmaceuticals Inc Costa | Methods and compositions for regulation of cd28 expression |
GB9505438D0 (en) | 1995-03-17 | 1995-05-03 | Sod Conseils Rech Applic | Antisense oligonucleotides |
US5703057A (en) | 1995-04-07 | 1997-12-30 | Board Of Regents The University Of Texas System | Expression library immunization |
AU716486B2 (en) | 1995-04-13 | 2000-02-24 | Milkhaus Laboratory, Inc. | Methods for treating respiratory disease |
US6096721A (en) * | 1995-04-13 | 2000-08-01 | Milkhaus Laboratory, Inc. | Method for treating mucositis by sublingual administration of DNA |
UA56132C2 (en) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine |
CA2220433C (en) | 1995-05-11 | 2010-02-16 | Applied Research Systems Ars Holding N.V. | Il-6 activity inhibitor |
US5955059A (en) * | 1995-06-06 | 1999-09-21 | Trustees Of Boston University | Use of locally applied DNA fragments |
US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
IL122290A0 (en) | 1995-06-07 | 1998-04-05 | Inex Pharmaceuticals Corp | Lipid-nucleic acid complex its preparation and use |
US5830878A (en) | 1995-06-07 | 1998-11-03 | Megabios Corporation | Cationic lipid: DNA complexes for gene targeting |
US5994315A (en) | 1995-06-07 | 1999-11-30 | East Carolina University | Low adenosine agent, composition, kit and method for treatment of airway disease |
US6025339A (en) * | 1995-06-07 | 2000-02-15 | East Carolina University | Composition, kit and method for treatment of disorders associated with bronchoconstriction and lung inflammation |
US7034007B1 (en) * | 1995-06-07 | 2006-04-25 | East Carolina University | Low adenosine anti-sense oligonucleotide, compositions, kit & method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) & surfactant depletion |
US6040296A (en) * | 1995-06-07 | 2000-03-21 | East Carolina University | Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation |
CA2225460A1 (en) | 1995-06-23 | 1997-01-09 | Winston Campbell Patterson | Transcriptional regulation of genes encoding vascular endothelial growth factor receptors |
US5985662A (en) | 1995-07-13 | 1999-11-16 | Isis Pharmaceuticals Inc. | Antisense inhibition of hepatitis B virus replication |
US6248720B1 (en) * | 1996-07-03 | 2001-06-19 | Brown University Research Foundation | Method for gene therapy using nucleic acid loaded polymeric microparticles |
JPH11510142A (en) | 1995-07-21 | 1999-09-07 | ブラウン・ユニバーシティ・リサーチ・ファンデーション | Gene therapy using nucleic acid-loaded polymer microparticles |
US5968909A (en) | 1995-08-04 | 1999-10-19 | Hybridon, Inc. | Method of modulating gene expression with reduced immunostimulatory response |
US6667293B1 (en) * | 1995-09-12 | 2003-12-23 | Hybridon, Inc. | Use of cyclodextrins to modulate gene expression with reduced immunostimulatory response |
JP3631496B2 (en) | 1995-10-04 | 2005-03-23 | イミュネックス・コーポレーション | Dendritic cell stimulating factor |
US5780448A (en) | 1995-11-07 | 1998-07-14 | Ottawa Civic Hospital Loeb Research | DNA-based vaccination of fish |
ATE437943T1 (en) | 1996-01-30 | 2009-08-15 | Univ California | EXPRESSION VECTORS THAT INDUCE AN ANTIGEN-SPECIFIC IMMUNE RESPONSE AND METHODS FOR THEIR USE. |
US5994316A (en) | 1996-02-21 | 1999-11-30 | The Immune Response Corporation | Method of preparing polynucleotide-carrier complexes for delivery to cells |
SE9600647D0 (en) | 1996-02-21 | 1996-02-21 | Bror Morein | New use |
US5843770A (en) | 1996-03-11 | 1998-12-01 | The Immune Response Corporation | Antisense constructs directed against viral post-transcriptional regulatory sequences |
US6620805B1 (en) | 1996-03-14 | 2003-09-16 | Yale University | Delivery of nucleic acids by porphyrins |
US6121247A (en) | 1996-03-29 | 2000-09-19 | The Johns Hopkins University | Therapy for allergic diseases |
US6184037B1 (en) | 1996-05-17 | 2001-02-06 | Genemedicine, Inc. | Chitosan related compositions and methods for delivery of nucleic acids and oligonucleotides into a cell |
JP2002514047A (en) | 1996-07-10 | 2002-05-14 | イミュネックス・コーポレーション | How to activate dendritic cells |
EP0819758B1 (en) | 1996-07-16 | 2006-09-20 | Archibald James Mixson | Cationic vehicle: DNA complexes and their use in gene therapy |
US5854418A (en) | 1996-07-25 | 1998-12-29 | The Trustees Of Columbia University In The City Of New York | Kaposi's sarcoma-associated herpesvirus (KSHV) viral macrophage inflammatory protein-1α II (vMIP-1α II) and uses thereof |
US5856462A (en) | 1996-09-10 | 1999-01-05 | Hybridon Incorporated | Oligonucleotides having modified CpG dinucleosides |
DE19637223A1 (en) * | 1996-09-13 | 1998-04-09 | Beiersdorf Ag | Removable, self-adhesive device |
ES2241042T3 (en) * | 1996-10-11 | 2005-10-16 | The Regents Of The University Of California | IMMUNO STIMULATOR POLINUCLEOTIDE CONJUGATES / IMMUNOMODULATOR MOLECULA. |
US6562345B1 (en) * | 1996-11-12 | 2003-05-13 | City Of Hope | Immuno-reactive peptide CTL epitopes of human cytomegalovirus |
US20060002959A1 (en) * | 1996-11-14 | 2006-01-05 | Government Of The United States | Skin-sctive adjuvants for transcutaneous immuization |
US6797276B1 (en) * | 1996-11-14 | 2004-09-28 | The United States Of America As Represented By The Secretary Of The Army | Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response |
US20060002949A1 (en) * | 1996-11-14 | 2006-01-05 | Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. | Transcutaneous immunization without heterologous adjuvant |
SE9604296D0 (en) | 1996-11-22 | 1996-11-22 | Astra Ab | New pharmaceutical formulation of polypeptides |
FR2757876B1 (en) | 1996-12-27 | 1999-04-09 | Biovector Therapeutics Sa | CONJUGATES OF A PARTICULATE VECTOR AND OLIGONUCLEOTIDES, THEIR PREPARATION METHOD AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
PL334197A1 (en) | 1996-12-27 | 2000-02-14 | Icn Pharmaceuticals | Oligonucleotidic aptamers of high g content and methods of modulating immunilogical response |
US20030064945A1 (en) * | 1997-01-31 | 2003-04-03 | Saghir Akhtar | Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors |
GB9702021D0 (en) | 1997-01-31 | 1997-03-19 | Imperial College | Medicaments |
US7517952B1 (en) * | 1997-02-25 | 2009-04-14 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of prostate cancer |
WO1998040100A1 (en) * | 1997-03-10 | 1998-09-17 | Ottawa Civic Loeb Research Institute | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT |
US5965542A (en) | 1997-03-18 | 1999-10-12 | Inex Pharmaceuticals Corp. | Use of temperature to control the size of cationic liposome/plasmid DNA complexes |
US6426334B1 (en) | 1997-04-30 | 2002-07-30 | Hybridon, Inc. | Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal |
CA2289702C (en) * | 1997-05-14 | 2008-02-19 | Inex Pharmaceuticals Corp. | High efficiency encapsulation of charged therapeutic agents in lipid vesicles |
US20030104044A1 (en) * | 1997-05-14 | 2003-06-05 | Semple Sean C. | Compositions for stimulating cytokine secretion and inducing an immune response |
US6835395B1 (en) | 1997-05-14 | 2004-12-28 | The University Of British Columbia | Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles |
EP0983289A4 (en) | 1997-05-19 | 2001-04-25 | Merck & Co Inc | Oligonucleotide adjuvant |
US6589940B1 (en) | 1997-06-06 | 2003-07-08 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
WO1999005303A1 (en) | 1997-07-24 | 1999-02-04 | Inex Pharmaceuticals Corporation | Preparation of lipid-nucleic acid particles using a solvent extraction and direct hydration method |
US5877309A (en) * | 1997-08-13 | 1999-03-02 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides against JNK |
WO1999009154A2 (en) | 1997-08-19 | 1999-02-25 | Hybridon, Inc. | Novel hiv-specific synthetic oligonucleotides and methods of their use |
US6749856B1 (en) | 1997-09-11 | 2004-06-15 | The United States Of America, As Represented By The Department Of Health And Human Services | Mucosal cytotoxic T lymphocyte responses |
EP1035867A1 (en) * | 1997-12-02 | 2000-09-20 | Powderject Vaccines, Inc. | Transdermal delivery of particulate vaccine compositions |
AU1656799A (en) | 1997-12-12 | 1999-07-05 | Inex Pharmaceuticals Corp. | Cationic drugs encapsulated in anionic liposomes |
US7393630B2 (en) * | 1997-12-16 | 2008-07-01 | Novartis Vaccines And Diagnostics, Inc. | Use of microparticles combined with submicron oil-in-water emulsions |
AU751434B2 (en) | 1997-12-23 | 2002-08-15 | Inex Pharmaceuticals Corporation | Polyamide oligomers |
GB9727262D0 (en) | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
US20050031638A1 (en) * | 1997-12-24 | 2005-02-10 | Smithkline Beecham Biologicals S.A. | Vaccine |
JPH11209289A (en) * | 1998-01-22 | 1999-08-03 | Taisho Pharmaceut Co Ltd | Mucosal immunity inducer |
BR9908278A (en) | 1998-02-25 | 2002-01-02 | Iomai Corp | Use of agents to improve penetration and break through skin barriers, improve the immune transcutaneous response induced by the adp ribosylation ethoxine |
NZ505056A (en) * | 1998-03-12 | 2003-05-30 | Lucite Int Uk Ltd | A branched polymer composition containing a monofunctional monomer, a polyfunctional monomer and a chain transfer agent |
HUP0101619A3 (en) | 1998-04-09 | 2003-11-28 | Smithkline Beecham Biolog | Adjuvant compositions |
WO1999055743A1 (en) | 1998-04-28 | 1999-11-04 | Inex Pharmaceuticals Corporation | Polyanionic polymers which enhance fusogenicity |
AU3884199A (en) | 1998-05-06 | 1999-11-23 | Ottawa Health Research Institute | Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides |
SI1077722T1 (en) | 1998-05-22 | 2007-02-28 | Ottawa Health Research Inst | Methods and products for inducing mucosal immunity |
US6881561B1 (en) | 1998-05-27 | 2005-04-19 | Cheil Jedang Corporation | Endonuclease of immune cell, process for producing the same and immune adjuvant using the same |
US6248329B1 (en) * | 1998-06-01 | 2001-06-19 | Ramaswamy Chandrashekar | Parasitic helminth cuticlin nucleic acid molecules and uses thereof |
US6562798B1 (en) * | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
DE69919869T2 (en) | 1998-06-10 | 2005-09-29 | Biognostik Gesellschaft für Biomolekulare Diagnostik mbH | STIMULATION OF THE IMMUNE SYSTEM |
US20030022854A1 (en) | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
US20040247662A1 (en) | 1998-06-25 | 2004-12-09 | Dow Steven W. | Systemic immune activation method using nucleic acid-lipid complexes |
US6693086B1 (en) | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
EP1096921B1 (en) | 1998-07-20 | 2003-04-16 | Protiva Biotherapeutics Inc. | Liposomal encapsulated nucleic acid-complexes |
JP2002521489A (en) | 1998-07-27 | 2002-07-16 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | Stereoisomers of CpG oligonucleotides and related methods |
GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
EP0979869A1 (en) | 1998-08-07 | 2000-02-16 | Hoechst Marion Roussel Deutschland GmbH | Short oligonucleotides for the inhibition of VEGF expression |
US20010034330A1 (en) | 1998-08-10 | 2001-10-25 | Charlotte Kensil | Innate immunity-stimulating compositions of CpG and saponin and methods thereof |
PT1104306E (en) * | 1998-08-10 | 2006-05-31 | Antigenics Inc | CPG COMPOSITIONS AND SAPONIN ADJUVANTS AND THEIR METHODS |
AU5674699A (en) * | 1998-08-20 | 2000-03-14 | E.I. Du Pont De Nemours And Company | Genes for plant fatty acid modifying enzymes associated with conjugated double bond formation |
WO2000014217A2 (en) | 1998-09-03 | 2000-03-16 | Coley Pharmaceutical Gmbh | G-motif oligonucleotides and uses thereof |
US20020065236A1 (en) * | 1998-09-09 | 2002-05-30 | Yew Nelson S. | CpG reduced plasmids and viral vectors |
FR2783170B1 (en) * | 1998-09-11 | 2004-07-16 | Pasteur Merieux Serums Vacc | IMMUNOSTIMULATING EMULSION |
EP1671646A3 (en) | 1998-09-18 | 2007-08-29 | Dynavax Technologies Corporation | Methods of treating IgE-associated disorders and compositions for use therein |
WO2000016804A1 (en) | 1998-09-18 | 2000-03-30 | Dynavax Technologies Corporation | METHODS OF TREATING IgE-ASSOCIATED DISORDERS AND COMPOSITIONS FOR USE THEREIN |
EP1119375A4 (en) | 1998-10-05 | 2005-02-02 | Regetns Of The University Of C | Methods and adjuvants for stimulating mucosal immunity |
WO2000021556A1 (en) | 1998-10-09 | 2000-04-20 | Dynavax Technologies Corporation | Anti hiv compositions comprising immunostimulatory polynucleotides and hiv antigens |
HU228473B1 (en) | 1998-10-16 | 2013-03-28 | Smithkline Beecham Biolog | Adjuvant systems and vaccines |
AUPP807399A0 (en) | 1999-01-08 | 1999-02-04 | Csl Limited | Improved immunogenic lhrh composition and methods relating thereto |
US6887464B1 (en) * | 1999-02-02 | 2005-05-03 | Biocache Pharmaceuticals, Inc. | Advanced antigen presentation platform |
EP1165773A4 (en) | 1999-02-02 | 2005-01-05 | Biocache Pharmaceuticals Inc | Advanced antigen presentation platform |
CA2361459A1 (en) | 1999-02-05 | 2000-08-10 | Salam Abdul Kadhim | Use of cationic lipids to generate anti-tumor immunity |
US6207819B1 (en) | 1999-02-12 | 2001-03-27 | Isis Pharmaceuticals, Inc. | Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds |
WO2000054803A2 (en) * | 1999-03-16 | 2000-09-21 | Panacea Pharmaceuticals, Llc | Immunostimulatory nucleic acids and antigens |
JP2002540074A (en) | 1999-03-19 | 2002-11-26 | スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム | vaccine |
FR2790955B1 (en) | 1999-03-19 | 2003-01-17 | Assist Publ Hopitaux De Paris | USE OF STABILIZED OLIGONUCLEOTIDES AS ANTI-TUMOR ACTIVE INGREDIENT |
US6625426B2 (en) * | 1999-03-22 | 2003-09-23 | Ronald Baratono | Combined rear view mirror and telephone |
US6977245B2 (en) * | 1999-04-12 | 2005-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
AU4343700A (en) | 1999-04-12 | 2000-11-14 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Oligodeoxynucleotide and its use to induce an immune response |
WO2000062787A1 (en) | 1999-04-15 | 2000-10-26 | The Regents Of The University Of California | Methods and compositions for use in potentiating antigen presentation by antigen presenting cells |
BRPI0010612B8 (en) | 1999-04-19 | 2021-05-25 | Smithkline Beecham Biologicals S A | vaccines |
US6558670B1 (en) * | 1999-04-19 | 2003-05-06 | Smithkline Beechman Biologicals S.A. | Vaccine adjuvants |
WO2000067023A1 (en) | 1999-04-29 | 2000-11-09 | Coley Pharmaceutical Gmbh | Screening for immunostimulatory dna functional modifyers |
OA11937A (en) | 1999-05-06 | 2006-04-12 | Immune Response Corp Inc | HIV immunogenic compositions and methods. |
US6737066B1 (en) * | 1999-05-06 | 2004-05-18 | The Immune Response Corporation | HIV immunogenic compositions and methods |
AU776268B2 (en) | 1999-06-08 | 2004-09-02 | Aventis Pasteur | Immunostimulant oligonucleotide |
CA2412345A1 (en) | 1999-06-16 | 2000-12-21 | University Of Iowa Research Foundation | Antagonism of immunostimulatory cpg-oligonucleotides by 4-aminoquinolines and other weak bases |
GB9915204D0 (en) | 1999-06-29 | 1999-09-01 | Smithkline Beecham Biolog | Vaccine |
US20050002958A1 (en) * | 1999-06-29 | 2005-01-06 | Smithkline Beecham Biologicals Sa | Vaccines |
ES2250151T3 (en) | 1999-06-29 | 2006-04-16 | Glaxosmithkline Biologicals S.A. | USE OF CPG AS A VACCINE ASSISTANT AGAINST HIV. |
US6514948B1 (en) | 1999-07-02 | 2003-02-04 | The Regents Of The University Of California | Method for enhancing an immune response |
FR2795963A1 (en) * | 1999-07-08 | 2001-01-12 | Pasteur Merieux Serums Vacc | New polynucleotides are useful as vaccines for humans |
DE19935756A1 (en) * | 1999-07-27 | 2001-02-08 | Mologen Forschungs Entwicklung | Covalently closed nucleic acid molecule for immune stimulation |
CA2784789A1 (en) | 1999-08-13 | 2001-02-22 | Idera Pharmaceuticals, Inc. | Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides |
DE60041335D1 (en) | 1999-08-19 | 2009-02-26 | Dynavax Tech Corp | METHOD FOR MODULATING AN IMMUNE RESPONSE WITH IMMUNOSTIMULATING SEQUENCES AND COMPOSITIONS THEREFOR |
US20050249794A1 (en) | 1999-08-27 | 2005-11-10 | Semple Sean C | Compositions for stimulating cytokine secretion and inducing an immune response |
US6395678B1 (en) * | 1999-09-01 | 2002-05-28 | Aero-Terra-Aqua Technologies Corporation | Bead and process for removing dissolved metal contaminants |
GB9921147D0 (en) | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
GB9921146D0 (en) | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
WO2001022990A2 (en) * | 1999-09-27 | 2001-04-05 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
US6949520B1 (en) * | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
JP2003512826A (en) * | 1999-10-27 | 2003-04-08 | カイロン コーポレイション | Activation of HCV-specific T cells |
US7223398B1 (en) | 1999-11-15 | 2007-05-29 | Dynavax Technologies Corporation | Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof |
CA2391843C (en) | 1999-11-19 | 2011-10-18 | Csl Limited | Hcv vaccine compositions |
US20010031262A1 (en) * | 1999-12-06 | 2001-10-18 | Michael Caplan | Controlled delivery of antigens |
AU2593701A (en) | 1999-12-21 | 2001-07-03 | Regents Of The University Of California, The | Method for preventing an anaphylactic reaction |
AU781812B2 (en) | 2000-01-13 | 2005-06-16 | Antigenics, Inc. | Innate immunity-stimulating compositions of CPG and saponin and methods thereof |
EP1322655B1 (en) * | 2000-01-14 | 2007-11-14 | The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services | Oligodeoxynucleotide and its use to induce an immune response |
US20010044416A1 (en) * | 2000-01-20 | 2001-11-22 | Mccluskie Michael J. | Immunostimulatory nucleic acids for inducing a Th2 immune response |
US6852705B2 (en) | 2000-01-21 | 2005-02-08 | Merial | DNA vaccines for farm animals, in particular bovines and porcines |
JP4443810B2 (en) | 2000-01-26 | 2010-03-31 | イデラ ファーマシューティカルズ インコーポレイテッド | Regulation of oligonucleotide CpG-induced immune stimulation by positional modification of nucleosides |
AT409085B (en) | 2000-01-28 | 2002-05-27 | Cistem Biotechnologies Gmbh | PHARMACEUTICAL COMPOSITION FOR IMMUNULATING AND PRODUCING VACCINES |
US6552006B2 (en) * | 2000-01-31 | 2003-04-22 | The Regents Of The University Of California | Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen |
KR100808348B1 (en) | 2000-01-31 | 2008-02-27 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | Vaccine for the prophylactic or therapeutic immunization against hiv |
FR2805265B1 (en) | 2000-02-18 | 2002-04-12 | Aventis Pasteur | IMMUNOSTIMULATING OLIGONUCLEOTIDES |
AU4175101A (en) | 2000-02-23 | 2001-09-03 | Univ California | Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
US20030130217A1 (en) * | 2000-02-23 | 2003-07-10 | Eyal Raz | Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
JP2003523398A (en) | 2000-02-24 | 2003-08-05 | ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ | Adjuvant therapy by in vivo activation of dendritic cells |
US20020156033A1 (en) * | 2000-03-03 | 2002-10-24 | Bratzler Robert L. | Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer |
US20040131628A1 (en) * | 2000-03-08 | 2004-07-08 | Bratzler Robert L. | Nucleic acids for the treatment of disorders associated with microorganisms |
US20020107212A1 (en) | 2000-03-10 | 2002-08-08 | Nest Gary Van | Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences |
US6851845B2 (en) * | 2000-03-10 | 2005-02-08 | The Maitland Company, Inc. | Method and apparatus for processing waste material |
US20020098199A1 (en) | 2000-03-10 | 2002-07-25 | Gary Van Nest | Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences |
US20010046967A1 (en) | 2000-03-10 | 2001-11-29 | Gary Van Nest | Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide |
US20020028784A1 (en) * | 2000-03-10 | 2002-03-07 | Nest Gary Van | Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences |
EP1267618A1 (en) | 2000-03-28 | 2003-01-02 | The Regents Of The University Of California | Methods for increasing a cytotoxic t lymphocyte response in vivo |
US8246945B2 (en) * | 2000-04-06 | 2012-08-21 | University Of Arkansas | Methods and reagents for decreasing clinical reaction to allergy |
AU2001251407A1 (en) | 2000-04-07 | 2001-10-23 | The Regents Of The University Of California | Synergistic improvements to polynucleotide vaccines |
US7524826B2 (en) | 2000-04-14 | 2009-04-28 | Mcmaster University And Hamilton Health Sciences Corporation | Method of inhibiting the generation of active thrombin on the surface of a cell within an atherosclerotic plaque |
US6321873B1 (en) * | 2000-04-21 | 2001-11-27 | Tra-Lor-Mate, Inc. | Ladder mounting system |
PT1278761E (en) | 2000-05-01 | 2005-08-31 | Hybridon Inc | MODULATION OF IMMUNITARY STIMULATION MEASURED BY OLGONUCLEOTIDES OF CPG, BY POSITIONAL MODIFICATION OF NUCLEOSIDOS |
WO2001085910A2 (en) * | 2000-05-05 | 2001-11-15 | The Regents Of The University Of California | Agents that modulate dna-pk activity and methods of use thereof |
WO2001085751A1 (en) | 2000-05-09 | 2001-11-15 | Reliable Biopharmaceutical, Inc. | Polymeric compounds useful as prodrugs |
PT1280521E (en) * | 2000-05-12 | 2005-10-31 | Pharmacia & Upjohn Co Llc | VACCINE COMPOSITION, METHOD FOR PREPARATION, AND METHOD OF VACCINATION OF VERTEBRATES |
US6339630B1 (en) * | 2000-05-18 | 2002-01-15 | The United States Of America As Represented By The United States Department Of Energy | Sealed drive screw operator |
AU2001275294A1 (en) * | 2000-06-07 | 2001-12-17 | Biosynexus Incorporated. | Immunostimulatory RNA/DNA hybrid molecules |
US20020165178A1 (en) * | 2000-06-28 | 2002-11-07 | Christian Schetter | Immunostimulatory nucleic acids for the treatment of anemia, thrombocytopenia, and neutropenia |
AU2001280883A1 (en) | 2000-07-27 | 2002-02-13 | The Children's Hospital & Research Center At Oakland | Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis |
CN1549726A (en) | 2000-07-31 | 2004-11-24 | 耶鲁大学 | Innate immune system-directed vaccines |
US20020198165A1 (en) * | 2000-08-01 | 2002-12-26 | Bratzler Robert L. | Nucleic acids for the prevention and treatment of gastric ulcers |
US20040234960A1 (en) | 2000-09-01 | 2004-11-25 | Alexander Olek | Method for determining the degree of methylation of defined cytosines in genomic dna in the sequence context 5'-cpg-3' |
WO2002018631A2 (en) * | 2000-09-01 | 2002-03-07 | Epigenomics Ag | Diagnosis of illnesses or predisposition to certain illnesses |
US20020091097A1 (en) * | 2000-09-07 | 2002-07-11 | Bratzler Robert L. | Nucleic acids for the prevention and treatment of sexually transmitted diseases |
JP2005500806A (en) * | 2000-09-15 | 2005-01-13 | コーリー ファーマシューティカル ゲーエムベーハー | Process for high-throughput screening of immune agonist / immunoantagonists based on CpG |
GB0023008D0 (en) | 2000-09-20 | 2000-11-01 | Glaxo Group Ltd | Improvements in vaccination |
US6787524B2 (en) * | 2000-09-22 | 2004-09-07 | Tanox, Inc. | CpG oligonucleotides and related compounds for enhancing ADCC induced by anti-IgE antibodies |
ES2298269T3 (en) | 2000-09-26 | 2008-05-16 | Idera Pharmaceuticals, Inc. | MODULATION OF THE IMMUNO-STIMULATING ACTIVITY OF OLIGONUCLEOTIDIC ANALOGS IMMUNO-STIMULANTS THROUGH POSITIONAL CHEMICAL CHANGES. |
SE0003538D0 (en) * | 2000-09-29 | 2000-09-29 | Isconova Ab | New immunogenic complex |
US7537772B1 (en) * | 2000-10-02 | 2009-05-26 | Emergent Product Development Gaithersburg Inc. | Chlamydia protein, gene sequence and the uses thereof |
FR2814958B1 (en) | 2000-10-06 | 2003-03-07 | Aventis Pasteur | VACCINE COMPOSITION |
GB0025577D0 (en) | 2000-10-18 | 2000-12-06 | Smithkline Beecham Biolog | Vaccine |
ATE534401T1 (en) * | 2000-10-18 | 2011-12-15 | Glaxosmithkline Biolog Sa | VACCINES CONTAINING MAGE ANTIGEN COUPLED TO A PROTEIN D FRAGMENT |
EP1330520A2 (en) | 2000-11-02 | 2003-07-30 | Inex Pharmaceuticals Corp. | Therapeutic oligonucleotides of reduced toxicity |
WO2002069369A2 (en) | 2000-12-08 | 2002-09-06 | Coley Pharmaceutical Gmbh | Cpg-like nucleic acids and methods of use thereof |
US20020110840A1 (en) * | 2000-12-08 | 2002-08-15 | 3M Innovative Properties Company | Screening method for identifying compounds that selectively induce interferon alpha |
US7337306B2 (en) * | 2000-12-29 | 2008-02-26 | Stmicroelectronics, Inc. | Executing conditional branch instructions in a data processor having a clustered architecture |
US7713942B2 (en) | 2001-04-04 | 2010-05-11 | Nordic Vaccine Technology A/S | Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides |
US7176296B2 (en) | 2001-04-30 | 2007-02-13 | Idera Pharmaceuticals, Inc. | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
US7105495B2 (en) | 2001-04-30 | 2006-09-12 | Idera Pharmaceuticals, Inc. | Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides |
US20030129605A1 (en) | 2001-05-04 | 2003-07-10 | Dong Yu | Immunostimulatory activity of CpG oligonucleotides containing non-ionic methylphosophonate linkages |
WO2004030608A2 (en) * | 2001-06-05 | 2004-04-15 | The Regents Of The University Of Michigan | Nanoemulsion vaccines |
AU2002312487A1 (en) | 2001-06-15 | 2003-01-02 | Ribapharm | Nucleoside vaccine adjuvants |
US7785610B2 (en) | 2001-06-21 | 2010-08-31 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same—III |
US20040132677A1 (en) | 2001-06-21 | 2004-07-08 | Fearon Karen L. | Chimeric immunomodulatory compounds and methods of using the same-IV |
DK2423335T3 (en) | 2001-06-21 | 2014-08-18 | Dynavax Tech Corp | CHEMICAL IMMUNAL MODULATOR RELATIONS AND PROCEDURES FOR USE THEREOF |
WO2003000232A2 (en) | 2001-06-25 | 2003-01-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Method for preparation of vesicles loaded with immunostimulator y oligodeoxynucleotides |
US20030003970A1 (en) | 2001-06-28 | 2003-01-02 | Alan Johnson | Portable communications device |
NZ530632A (en) | 2001-06-29 | 2007-04-27 | Chiron Corp | HCV E1E2 vaccine compositions comprising E1E2 antigens, submicron oil-in-water emulsions and/or CpG oligonucleotides |
US7666674B2 (en) | 2001-07-27 | 2010-02-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo |
WO2003040308A2 (en) | 2001-07-27 | 2003-05-15 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of sterically stabilized cationic liposomes to efficiently deliver cpg oligonucleotides in vivo |
US20030148316A1 (en) * | 2001-08-01 | 2003-08-07 | Lipford Grayson B. | Methods and compositions relating to plasmacytoid dendritic cells |
AU2002326561B2 (en) * | 2001-08-07 | 2008-04-03 | Dynavax Technologies Corporation | Immunomodulatory compositions, formulations, and methods for use thereof |
JP2005510462A (en) | 2001-08-10 | 2005-04-21 | ダイナバックス テクノロジーズ コーポレイション | Production of immunomodulating oligonucleotides and methods of use thereof |
WO2003020884A2 (en) * | 2001-08-14 | 2003-03-13 | The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services | Method for rapid generation of mature dendritic cells |
ES2314099T3 (en) * | 2001-08-17 | 2009-03-16 | Coley Pharmaceutical Gmbh | IMMUNO STIMULANT OLIGONUCLEOTIDES WITH REASONS COMBINED WITH IMPROVED ACTIVITY. |
MXPA04001972A (en) | 2001-08-30 | 2005-02-17 | 3M Innovative Properties Co | Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules. |
AU2002353783A1 (en) * | 2001-09-24 | 2003-04-07 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE |
US20030119774A1 (en) * | 2001-09-25 | 2003-06-26 | Marianna Foldvari | Compositions and methods for stimulating an immune response |
WO2003028634A2 (en) | 2001-09-28 | 2003-04-10 | Purdue Research Foundation | Method of treatment using ligand-immunogen conjugates |
KR20050034583A (en) * | 2001-10-05 | 2005-04-14 | 콜리 파마슈티칼 게엠베하 | Toll-like receptor 3 signaling agonists and antagonists |
WO2003030656A2 (en) | 2001-10-06 | 2003-04-17 | Merial Limited | Methods and compositions for promoting growth and innate immunity in young animals |
KR20050048539A (en) | 2001-10-06 | 2005-05-24 | 메리얼엘엘씨 | CpG formulations and related methods |
EP1478371A4 (en) * | 2001-10-12 | 2007-11-07 | Univ Iowa Res Found | Methods and products for enhancing immune responses using imidazoquinoline compounds |
US7276489B2 (en) | 2002-10-24 | 2007-10-02 | Idera Pharmaceuticals, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends |
WO2003035836A2 (en) | 2001-10-24 | 2003-05-01 | Hybridon Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
WO2003039595A2 (en) | 2001-11-07 | 2003-05-15 | Inex Pharmaceuticals Corporation | Mucosal adjuvants comprising an oligonucleotide and a cationic lipid |
WO2003043572A2 (en) | 2001-11-16 | 2003-05-30 | 3M Innovative Properties Company | Methods and compositions related to irm compounds and toll-like receptor pathways |
TW200303759A (en) * | 2001-11-27 | 2003-09-16 | Schering Corp | Methods for treating cancer |
US7541040B2 (en) * | 2001-12-04 | 2009-06-02 | The United States Of America As Represented By The Department Of Health And Human Serivces | Chimeric molecule for the treatment of th2-like cytokine mediated disorders |
DE10161755B4 (en) * | 2001-12-15 | 2005-12-15 | Infineon Technologies Ag | Contact pin for testing microelectronic components with spherical contacts |
US8466116B2 (en) * | 2001-12-20 | 2013-06-18 | The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of CpG oligodeoxynucleotides to induce epithelial cell growth |
AU2002366710A1 (en) * | 2001-12-20 | 2003-07-09 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS |
EP1467755A1 (en) | 2001-12-21 | 2004-10-20 | Antigenics Inc. | Compositions comprising immunoreactive reagents and saponins, and methods of use thereof |
EP1474432A1 (en) | 2002-02-04 | 2004-11-10 | Biomira Inc. | Immunostimulatory, covalently lipidated oligonucleotides |
US8088388B2 (en) | 2002-02-14 | 2012-01-03 | United Biomedical, Inc. | Stabilized synthetic immunogen delivery system |
US20030232443A1 (en) | 2002-06-18 | 2003-12-18 | Isis Pharmaceuticals Inc. | Antisense modulation of centromere protein B expression |
ES2734652T3 (en) | 2002-04-04 | 2019-12-11 | Zoetis Belgium S A | Immunostimulatory oligonucleotides containing G and U |
IL164214A0 (en) * | 2002-04-11 | 2005-12-18 | Zymogenetics Inc | Use of interleukin-24 to treat ovarian cancer |
KR20050009697A (en) * | 2002-04-22 | 2005-01-25 | 바이오니취 라이프 사이언시즈 인코포레이티드 | Oligonucleotide compositions and their use for the modulation of immune responses |
US6948271B2 (en) * | 2002-05-06 | 2005-09-27 | Innovative Supply, Inc. | Identification and tracking system for deceased bodies |
CN1304103C (en) * | 2002-05-08 | 2007-03-14 | 达纳公司 | Plasma-assisted carbon structure forming |
US20040009944A1 (en) | 2002-05-10 | 2004-01-15 | Inex Pharmaceuticals Corporation | Methylated immunostimulatory oligonucleotides and methods of using the same |
ATE404152T1 (en) | 2002-05-10 | 2008-08-15 | Tekmira Pharmaceuticals Corp | PATHOGENIC VACCINES AND METHODS OF USE THEREOF |
JP2005530761A (en) | 2002-05-10 | 2005-10-13 | イネックス ファーマシューティカルズ コーポレイション | Cancer vaccine and method of use thereof |
CA2487452A1 (en) | 2002-05-28 | 2003-12-04 | Robinson Ramirez-Pineda | A method for generating antigen-presenting cells |
CA2388049A1 (en) | 2002-05-30 | 2003-11-30 | Immunotech S.A. | Immunostimulatory oligonucleotides and uses thereof |
US20040013688A1 (en) | 2002-07-03 | 2004-01-22 | Cambridge Scientific, Inc. | Vaccines to induce mucosal immunity |
US20040053880A1 (en) * | 2002-07-03 | 2004-03-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7605138B2 (en) | 2002-07-03 | 2009-10-20 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7807803B2 (en) * | 2002-07-03 | 2010-10-05 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
AU2003255969A1 (en) | 2002-07-17 | 2004-02-02 | Coley Pharmaceutical Gmbh | Use of cpg nucleic acids in prion-disease |
CN1468957A (en) | 2002-07-19 | 2004-01-21 | 中国人民解放军第二军医大学 | Plasmid used as human therapeutic vaccine adjuvant |
US20050209183A1 (en) | 2002-07-25 | 2005-09-22 | Phenion Gmbh & Co. Kg | Cosmetic or pharmaceutical preparations comprising nucleic acids based on non-methylated CPG motifs |
EP1393745A1 (en) | 2002-07-29 | 2004-03-03 | Hybridon, Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5'ends |
EP1575504A4 (en) | 2002-08-01 | 2009-11-04 | Us Gov Health & Human Serv | Method of treating inflammatory arthropathies with suppressors of cpg oligonucleotides |
SG172476A1 (en) * | 2002-08-12 | 2011-07-28 | Dynavax Tech Corp | Immunomodulatory compositions comprising a cationic condensing agent, an immunostimulatory compound comprising 5'-cg-3', an a non ionic detergent |
US6928476B2 (en) * | 2002-08-23 | 2005-08-09 | Mirra, Inc. | Peer to peer remote data storage and collaboration |
US6744084B2 (en) * | 2002-08-29 | 2004-06-01 | Micro Technology, Inc. | Two-transistor pixel with buried reset channel and method of formation |
PT1572095E (en) * | 2002-09-13 | 2015-10-13 | Novartis Ag | Beta-l-2'-deoxynucleosides for use in the treatment of resistant hbv strains |
US8263091B2 (en) * | 2002-09-18 | 2012-09-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides |
US6994870B2 (en) * | 2002-09-18 | 2006-02-07 | Jaw-Ji Tsai | Local nasal immunotherapy with allergen strip for allergic rhinitis |
AU2003278845A1 (en) | 2002-09-19 | 2004-04-08 | Coley Pharmaceutical Gmbh | Toll-like receptor 9 (tlr9) from various mammalian species |
US6988995B2 (en) * | 2002-09-30 | 2006-01-24 | Carl Zeiss Meditec, Inc. | Method and system for detecting the effects of Alzheimer's disease in the human retina |
US8043622B2 (en) * | 2002-10-08 | 2011-10-25 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides |
US20040248837A1 (en) | 2002-11-01 | 2004-12-09 | Eyal Raz | Methods of treating pulmonary fibrotic disorders |
JP4976653B2 (en) * | 2002-11-01 | 2012-07-18 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシス | Method for preventing infections caused by bioterrorism pathogens using immunostimulatory CpG oligonucleotides |
WO2004053104A2 (en) * | 2002-12-11 | 2004-06-24 | Coley Pharmaceutical Group, Inc. | 5’ cpg nucleic acids and methods of use |
KR100525321B1 (en) | 2002-12-13 | 2005-11-02 | 안웅식 | Pharmaceutical composition for prophylaxis and treatment of papillomavirus-derived diseases comprising papillomavirus antigen protein and CpG-oligodeoxynucleotide |
WO2004058159A2 (en) | 2002-12-23 | 2004-07-15 | Dynavax Technologies Corporation | Branched immunomodulatory compounds and methods of using the same |
NZ541027A (en) * | 2002-12-23 | 2008-04-30 | Dynavax Tech Corp | Immunostimulatory sequence oligonucleotides and methods of using the same |
JP4726630B2 (en) | 2003-01-16 | 2011-07-20 | イデラ ファーマシューティカルズ インコーポレイテッド | Modulating the immunostimulatory properties of oligonucleotide-based compounds by using modified immunostimulatory dinucleotides |
US7189781B2 (en) * | 2003-03-13 | 2007-03-13 | H.B. Fuller Licensing & Finance Inc. | Moisture curable, radiation curable sealant composition |
CN100355453C (en) | 2003-03-24 | 2007-12-19 | 英特塞尔股份公司 | Improved vaccines |
NZ542323A (en) | 2003-03-26 | 2008-07-31 | Cytos Biotechnology Ag | Melan-A peptide analogue-virus-like-particle conjugates |
EP1608403A2 (en) | 2003-04-02 | 2005-12-28 | Coley Pharmaceutical Group, Ltd. | Immunostimulatory nucleic acid oil-in-water formulations for topical application |
US20050004144A1 (en) * | 2003-04-14 | 2005-01-06 | Regents Of The University Of California | Combined use of IMPDH inhibitors with toll-like receptor agonists |
EP1631687A2 (en) | 2003-04-22 | 2006-03-08 | Coley Pharmaceutical GmbH | Methods and products for identification and assessment of tlr ligands |
JP3887346B2 (en) * | 2003-04-28 | 2007-02-28 | 株式会社東芝 | Video signal processing apparatus, video signal processing method, and video display apparatus |
AU2004241093B2 (en) | 2003-05-16 | 2009-08-27 | Idera Pharmaceuticals, Inc. | Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents |
EP1484336A1 (en) * | 2003-06-02 | 2004-12-08 | Pevion Biotech Ltd. | Methods for synthesizing conformationally constrained peptides, peptidometics and the use thereof as synthetic vaccines |
KR101137572B1 (en) | 2003-06-11 | 2012-05-30 | 이데라 파마슈티칼즈, 인코포레이티드 | Stabilized immunomodulatory oligonucleotides |
WO2004110489A1 (en) * | 2003-06-13 | 2004-12-23 | Daiichi Asubio Pharma Co., Ltd. | MEDICINAL COMPOSITION FOR PREVENTING OR TREATING Th1 TYPE IMMUNOLOGICAL DISEASE |
JP5127224B2 (en) * | 2003-06-17 | 2013-01-23 | マンカインド コーポレイション | Methods for inducing, enhancing and maintaining an immune response against MHC class I restricted epitopes for prophylactic or therapeutic purposes |
EP1635846A4 (en) | 2003-06-20 | 2009-01-28 | Coley Pharm Gmbh | Small molecule toll-like receptor (tlr) antagonists |
US20040265833A1 (en) | 2003-06-23 | 2004-12-30 | Cathy Lofton-Day | Methods and nucleic acids for the analysis of colorectal cell proliferative disorders |
WO2005004907A1 (en) | 2003-07-10 | 2005-01-20 | Cytos Biotechnology Ag | Packaged virus-like particles |
CN1822856B (en) | 2003-07-11 | 2010-04-28 | 英特塞尔股份公司 | HCV vaccines |
US20050013812A1 (en) * | 2003-07-14 | 2005-01-20 | Dow Steven W. | Vaccines using pattern recognition receptor-ligand:lipid complexes |
JP2007531699A (en) | 2003-07-15 | 2007-11-08 | イデラ ファーマシューティカルズ インコーポレイテッド | Synergistic stimulation of the immune system using immunostimulatory oligonucleotides and / or immunomeric compounds in combination with cytokines and / or chemotherapeutic agents or radiation therapy |
WO2005014110A1 (en) * | 2003-07-22 | 2005-02-17 | Cytos Biotechnology Ag | Cpg-packaged liposomes |
CN101291691A (en) | 2003-08-28 | 2008-10-22 | 免疫反应公司 | Immunogenic HIV compositions and related methods |
OA13310A (en) * | 2003-09-05 | 2007-04-13 | Anadys Pharmaceuticals Inc | TLR7 ligands for the treatment of hepatitis C. |
EP1671643A1 (en) | 2003-09-08 | 2006-06-21 | Intellectual Property Consulting Inc. | Medicinal composition for treating chronic hepatitis c |
GB0321615D0 (en) * | 2003-09-15 | 2003-10-15 | Glaxo Group Ltd | Improvements in vaccination |
WO2005027920A1 (en) * | 2003-09-19 | 2005-03-31 | Pfizer Products Inc. | 2-alkylidene-19-nor-vitamin d derivatives for the treatment of rickets or vitamin d deficiency |
US7615539B2 (en) | 2003-09-25 | 2009-11-10 | Coley Pharmaceutical Group, Inc. | Nucleic acid-lipophilic conjugates |
AU2004280143A1 (en) | 2003-10-11 | 2005-04-21 | Tekmira Pharmaceuticals Corporation | Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity |
US20050087538A1 (en) * | 2003-10-23 | 2005-04-28 | Wolfe Darrell R. | Iceless multiple can cooler |
US20050215501A1 (en) | 2003-10-24 | 2005-09-29 | Coley Pharmaceutical Group, Inc. | Methods and products for enhancing epitope spreading |
US8188254B2 (en) | 2003-10-30 | 2012-05-29 | Coley Pharmaceutical Gmbh | C-class oligonucleotide analogs with enhanced immunostimulatory potency |
US20050239733A1 (en) | 2003-10-31 | 2005-10-27 | Coley Pharmaceutical Gmbh | Sequence requirements for inhibitory oligonucleotides |
JP4088246B2 (en) * | 2003-12-05 | 2008-05-21 | 富士通株式会社 | Ring network master setting method and apparatus |
WO2005060377A2 (en) | 2003-12-08 | 2005-07-07 | Hybridon, Inc. | Modulation of immunostimulatory properties by small oligonucleotide-based compounds |
US9090673B2 (en) | 2003-12-12 | 2015-07-28 | City Of Hope | Synthetic conjugate of CpG DNA and T-help/CTL peptide |
US20070172315A1 (en) * | 2003-12-18 | 2007-07-26 | Barrett Robert K | Method and Apparatus for Creating Soil or Rock Subsurface Support |
EP1550458A1 (en) | 2003-12-23 | 2005-07-06 | Vectron Therapeutics AG | Synergistic liposomal adjuvants |
KR100558851B1 (en) | 2004-01-08 | 2006-03-10 | 학교법인연세대학교 | Modified CpG oligodeoxynucleotide with improved immunoregulatory function |
AU2005213460A1 (en) * | 2004-02-06 | 2005-08-25 | Mayo Foundation For Medical Education And Research | Complexed polypeptide and adjuvant for improved vaccines |
US20050181035A1 (en) | 2004-02-17 | 2005-08-18 | Dow Steven W. | Systemic immune activation method using non CpG nucleic acids |
EP2415481A3 (en) | 2004-02-19 | 2012-04-18 | Coley Pharmaceutical Group, Inc. | Immunostimulatory viral RNA oligonucleotides |
CN1918293A (en) | 2004-02-20 | 2007-02-21 | 莫洛根股份公司 | Substituted non-coding nucleic acid molecule for therapeutic or prophylaxis immunological stimulus for human and higher animal |
CN101217973A (en) | 2004-03-12 | 2008-07-09 | 海布里顿公司 | Enhanced activity of HIV vaccine using a second generation immunomodulatory oligonucleotide |
US7303881B2 (en) * | 2004-04-30 | 2007-12-04 | Pds Biotechnology Corporation | Antigen delivery compositions and methods of use |
WO2005115449A1 (en) * | 2004-05-28 | 2005-12-08 | Alk-Abelló A/S | Method of treating allergy and infection by eliciting an iga antibody response |
US8399025B2 (en) * | 2004-06-04 | 2013-03-19 | Board Of Regents, The University Of Texas System | Polyamine modified particles |
CA2567789A1 (en) * | 2004-06-08 | 2006-08-03 | Coley Pharmaceutical Gmbh | Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist |
US7756043B1 (en) * | 2004-06-09 | 2010-07-13 | Sprint Communications Company L.P. | Method for identifying high traffic origin-destination node pairs in a packet based network |
EP2901856B1 (en) | 2004-06-15 | 2017-08-09 | Idera Pharmaceuticals, Inc. | Immunostimulatory oligonucleotide multimers |
US7427405B2 (en) | 2004-06-15 | 2008-09-23 | Idera Pharmaceuticals, Inc. | Immunostimulatory oligonucleotide multimers |
EP1766610A1 (en) * | 2004-06-25 | 2007-03-28 | TC Electronic A/S | Method of evaluating perception intensity of an audio signal and a method of controlling an input audio signal on the basis of the evaluation |
WO2006080951A2 (en) * | 2004-07-01 | 2006-08-03 | Yale University | Targeted and high density drug loaded polymeric materials |
EP1781325A2 (en) | 2004-07-18 | 2007-05-09 | CSL Limited | Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses |
WO2006015560A1 (en) | 2004-08-09 | 2006-02-16 | Mologen Ag | Immunomodulating agent used in conjunction with chemotherapy |
US20060058261A1 (en) * | 2004-09-15 | 2006-03-16 | Andre Aube | Chitin derivatives for hyperlipidemia |
MY159370A (en) * | 2004-10-20 | 2016-12-30 | Coley Pharm Group Inc | Semi-soft-class immunostimulatory oligonucleotides |
KR100721928B1 (en) * | 2004-11-05 | 2007-05-28 | 주식회사 바이오씨에스 | Pharmaceutical composition for treating or preventing dermatitis comprising CpG oligodeoxynucleotide |
US20060105979A1 (en) | 2004-11-08 | 2006-05-18 | Hybridon, Inc. | Synergistic inhibition of VEGF and modulation of the immune response |
AU2006204554A1 (en) | 2005-01-07 | 2006-07-13 | Alk-Abello A/S | Method of preventive treatment of allergy by oromucosal administration of an allergy vaccine |
CA2598992A1 (en) * | 2005-02-24 | 2006-08-31 | Coley Pharmaceutical Group, Inc. | Immunostimulatory oligonucleotides |
US20060229271A1 (en) | 2005-04-08 | 2006-10-12 | Coley Pharmaceutical Group, Inc. | Methods for treating infectious disease exacerbated asthma |
CA2609788A1 (en) | 2005-04-26 | 2006-11-02 | Coley Pharmaceutical Gmbh | Modified oligoribonucleotide analogs with enhanced immunostimulatory activity |
SG163583A1 (en) * | 2005-07-07 | 2010-08-30 | Coley Pharm Group Inc | Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment |
WO2007027718A1 (en) * | 2005-08-31 | 2007-03-08 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Methods of altering an immune response induced by cpg oligodeoxynucleotides |
EP1924692A2 (en) | 2005-09-16 | 2008-05-28 | Coley Pharmaceutical GmbH | Modulation of immunostimulatory properties of short interfering ribonucleic acid (sirna) by nucleotide modification |
EA013468B1 (en) | 2005-09-16 | 2010-04-30 | Коли Фармасьютикал Гмбх | Immunostimulatory single-stranded ribonucleic acid with phosphodiester backbone |
AU2006294528A1 (en) | 2005-09-27 | 2007-04-05 | Coley Pharmaceutical Gmbh | Modulation of TLR-mediated immune responses using adaptor oligonucleotides |
EA200801045A1 (en) * | 2005-10-12 | 2008-10-30 | Кэнсер Рисерч Текнолоджи Лтд. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF IMMUNE DISORDERS |
US20070093439A1 (en) | 2005-10-25 | 2007-04-26 | Idera Pharmaceuticals, Inc. | Short immunomodulatory oligonucleotides |
AU2006306805A1 (en) * | 2005-10-28 | 2007-05-03 | Index Pharmaceuticals Ab | Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease |
US20070243209A1 (en) * | 2005-10-28 | 2007-10-18 | Health Research, Inc. | Compositions and methods for prevention and treatment of fungal diseases |
EP1951299B1 (en) | 2005-11-04 | 2012-01-04 | Novartis Vaccines and Diagnostics S.r.l. | Influenza vaccines including combinations of particulate adjuvants and immunopotentiators |
JP2009514839A (en) | 2005-11-04 | 2009-04-09 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | Adjuvant influenza vaccine containing cytokine inducer |
US7470674B2 (en) | 2005-11-07 | 2008-12-30 | Idera Pharmaceuticals, Inc. | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
EP1945653A4 (en) | 2005-11-07 | 2012-03-14 | Idera Pharmaceuticals | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
US7776834B2 (en) | 2005-11-07 | 2010-08-17 | Idera Pharmaceuticals, Inc. | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
EP2371956A3 (en) | 2005-11-07 | 2012-01-04 | Idera Pharmaceuticals | Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides |
EP1957647B1 (en) * | 2005-11-25 | 2015-03-04 | Zoetis Belgium S.A. | Immunostimulatory oligoribonucleotides |
AU2006331879A1 (en) | 2005-12-20 | 2007-07-05 | Idera Pharmaceuticals, Inc. | Immunostimulatory activity of palindromic immune modulatory oligonucleotides (IMO TM) contiaining different lengths of palindromic segments |
CA2642152C (en) * | 2006-02-15 | 2016-11-01 | Coley Pharmaceutical Gmbh | Compositions and methods for oligonucleotide formulations |
DE102006007433A1 (en) | 2006-02-17 | 2007-08-23 | Curevac Gmbh | Immunostimulant adjuvant useful in vaccines against cancer or infectious diseases comprises a lipid-modified nucleic acid |
US20090081156A1 (en) * | 2006-08-03 | 2009-03-26 | William Soo Hoo | Bioactive molecular matrix and methods of use in the treatment of disease |
US20080124366A1 (en) * | 2006-08-06 | 2008-05-29 | Ohlfest John R | Methods and Compositions for Treating Tumors |
US20080171716A1 (en) * | 2006-08-16 | 2008-07-17 | Protiva Biotherapeutics, Inc. | Nucleic acid modulation of toll-like receptor-mediated immune stimulation |
US8027888B2 (en) | 2006-08-31 | 2011-09-27 | Experian Interactive Innovation Center, Llc | Online credit card prescreen systems and methods |
WO2008033432A2 (en) | 2006-09-12 | 2008-03-20 | Coley Pharmaceutical Group, Inc. | Immune modulation by chemically modified ribonucleosides and oligoribonucleotides |
US20090181078A1 (en) * | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
TR201807756T4 (en) * | 2006-09-26 | 2018-06-21 | Infectious Disease Res Inst | Vaccine composition containing synthetic adjuvant. |
CA2664156A1 (en) | 2006-09-27 | 2008-04-03 | Coley Pharmaceutical Group, Inc. | Compositions of tlr ligands and antivirals |
CN101517082B (en) | 2006-09-27 | 2014-01-22 | 科勒制药有限责任公司 | Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity |
AU2007353120A1 (en) * | 2006-10-26 | 2008-11-20 | Coley Pharmaceutical Gmbh | Oligoribonucleotides and uses thereof |
WO2008057529A2 (en) * | 2006-11-06 | 2008-05-15 | Coley Pharmaceutical Group, Inc. | Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (cetp) |
EP2089411A4 (en) * | 2006-12-04 | 2010-01-27 | Univ Illinois | Compositions and methods to treat cancer with cupredoxins and cpg rich dna |
EP2526966B1 (en) * | 2006-12-28 | 2016-03-23 | The Trustees of The University of Pennsylvania | Herpes simplex virus combined subunit vaccines and methods of use thereof |
US8057804B2 (en) * | 2006-12-28 | 2011-11-15 | The Trustees Of The University Of Pennsylvania | Herpes simplex virus combined subunit vaccines and methods of use thereof |
PE20090146A1 (en) * | 2007-04-20 | 2009-03-23 | Glaxosmithkline Biolog Sa | IMMUNOGENIC COMPOSITION AGAINST THE INFLUENZA VIRUS |
AU2008252577A1 (en) | 2007-05-17 | 2008-11-27 | Coley Pharmaceutical Gmbh | Class A oligonucleotides with immunostimulatory potency |
EP2591787A1 (en) * | 2007-08-13 | 2013-05-15 | Pfizer Inc | Combination motif immune stimulatory oligonucleotides with improved activity |
CA2697049A1 (en) * | 2007-08-21 | 2009-02-26 | Dynavax Technologies Corporation | Composition and methods of making and using influenza proteins |
EP2185160B1 (en) * | 2007-08-31 | 2019-02-13 | Neurimmune Holding AG | Method of providing patient specific immune response in amyloidoses and protein aggregation disorders |
US7892567B2 (en) * | 2007-10-01 | 2011-02-22 | Board Of Regents, The University Of Texas System | Methods and compositions for immunization against chlamydial infection and disease |
RU2010112771A (en) | 2007-10-09 | 2011-11-20 | Коули Фармасьютикал ГмбХ (DE) | IMMUNITY MULATING ANALOGUES OF OLIGONUCLEOTIDES CONTAINING MODIFIED SUGAR GROUPS |
AR069704A1 (en) * | 2007-12-18 | 2010-02-10 | Alcon Res Ltd | SYSTEM OF ADMINISTRATION OF RNAI OF INTERFERENCE AND USES OF THE SAME |
US7720322B2 (en) * | 2008-06-30 | 2010-05-18 | Intuitive Surgical, Inc. | Fiber optic shape sensor |
TWI351288B (en) * | 2008-07-04 | 2011-11-01 | Univ Nat Pingtung Sci & Tech | Cpg dna adjuvant in avian vaccines |
US20100166782A1 (en) * | 2008-07-25 | 2010-07-01 | Martha Karen Newell | Clip inhibitors and methods of modulating immune function |
US8053422B2 (en) * | 2008-12-04 | 2011-11-08 | The United States Of America As Represented By The Department Of Health And Human Services | Anti-cancer oligodeoxynucleotides |
-
1996
- 1996-10-30 US US08/738,652 patent/US6207646B1/en not_active Expired - Lifetime
-
1997
- 1997-10-30 ES ES10186177.1T patent/ES2624859T3/en not_active Expired - Lifetime
- 1997-10-30 DE DE69736331T patent/DE69736331T2/en not_active Revoked
- 1997-10-30 CA CA2270345A patent/CA2270345C/en not_active Expired - Lifetime
- 1997-10-30 EP EP06115792A patent/EP1714969A3/en not_active Withdrawn
- 1997-10-30 CN CNB971993521A patent/CN100338086C/en not_active Expired - Lifetime
- 1997-10-30 AT AT97947311T patent/ATE332966T1/en active
- 1997-10-30 WO PCT/US1997/019791 patent/WO1998018810A1/en active IP Right Grant
- 1997-10-30 DK DK97947311T patent/DK0948510T3/en active
- 1997-10-30 EP EP06115801A patent/EP1746159A3/en not_active Withdrawn
- 1997-10-30 CN CNA2007101300520A patent/CN101265285A/en active Pending
- 1997-10-30 NZ NZ335397A patent/NZ335397A/en not_active IP Right Cessation
- 1997-10-30 ES ES97947311T patent/ES2268736T3/en not_active Expired - Lifetime
- 1997-10-30 JP JP52078498A patent/JP2001503267A/en active Pending
- 1997-10-30 EP EP97947311A patent/EP0948510B1/en not_active Revoked
- 1997-10-30 EP EP10186177.1A patent/EP2360252B8/en not_active Expired - Lifetime
- 1997-10-30 EP EP10186108A patent/EP2322615A1/en not_active Withdrawn
- 1997-10-30 PT PT97947311T patent/PT948510E/en unknown
- 1997-10-30 AU AU52424/98A patent/AU5242498A/en not_active Abandoned
- 1997-10-30 KR KR1019997003873A patent/KR100689942B1/en not_active IP Right Cessation
-
2001
- 2001-03-27 US US09/818,918 patent/US20030050261A1/en not_active Abandoned
- 2001-12-14 AU AU97249/01A patent/AU775185B2/en not_active Expired
-
2003
- 2003-03-03 JP JP2003056446A patent/JP2003286174A/en not_active Withdrawn
- 2003-05-09 US US10/435,656 patent/US20050277604A1/en not_active Abandoned
- 2003-07-03 US US10/613,916 patent/US20050070491A1/en not_active Abandoned
- 2003-09-10 JP JP2003319045A patent/JP2004041224A/en not_active Withdrawn
- 2003-10-03 US US10/679,710 patent/US20040147468A1/en not_active Abandoned
- 2003-12-22 US US10/743,625 patent/US20040132685A1/en not_active Abandoned
-
2004
- 2004-01-30 US US10/769,282 patent/US7674777B2/en not_active Expired - Fee Related
- 2004-04-02 US US10/817,165 patent/US20040198688A1/en not_active Abandoned
- 2004-04-23 US US10/831,647 patent/US7402572B2/en not_active Expired - Fee Related
- 2004-05-17 US US10/847,642 patent/US20050004061A1/en not_active Abandoned
- 2004-06-24 US US10/877,407 patent/US20040229835A1/en not_active Abandoned
- 2004-07-02 US US10/884,852 patent/US20050059625A1/en not_active Abandoned
- 2004-07-09 US US10/888,785 patent/US7517861B2/en not_active Expired - Fee Related
- 2004-07-09 US US10/888,449 patent/US20050049215A1/en not_active Abandoned
- 2004-07-16 US US10/894,862 patent/US8058249B2/en not_active Expired - Fee Related
- 2004-07-16 US US10/894,657 patent/US20050054602A1/en not_active Abandoned
- 2004-08-26 US US10/928,762 patent/US20050123523A1/en not_active Abandoned
- 2004-10-01 US US10/956,745 patent/US20050239732A1/en not_active Abandoned
- 2004-10-01 US US10/956,494 patent/US7879810B2/en not_active Expired - Fee Related
- 2004-10-13 AU AU2004218696A patent/AU2004218696B2/en not_active Expired
- 2004-10-22 US US10/972,301 patent/US20050215500A1/en not_active Abandoned
- 2004-11-12 US US10/987,146 patent/US20050148537A1/en not_active Abandoned
-
2005
- 2005-01-07 US US11/031,460 patent/US8158592B2/en not_active Expired - Fee Related
- 2005-01-14 US US11/036,527 patent/US7723022B2/en not_active Expired - Fee Related
- 2005-02-25 US US11/067,587 patent/US8129351B2/en not_active Expired - Fee Related
- 2005-05-23 US US11/134,918 patent/US20050267064A1/en not_active Abandoned
- 2005-12-07 US US11/296,572 patent/US20060089326A1/en not_active Abandoned
-
2006
- 2006-08-11 US US11/503,483 patent/US7723500B2/en not_active Expired - Fee Related
- 2006-09-22 US US11/526,197 patent/US20070078104A1/en not_active Abandoned
- 2006-11-10 US US11/598,207 patent/US8258106B2/en not_active Expired - Fee Related
-
2007
- 2007-06-05 US US11/810,353 patent/US20080026011A1/en not_active Abandoned
-
2008
- 2008-07-25 JP JP2008192729A patent/JP5082063B2/en not_active Expired - Lifetime
- 2008-10-09 US US12/248,493 patent/US20090202575A1/en not_active Abandoned
-
2009
- 2009-03-25 US US12/383,824 patent/US7888327B2/en not_active Expired - Fee Related
-
2010
- 2010-03-10 JP JP2010053784A patent/JP2010150280A/en active Pending
Patent Citations (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5023243A (en) * | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
US5766920A (en) * | 1982-08-11 | 1998-06-16 | Cellcor, Inc. | Ex vivo activation of immune cells |
US4452775A (en) * | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
US5178860A (en) * | 1989-09-01 | 1993-01-12 | Coopers Animal Health Limited | Adjuvant complexes and vaccine made therefrom |
US5527899A (en) * | 1989-10-23 | 1996-06-18 | Gilead Sciences, Inc. | Oligonucleotides with inverted polarity |
US4981684A (en) * | 1989-10-24 | 1991-01-01 | Coopers Animal Health Limited | Formation of adjuvant complexes |
US5514577A (en) * | 1990-02-26 | 1996-05-07 | Isis Pharmaceuticals, Inc. | Oligonucleotide therapies for modulating the effects of herpes viruses |
US6030954A (en) * | 1991-09-05 | 2000-02-29 | University Of Connecticut | Targeted delivery of poly- or oligonucleotides to cells |
US6184369B1 (en) * | 1993-04-23 | 2001-02-06 | Aronex Pharmaceuticals, Inc. | Anti-viral guanosine-rich oligonucleotides |
US6191257B1 (en) * | 1993-04-27 | 2001-02-20 | Baylor College Of Medicine | Natural or recombinant DNA binding proteins as carriers for gene transfer or gene therapy |
US5594122A (en) * | 1993-06-23 | 1997-01-14 | Genesys Pharma Inc. | Antisense oligonucleotides targeted against human immunodeficiency virus |
US20030027782A1 (en) * | 1993-08-26 | 2003-02-06 | Carson Dennis A. | Method for treating allergic lung disease |
US6348312B1 (en) * | 1993-11-12 | 2002-02-19 | Hoescht Aktiengesellschaft | Stabilized oligonucleotides and their use |
US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
US5728518A (en) * | 1994-01-12 | 1998-03-17 | The Immune Response Corporation | Antiviral poly-and oligonucleotides |
US6031086A (en) * | 1994-03-18 | 2000-02-29 | The Regents Of The University Of California | Antisense oligonucleitide containing compositions and method of forming duplexes |
US20050075302A1 (en) * | 1994-03-25 | 2005-04-07 | Coley Pharmaceutical Group, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US6727230B1 (en) * | 1994-03-25 | 2004-04-27 | Coley Pharmaceutical Group, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US5723335A (en) * | 1994-03-25 | 1998-03-03 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US20050070491A1 (en) * | 1994-07-15 | 2005-03-31 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20050059625A1 (en) * | 1994-07-15 | 2005-03-17 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20050037985A1 (en) * | 1994-07-15 | 2005-02-17 | Krieg Arthur M. | Methods and products for treating HIV infection |
US20050037403A1 (en) * | 1994-07-15 | 2005-02-17 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
US6194388B1 (en) * | 1994-07-15 | 2001-02-27 | The University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20050032736A1 (en) * | 1994-07-15 | 2005-02-10 | The University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US7223741B2 (en) * | 1994-07-15 | 2007-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20070078104A1 (en) * | 1994-07-15 | 2007-04-05 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20050009774A1 (en) * | 1994-07-15 | 2005-01-13 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
US6239116B1 (en) * | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20050004061A1 (en) * | 1994-07-15 | 2005-01-06 | The University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20050004062A1 (en) * | 1994-07-15 | 2005-01-06 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
US20070066553A1 (en) * | 1994-07-15 | 2007-03-22 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20070065467A1 (en) * | 1994-07-15 | 2007-03-22 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US20050049216A1 (en) * | 1994-07-15 | 2005-03-03 | The University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20070010470A9 (en) * | 1994-07-15 | 2007-01-11 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
US20070009482A9 (en) * | 1994-07-15 | 2007-01-11 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
US20040087534A1 (en) * | 1994-07-15 | 2004-05-06 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
US20060094683A1 (en) * | 1994-07-15 | 2006-05-04 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
US20040087538A1 (en) * | 1994-07-15 | 2004-05-06 | University Of Iowa Research Foundation | Methods of treating cancer using immunostimulatory oligonucleotides |
US20030050263A1 (en) * | 1994-07-15 | 2003-03-13 | The University Of Iowa Research Foundation | Methods and products for treating HIV infection |
US20060089326A1 (en) * | 1994-07-15 | 2006-04-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20030050261A1 (en) * | 1994-07-15 | 2003-03-13 | Krieg Arthur M. | Immunostimulatory nucleic acid molecules |
US20060058251A1 (en) * | 1994-07-15 | 2006-03-16 | University Of Iowa Research Foundation | Methods for treating and preventing infectious disease |
US20050054602A1 (en) * | 1994-07-15 | 2005-03-10 | The University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20060003955A1 (en) * | 1994-07-15 | 2006-01-05 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20050101557A1 (en) * | 1994-07-15 | 2005-05-12 | The University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20030100527A1 (en) * | 1994-07-15 | 2003-05-29 | The University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US20050101554A1 (en) * | 1994-07-15 | 2005-05-12 | University Of Iowa Research Foundation | Methods for treating and preventing infectious disease |
US6503533B1 (en) * | 1994-07-28 | 2003-01-07 | Georgetown University | Antisense ogligonucleotides against Hepatitis B viral replication |
US5753613A (en) * | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
US6027726A (en) * | 1994-09-30 | 2000-02-22 | Inex Phamaceuticals Corp. | Glycosylated protein-liposome conjugates and methods for their preparation |
US5858987A (en) * | 1995-05-05 | 1999-01-12 | Mitotix, Inc. | E6AP antisense constructs and methods of use |
US5705385A (en) * | 1995-06-07 | 1998-01-06 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
US5736152A (en) * | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
US20030078223A1 (en) * | 1996-01-30 | 2003-04-24 | Eyal Raz | Compositions and methods for modulating an immune response |
US6027732A (en) * | 1996-02-21 | 2000-02-22 | Morein; Bror | Iscom or iscom-matrix comprising hydrophobic receptor molecules for antigenic substances |
US6030955A (en) * | 1996-03-21 | 2000-02-29 | The Trustees Of Columbia University In The City Of New York And Imclone Systems, Inc. | Methods of affecting intracellular phosphorylation of tyrosine using phosphorothioate oligonucleotides, and antiangiogenic and antiproliferative uses thereof |
US6174872B1 (en) * | 1996-10-04 | 2001-01-16 | The Regents Of The University Of California | Method for treating allergic lung disease |
US7001890B1 (en) * | 1997-01-23 | 2006-02-21 | Coley Pharmaceutical Gmbh | Pharmaceutical compositions comprising a polynucleotide and optionally an antigen especially for vaccination |
US20050054601A1 (en) * | 1997-01-23 | 2005-03-10 | Coley Pharmaceutical Gmbh | Pharmaceutical composition comprising a polynucleotide and optionally an antigen especially for vaccination |
US6214806B1 (en) * | 1997-02-28 | 2001-04-10 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CPC dinucleotide in the treatment of LPS-associated disorders |
US20050043529A1 (en) * | 1997-03-10 | 2005-02-24 | Coley Pharmaceutical Gmbh | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
US20030091599A1 (en) * | 1997-03-10 | 2003-05-15 | Coley Pharmaceutical Gmbh | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
US20050032734A1 (en) * | 1997-05-20 | 2005-02-10 | Krieg Arthur M. | Vectors and methods for immunization or therapeutic protocols |
US6339068B1 (en) * | 1997-05-20 | 2002-01-15 | University Of Iowa Research Foundation | Vectors and methods for immunization or therapeutic protocols |
US6225292B1 (en) * | 1997-06-06 | 2001-05-01 | The Regents Of The University Of California | Inhibitors of DNA immunostimulatory sequence activity |
US6521637B2 (en) * | 1997-07-03 | 2003-02-18 | University Of Iowa Research Foundation | Methods for inhibiting immunostimulatory DNA associated responses |
US6221882B1 (en) * | 1997-07-03 | 2001-04-24 | University Of Iowa Research Foundation | Methods for inhibiting immunostimulatory DNA associated responses |
US20030092663A1 (en) * | 1997-09-05 | 2003-05-15 | Eyal Raz | Immunization-free methods for treating antigen-stimulated inflammation in a mammalian host and shifting the host's antigen immune responsiveness to a Th1 phenotype |
US6218371B1 (en) * | 1998-04-03 | 2001-04-17 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
US20020064515A1 (en) * | 1998-04-03 | 2002-05-30 | Krieg Arthur M. | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
US20040030118A1 (en) * | 1998-05-14 | 2004-02-12 | Hermann Wagner | Methods for regulating hematopoiesis using CpG-oligonucleotides |
US20040006034A1 (en) * | 1998-06-05 | 2004-01-08 | Eyal Raz | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
US7214380B1 (en) * | 1998-06-23 | 2007-05-08 | The Board Of Trustees Of The Leland Stanford Junior University | Adjuvant therapy |
US20070066554A1 (en) * | 1999-09-25 | 2007-03-22 | Coley Pharmaceutical Gmbh | Immunostimulatory nucleic acids |
US20070037767A1 (en) * | 2000-02-03 | 2007-02-15 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
US20040067902A9 (en) * | 2000-02-03 | 2004-04-08 | Bratzler Robert L. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
US20030022852A1 (en) * | 2000-03-10 | 2003-01-30 | Nest Gary Van | Biodegradable immunomodulatory formulations and methods for use thereof |
US20020055477A1 (en) * | 2000-03-10 | 2002-05-09 | Nest Gary Van | Immunomodulatory formulations and methods for use thereof |
US20030059773A1 (en) * | 2000-03-10 | 2003-03-27 | Gary Van Nest | Immunomodulatory formulations and methods for use thereof |
US7183111B2 (en) * | 2000-03-10 | 2007-02-27 | Dynavax Technologies Corporation | Immunomodulatory formulations and methods for use thereof |
US7157437B2 (en) * | 2000-03-10 | 2007-01-02 | Dynavax Technologies Corporation | Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences |
US20040053882A1 (en) * | 2000-05-18 | 2004-03-18 | Smith Mark Peart | Combination chemotherapy |
US20030026801A1 (en) * | 2000-06-22 | 2003-02-06 | George Weiner | Methods for enhancing antibody-induced cell lysis and treating cancer |
US20030055014A1 (en) * | 2000-12-14 | 2003-03-20 | Bratzler Robert L. | Inhibition of angiogenesis by nucleic acids |
US20030049266A1 (en) * | 2000-12-27 | 2003-03-13 | Fearon Karen L. | Immunomodulatory polynucleotides and methods of using the same |
US20030050268A1 (en) * | 2001-03-29 | 2003-03-13 | Krieg Arthur M. | Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases |
US20030029783A1 (en) * | 2001-07-13 | 2003-02-13 | Donald Hubbard H. | Aerobic treatment plant with filter pipe |
US20040009949A1 (en) * | 2002-06-05 | 2004-01-15 | Coley Pharmaceutical Group, Inc. | Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory CpG nucleic acids |
US20040092472A1 (en) * | 2002-07-03 | 2004-05-13 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US20040067905A1 (en) * | 2002-07-03 | 2004-04-08 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US20050059619A1 (en) * | 2002-08-19 | 2005-03-17 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids |
US20060003962A1 (en) * | 2002-10-29 | 2006-01-05 | Coley Pharmaceutical Group, Ltd. | Methods and products related to treatment and prevention of hepatitis C virus infection |
US20050100983A1 (en) * | 2003-11-06 | 2005-05-12 | Coley Pharmaceutical Gmbh | Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling |
US20060019916A1 (en) * | 2004-04-02 | 2006-01-26 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for inducing IL-10 responses |
US20060019923A1 (en) * | 2004-07-18 | 2006-01-26 | Coley Pharmaceutical Group, Ltd. | Methods and compositions for inducing innate immune responses |
US20070006010A1 (en) * | 2005-06-30 | 2007-01-04 | Paul Wallner | Synchronous signal generator |
Cited By (144)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050075302A1 (en) * | 1994-03-25 | 2005-04-07 | Coley Pharmaceutical Group, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US7888327B2 (en) | 1994-07-15 | 2011-02-15 | University Of Iowa Research Foundation | Methods of using immunostimulatory nucleic acid molecules to treat allergic conditions |
US20050239732A1 (en) * | 1994-07-15 | 2005-10-27 | Krieg Arthur M | Immunostimulatory nucleic acid molecules |
US8309527B2 (en) | 1994-07-15 | 2012-11-13 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
US8258106B2 (en) | 1994-07-15 | 2012-09-04 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20030191079A1 (en) * | 1994-07-15 | 2003-10-09 | University Of Iowa Research Foundation | Methods for treating and preventing infectious disease |
US8158592B2 (en) | 1994-07-15 | 2012-04-17 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acid molecules |
US8148340B2 (en) | 1994-07-15 | 2012-04-03 | The United States Of America As Represented By The Department Of Health And Human Services | Immunomodulatory oligonucleotides |
US8129351B2 (en) | 1994-07-15 | 2012-03-06 | The University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US8114848B2 (en) | 1994-07-15 | 2012-02-14 | The United States Of America As Represented By The Department Of Health And Human Services | Immunomodulatory oligonucleotides |
US8058249B2 (en) | 1994-07-15 | 2011-11-15 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US8008266B2 (en) | 1994-07-15 | 2011-08-30 | University Of Iowa Foundation | Methods of treating cancer using immunostimulatory oligonucleotides |
US20040106568A1 (en) * | 1994-07-15 | 2004-06-03 | University Of Iowa Research Foundation | Methods for treating and preventing infectious disease |
US7935675B1 (en) | 1994-07-15 | 2011-05-03 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20040142469A1 (en) * | 1994-07-15 | 2004-07-22 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
US20040147468A1 (en) * | 1994-07-15 | 2004-07-29 | Krieg Arthur M | Immunostimulatory nucleic acid molecules |
US7879810B2 (en) | 1994-07-15 | 2011-02-01 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20040152657A1 (en) * | 1994-07-15 | 2004-08-05 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
US7723022B2 (en) | 1994-07-15 | 2010-05-25 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20040167089A1 (en) * | 1994-07-15 | 2004-08-26 | The University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US7723500B2 (en) | 1994-07-15 | 2010-05-25 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20040171150A1 (en) * | 1994-07-15 | 2004-09-02 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
US20040181045A1 (en) * | 1994-07-15 | 2004-09-16 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
US20100125101A1 (en) * | 1994-07-15 | 2010-05-20 | Krieg Arthur M | Immunostimulatory nucleic acid molecules |
US20040229835A1 (en) * | 1994-07-15 | 2004-11-18 | The University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US7713529B2 (en) | 1994-07-15 | 2010-05-11 | University Of Iowa Research Foundation | Methods for treating and preventing infectious disease |
US7674777B2 (en) | 1994-07-15 | 2010-03-09 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20080031936A1 (en) * | 1994-07-15 | 2008-02-07 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20080026011A1 (en) * | 1994-07-15 | 2008-01-31 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20050004061A1 (en) * | 1994-07-15 | 2005-01-06 | The University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20050004062A1 (en) * | 1994-07-15 | 2005-01-06 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
US20050009774A1 (en) * | 1994-07-15 | 2005-01-13 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
US20070202128A1 (en) * | 1994-07-15 | 2007-08-30 | Coley Pharmaceutical Group, Inc | Immunomodulatory oligonucleotides |
US20050032736A1 (en) * | 1994-07-15 | 2005-02-10 | The University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20070078104A1 (en) * | 1994-07-15 | 2007-04-05 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20050049216A1 (en) * | 1994-07-15 | 2005-03-03 | The University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20050054602A1 (en) * | 1994-07-15 | 2005-03-10 | The University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20070065467A1 (en) * | 1994-07-15 | 2007-03-22 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US20040087538A1 (en) * | 1994-07-15 | 2004-05-06 | University Of Iowa Research Foundation | Methods of treating cancer using immunostimulatory oligonucleotides |
US20050070491A1 (en) * | 1994-07-15 | 2005-03-31 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20070010470A9 (en) * | 1994-07-15 | 2007-01-11 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
US20050101557A1 (en) * | 1994-07-15 | 2005-05-12 | The University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20050101554A1 (en) * | 1994-07-15 | 2005-05-12 | University Of Iowa Research Foundation | Methods for treating and preventing infectious disease |
US20060094683A1 (en) * | 1994-07-15 | 2006-05-04 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
US20060003955A1 (en) * | 1994-07-15 | 2006-01-05 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20050123523A1 (en) * | 1994-07-15 | 2005-06-09 | The University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20050277609A1 (en) * | 1994-07-15 | 2005-12-15 | The University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20050148537A1 (en) * | 1994-07-15 | 2005-07-07 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20050171047A1 (en) * | 1994-07-15 | 2005-08-04 | The University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20050277604A1 (en) * | 1994-07-15 | 2005-12-15 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20050267057A1 (en) * | 1994-07-15 | 2005-12-01 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20050233999A1 (en) * | 1994-07-15 | 2005-10-20 | Krieg Arthur M | Immunostimulatory nucleic acid molecules |
US20050245477A1 (en) * | 1994-07-15 | 2005-11-03 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
US20050244379A1 (en) * | 1994-07-15 | 2005-11-03 | University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
US20050054601A1 (en) * | 1997-01-23 | 2005-03-10 | Coley Pharmaceutical Gmbh | Pharmaceutical composition comprising a polynucleotide and optionally an antigen especially for vaccination |
US20090060927A1 (en) * | 1997-01-23 | 2009-03-05 | Coley Pharmaceutical Gmbh | Pharmaceutical compositions comprising a polynucleotide and optionally an antigen especially for vaccination |
US8202688B2 (en) | 1997-03-10 | 2012-06-19 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
US20030224010A1 (en) * | 1997-03-10 | 2003-12-04 | Coley Pharmaceutical Gmbh | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
US20020164341A1 (en) * | 1997-03-10 | 2002-11-07 | Loeb Health Research Institute At The Ottawa Hospital | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
US20050043529A1 (en) * | 1997-03-10 | 2005-02-24 | Coley Pharmaceutical Gmbh | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
US20030091599A1 (en) * | 1997-03-10 | 2003-05-15 | Coley Pharmaceutical Gmbh | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
US20110081366A1 (en) * | 1997-10-30 | 2011-04-07 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20050197314A1 (en) * | 1998-04-03 | 2005-09-08 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
US20040235777A1 (en) * | 1998-05-14 | 2004-11-25 | Coley Pharmaceutical Gmbh | Methods for regulating hematopoiesis using CpG-oligonucleotides |
US20040234512A1 (en) * | 1998-05-14 | 2004-11-25 | Coley Pharmaceutical Gmbh | Methods for regualting hematopoiesis using CpG-oligonucleotides |
US20040235778A1 (en) * | 1998-05-14 | 2004-11-25 | Coley Pharmaceutical Gmbh | Methods for regulating hematopoiesis using CpG-oligonucleotides |
US8574599B1 (en) | 1998-05-22 | 2013-11-05 | Ottawa Hospital Research Institute | Methods and products for inducing mucosal immunity |
US7741300B2 (en) | 1998-06-25 | 2010-06-22 | National Jewish Medical And Research Center | Methods of using nucleic acid vector-lipid complexes |
US20040157791A1 (en) * | 1998-06-25 | 2004-08-12 | Dow Steven W. | Systemic immune activation method using nucleic acid-lipid complexes |
US7776343B1 (en) | 1999-02-17 | 2010-08-17 | Csl Limited | Immunogenic complexes and methods relating thereto |
US8173141B2 (en) | 1999-02-17 | 2012-05-08 | Csl Limited | Immunogenic complexes and methods relating thereto |
US7271156B2 (en) | 1999-09-25 | 2007-09-18 | University Of Iowa Research Foundation | Immunostimulatory nucleic acids |
US20030212026A1 (en) * | 1999-09-25 | 2003-11-13 | University Of Iowa Research Foundation | Immunostimulatory nucleic acids |
US7776344B2 (en) | 1999-09-27 | 2010-08-17 | University Of Iowa Research Foundation | Methods related to immunostimulatory nucleic acid-induced interferon |
US20060286070A1 (en) * | 1999-09-27 | 2006-12-21 | Coley Pharmaceutical Gmbh | Methods related to immunostimulatory nucleic acid-induced interferon |
US20110033421A1 (en) * | 1999-09-27 | 2011-02-10 | Coley Pharmaceutical Gmbh | Methods related to immunostimulatory nucleic acid-induced interferon |
US20070037767A1 (en) * | 2000-02-03 | 2007-02-15 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
US20060154890A1 (en) * | 2000-02-03 | 2006-07-13 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
US20040235774A1 (en) * | 2000-02-03 | 2004-11-25 | Bratzler Robert L. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
US20040131628A1 (en) * | 2000-03-08 | 2004-07-08 | Bratzler Robert L. | Nucleic acids for the treatment of disorders associated with microorganisms |
US20030026801A1 (en) * | 2000-06-22 | 2003-02-06 | George Weiner | Methods for enhancing antibody-induced cell lysis and treating cancer |
US7534772B2 (en) | 2000-06-22 | 2009-05-19 | University Of Iowa Research Foundation | Methods for enhancing antibody-induced cell lysis and treating cancer |
US20070009710A1 (en) * | 2000-08-04 | 2007-01-11 | Toyo Boseki Kabushiki Kaisha | Flexible metal-clad laminate and method for producing the same |
US7820379B2 (en) | 2000-09-15 | 2010-10-26 | Coley Pharmaceutical Gmbh | Process for high throughput screening of CpG-based immuno-agonist/antagonist |
US20050181422A1 (en) * | 2000-09-15 | 2005-08-18 | Coley Pharmaceutical Gmbh | Process for high throughput screening of CpG-based immuno-agonist/antagonist |
US20080226649A1 (en) * | 2000-12-08 | 2008-09-18 | Coley Pharmaceutical Gmbh | CPG-like nucleic acids and methods of use thereof |
US8834900B2 (en) | 2001-08-17 | 2014-09-16 | University Of Iowa Research Foundation | Combination motif immune stimulatory oligonucleotides with improved activity |
US20030148976A1 (en) * | 2001-08-17 | 2003-08-07 | Krieg Arthur M. | Combination motif immune stimulatory oligonucleotides with improved activity |
US20030139364A1 (en) * | 2001-10-12 | 2003-07-24 | University Of Iowa Research Foundation | Methods and products for enhancing immune responses using imidazoquinoline compounds |
US8658607B2 (en) | 2002-04-04 | 2014-02-25 | Zoetis Belgium | Immunostimulatory G, U-containing oligoribonucleotides |
US9428536B2 (en) | 2002-04-04 | 2016-08-30 | Zoetis Belgium Sa | Immunostimulatory G, U-containing oligoribonucleotides |
US8153141B2 (en) | 2002-04-04 | 2012-04-10 | Coley Pharmaceutical Gmbh | Immunostimulatory G, U-containing oligoribonucleotides |
US20030232074A1 (en) * | 2002-04-04 | 2003-12-18 | Coley Pharmaceutical Gmbh | Immunostimulatory G, U-containing oligoribonucleotides |
US7807803B2 (en) | 2002-07-03 | 2010-10-05 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US20090311277A1 (en) * | 2002-07-03 | 2009-12-17 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US20040092472A1 (en) * | 2002-07-03 | 2004-05-13 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US20040198680A1 (en) * | 2002-07-03 | 2004-10-07 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US20040152649A1 (en) * | 2002-07-03 | 2004-08-05 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US8114419B2 (en) | 2002-07-03 | 2012-02-14 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US20040067905A1 (en) * | 2002-07-03 | 2004-04-08 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US8283328B2 (en) | 2002-08-19 | 2012-10-09 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids |
US8304396B2 (en) | 2002-08-19 | 2012-11-06 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids |
US20050059619A1 (en) * | 2002-08-19 | 2005-03-17 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids |
US20060003962A1 (en) * | 2002-10-29 | 2006-01-05 | Coley Pharmaceutical Group, Ltd. | Methods and products related to treatment and prevention of hepatitis C virus infection |
US7998492B2 (en) | 2002-10-29 | 2011-08-16 | Coley Pharmaceutical Group, Inc. | Methods and products related to treatment and prevention of hepatitis C virus infection |
US20060246035A1 (en) * | 2002-10-29 | 2006-11-02 | Coley Pharmaceutical Gmbh | Methods and products related to treatment and prevention of hepatitis c virus infection |
US20040171571A1 (en) * | 2002-12-11 | 2004-09-02 | Coley Pharmaceutical Group, Inc. | 5' CpG nucleic acids and methods of use |
US7956043B2 (en) | 2002-12-11 | 2011-06-07 | Coley Pharmaceutical Group, Inc. | 5′ CpG nucleic acids and methods of use |
US20050119273A1 (en) * | 2003-06-20 | 2005-06-02 | Coley Pharmaceutical Gmbh | Small molecule toll-like receptor (TLR) antagonists |
US7410975B2 (en) | 2003-06-20 | 2008-08-12 | Coley Pharmaceutical Group, Inc. | Small molecule toll-like receptor (TLR) antagonists |
US20050013812A1 (en) * | 2003-07-14 | 2005-01-20 | Dow Steven W. | Vaccines using pattern recognition receptor-ligand:lipid complexes |
US20100183639A1 (en) * | 2003-09-25 | 2010-07-22 | Coley Pharmaceutical Group, Inc. | Nucleic acid-lipophilic conjugates |
US20050130911A1 (en) * | 2003-09-25 | 2005-06-16 | Coley Pharmaceutical Group, Inc. | Nucleic acid-lipophilic conjugates |
US8188254B2 (en) | 2003-10-30 | 2012-05-29 | Coley Pharmaceutical Gmbh | C-class oligonucleotide analogs with enhanced immunostimulatory potency |
US20050239734A1 (en) * | 2003-10-30 | 2005-10-27 | Coley Pharmaceutical Gmbh | C-class oligonucleotide analogs with enhanced immunostimulatory potency |
US20050239733A1 (en) * | 2003-10-31 | 2005-10-27 | Coley Pharmaceutical Gmbh | Sequence requirements for inhibitory oligonucleotides |
US20050100983A1 (en) * | 2003-11-06 | 2005-05-12 | Coley Pharmaceutical Gmbh | Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling |
US20050256073A1 (en) * | 2004-02-19 | 2005-11-17 | Coley Pharmaceutical Group, Inc. | Immunostimulatory viral RNA oligonucleotides |
US20090137519A1 (en) * | 2004-10-20 | 2009-05-28 | Coley Pharmaceutical Group, Inc. | Semi-soft c-class immunostimulatory oligonucleotides |
US20060140875A1 (en) * | 2004-10-20 | 2006-06-29 | Coley Pharmaceutical Group, Inc. | Semi-soft C-class immunostimulatory oligonucleotides |
US20110201672A1 (en) * | 2004-10-20 | 2011-08-18 | Krieg Arthur M | Semi-soft c-class immunostimulatory oligonucleotides |
US7795235B2 (en) | 2004-10-20 | 2010-09-14 | Coley Pharmaceutical Gmbh | Semi-soft c-class immunostimulatory oligonucleotides |
US20060211644A1 (en) * | 2005-02-24 | 2006-09-21 | Coley Pharmaceutical Group, Inc. | Immunostimulatory oligonucleotides |
US20080009455A9 (en) * | 2005-02-24 | 2008-01-10 | Coley Pharmaceutical Group, Inc. | Immunostimulatory oligonucleotides |
US20060229271A1 (en) * | 2005-04-08 | 2006-10-12 | Coley Pharmaceutical Group, Inc. | Methods for treating infectious disease exacerbated asthma |
US20060241076A1 (en) * | 2005-04-26 | 2006-10-26 | Coley Pharmaceutical Gmbh | Modified oligoribonucleotide analogs with enhanced immunostimulatory activity |
US20090117132A1 (en) * | 2005-07-07 | 2009-05-07 | Pfizer, Inc. | Anti-Ctla-4 Antibody and Cpg-Motif-Containing Synthetic Oligodeoxynucleotide Combination Therapy for Cancer Treatment |
US20090306177A1 (en) * | 2005-09-16 | 2009-12-10 | Coley Pharmaceutical Gmbh | Modulation of Immunostimulatory Properties of Short Interfering Ribonucleic Acid (Sirna) by Nucleotide Modification |
US20090214578A1 (en) * | 2005-09-16 | 2009-08-27 | Coley Pharmaceutical Gmbh | Immunostimulatory Single-Stranded Ribonucleic Acid with Phosphodiester Backbone |
US7662949B2 (en) | 2005-11-25 | 2010-02-16 | Coley Pharmaceutical Gmbh | Immunostimulatory oligoribonucleotides |
US8354522B2 (en) | 2005-11-25 | 2013-01-15 | Coley Pharmaceutical Gmbh | Immunostimulatory oligoribonucleotides |
US20110206719A1 (en) * | 2005-11-25 | 2011-08-25 | Coley Pharmaceutical Gmbh | Immunostimulatory oligoribonucleotides |
US20100316659A1 (en) * | 2005-11-25 | 2010-12-16 | Coley Pharmaceutical Gmbh | Immunostimulatory oligoribonucleotides |
US20080045473A1 (en) * | 2006-02-15 | 2008-02-21 | Coley Pharmaceutical Gmbh | Compositions and methods for oligonucleotide formulations |
US20080026986A1 (en) * | 2006-06-05 | 2008-01-31 | Rong-Fu Wang | Reversal of the suppressive function of specific t cells via toll-like receptor 8 signaling |
US8580268B2 (en) | 2006-09-27 | 2013-11-12 | Coley Pharmaceutical Gmbh | CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity |
US9382545B2 (en) | 2006-09-27 | 2016-07-05 | Coley Pharmaceutical Gmbh | CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity |
US10260071B2 (en) | 2006-09-27 | 2019-04-16 | Coley Pharmaceutical Gmbh | CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity |
US20090142362A1 (en) * | 2006-11-06 | 2009-06-04 | Avant Immunotherapeutics, Inc. | Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP) |
US8883174B2 (en) | 2009-03-25 | 2014-11-11 | The Board Of Regents, The University Of Texas System | Compositions for stimulation of mammalian innate immune resistance to pathogens |
US9186400B2 (en) | 2009-03-25 | 2015-11-17 | The Board Of Regents, The University Of Texas System | Compositions for stimulation of mammalian innate immune resistance to pathogens |
US9504742B2 (en) | 2009-03-25 | 2016-11-29 | The Board Of Regents, The University Of Texas System | Compositions for stimulation of mammalian innate immune resistance to pathogens |
US10722573B2 (en) | 2009-03-25 | 2020-07-28 | The Board Of Regents, The University Of Texas System | Compositions for stimulation of mammalian innate immune resistance to pathogens |
US10286065B2 (en) | 2014-09-19 | 2019-05-14 | Board Of Regents, The University Of Texas System | Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20050049215A1 (en) | Immunostimulatory nucleic acid molecules | |
EP1167378B1 (en) | Immunomodulatory oligonucleotides | |
US8148340B2 (en) | Immunomodulatory oligonucleotides | |
US8008266B2 (en) | Methods of treating cancer using immunostimulatory oligonucleotides | |
AU754463B2 (en) | Immunomodulatory oligonucleotides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: COLEY PHARMACEUTICAL GROUP, INC., MASSACHUSETTS Free format text: CHANGE OF NAME;ASSIGNOR:CPG IMMUNOPHARMACEUTICALS, INC.;REEL/FRAME:015589/0687 Effective date: 20000121 Owner name: UNIVERSITY OF IOWA RESEARCH FOUNDATION, THE, IOWA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:KRIEG, ARTHUR M.;REEL/FRAME:015590/0277 Effective date: 19961211 Owner name: IOWA RESEARCH FOUNDATION, THE UNIVERSITY OF, IOWA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:KLINE, JOEL;REEL/FRAME:015590/0258 Effective date: 19970623 Owner name: CPG IMMUNOPHARMACEUTICALS, INC., MASSACHUSETTS Free format text: LETTER OF AGREEMENT;ASSIGNOR:STEINBERG, ALFRED D.;REEL/FRAME:015589/0698 Effective date: 19981030 Owner name: UNITED STATES OF AMERICA, AS REPRESENTED BY THE SE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:KLINMAN, DENNIS;REEL/FRAME:015589/0685 Effective date: 20000301 |
|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF IOWA;REEL/FRAME:021670/0807 Effective date: 20040809 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |